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Part I 
Introduction to the studies 

Chapter 1 
Airway smooth muscle function: 
Structural, electrophysiological, biochemical and mechanical 
aspects 
Structure of airway smooth muscle 
Airway smooth muscle is present in the airways from the trachea down to the 
smallest membranous bronchioles. In the trachea, smooth muscle is localised 
dorsally, were ramifying spindle-shaped muscle cells run in bundles in a transverse 
direction to connect the ends of the horse-shoe shaped cartilage plates and the 
annular ligaments. In the bronchi, airway smooth muscle inserts on the pe-
richondrium and runs in helicoidal strands around the airway circumference. 
Spirally oriented bundles of airway smooth muscle are also present in the walls 
of the smaller non-cartilaginous bronchi, where the screw-like turns are more 
widely spaced and constitute a relatively large part of the volume of the airway 
wall1• Elastin and collagen surround the muscle bundles, and blood vessels and 
nerves are localised in these connective tissue spaces between the muscle bundles2'3• 
Ultrastructure of airway smooth muscle 
Airway smooth muscle cells have an elongated spindle shape and a central cigar-
like nucleus. Their cytoplasm contains the contractile proteins actin and myosin, 
as demonstrated by electron microscopy and biochemical studies. Myosin is only 
present in one fifth of the amount found in striated muscle, and the myosin 
filaments are roughly 20% longer than in striated muscle. Another difference 
is that each myosin filament is surrounded by 12-14 actin filaments in airway 
smooth muscle, and by 6 actin filaments in skeletal muscle. The actin filaments 
are attached to the muscle cell membrane in the so-called dense bands, and 
are also connected to similar structures in the cytoplasm, the dense bodies3• 
The actomyosin complex together with the dense bands and -bodies are thought 
to represent the equivalent of striated muscle sarcomeres, and form the contractile 
element2 • Airway smooth muscle contains relatively few mitochondriae, and 
therefore produces only 10% of the amount of ATP produced by skeletal muscle2• 
Sarcoplasmic reticulum is also relatively sparse and is present as peripherally 
located saccular and tubular structures4 • A Golgi apparatus can usually be 
identified. The cell membrane forms bottle-shaped micro inpocketings or ca-
veolae, which may serve as a storage site for calcium ions4• 
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Gap junctions 
Where airway smooth muscle cells are apposed, small areas of tight junction 
can be seen that facilitate the propagation of electrical current by virtue of 
their low electrical impedance. These structures are called gap juctions5' 6 , and 
are believed to be important because their number and size is variable in time 
and responds to various stimuli7, which might influence airway smooth muscle 
contractile function in analogy to the changes in uterine smooth muscle during 
labor. 
Electrophysiology of airway smooth muscle 
Multi/single unit smooth muscle 
Smooth muscle can be classified as multi-unit, single-unit or intermediate type, 
which refers to the density of innervation and electrical coupling between the 
cells. Multi-unit smooth muscle is characterised by a separate innervation of 
the muscle cells with few gap junctions. Multi-unit smooth muscle displays no 
spontaneous rythmical activities, does not develop action potentials after electrical 
or pharmalogical stimulation, and responds to a graded membrane depolarisation 
with a gradual contraction. Single-unit smooth muscle is sparsely innervated 
but has many gap junctions and functions as a syncytium. This type of smooth 
muscle has spontaneous rythmic oscillations of the membrane potential, and 
can develop action potentials upon depolarisation. Characteristically, multi-unit 
smooth muscle is present in e.g. large blood vessels; single unit in the intestine, 
ureters and uterus at term3• 
Airway smooth muscle is an intermediate type of smooth muscle, because 
it has relatively few gap junctions2, and has no spontaneous electrical activitl-10 , 
but has a relatively sparse innervation8• 
Electrical activation of airway smooth muscle 
Studies on the electrophysiology of airway smooth muscle have mainly been 
conducted on canine, bovine and guinea-pig tracheal smooth muscle. Tracheal 
muscle cells have a stable resting membrane potential of approximately -48 to 
-55 mV9' 10• Pharmacological stimulation with contracting agonists or electrical 
stimulation causes a gradual depolarisation without action potentials9- 11 • A graded 
contraction begins when the membrane potential is elevated by more than 5 
mV. In airway smooth muscle, this is a slow process 11 • 
Vagal nerve stimulation leads to a sustained, small potential change in bovine 
tracheal smooth muscle, called the excitatory junctional potential (EJP)8• The 
EJP represents a summary of the synaptic potentials produced by neurotrans-
mitter release. The ensuing contraction is proportional to the degree of depo-
larisation, so in each muscle cell there is a graded response and not the 'all-or-none' 
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response that usually follows an action potential in other types of muscle cells 12 • 
Direct measurements of electrical activities of human airways have been made 
in a single study13 where action potentials were recorded in vivo using an 
intrabronchial electrode. An increased electrical activity was found during 
asthmatic bronchospasm; the significance ofthis finding for airway smooth muscle 
function, however, needs further elucidation. Because small airway smooth muscle 
is embedded in the peripheral lung tissue and is intermingled with connective 
tissue, this is technically a difficult tissue to study. Thusfar, no electrophysiological 
studies on peripheral airway smooth muscle have been reported. 
Several investigators have observed spontaneous electric activity and action 
potentials in airway smooth muscle14' 15 • These may, however, have resulted from 
metabolic depletion16 or inappropriate dissection procedures. 
Biochemistry of airway smooth muscle contraction 
The increase in smooth muscle cell membrane potential that follows neurotrans-
mitter release from nervous elements produces contractile element shortening 
via a highly complex series of biochemical events. This is schematically depicted 
in Figure 1. The actin and myosin protein filaments are arranged in parallel, 
BIOCHEMIC EVENTS LEADING TO AIRWAY SMOOTH MUSCLE CONTRACTION 
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Figure 1. Schematic and simplified representation of the biochemical events that cause airway smooth 
muscle contraction. 
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each myosin filament being surrounded by 12-14 actin molecules 17. Myosin 
consists of heavy chains (molecular weight, MW:200.000 Daltons) and two types 
of light chains (MW:20.000 and 17.000 D)18. Actin filaments are composed of 
two 42.000 D chains, wrapped in a helix. According to the sliding filament 
model, active transport of actin along myosin produces contraction of the smooth 
muscle cell. For this purpose, the myosin molecules have a globular end which 
possesses ATP-ase activity. Phosphorylation of the myosin light chains by myosin 
light chain kinase results in activation of this magnesium-dependent myosin ATP-
ase18'19. Activated myosin ATP-ase hydrolyses ATP, which leads to flexion of 
the globular myosin head. Formation, breakdown and reformation of cross-
bridges between the moving myosin molecules and actin filaments is called cross-
bridge cycling, and results in shortening and stiffening of the contractile element 
and the smooth muscle cell4'20 . 
The role of calcium 
Activation of myosin light chain kinase is a Ca2+-dependent process which starts 
when the intracellular [Ca2+] increases from a basal concentration of 10-8 to 
10-7M to above 10-6M21 . The intracellular Ca2+ -concentration is much lower than 
the extracellular concentration, which is approximately 10-3M. This gradient 
produces an inward Ca2+-current when the cell membrane is made more permeable 
to Ca2+. Penetration of Ca ions through the cell membrane is possible via the 
relatively ion-specific Ca channels. Ca channels are glycoprotein molecules in 
the cell membrane, which have an aqueous pore that opens to Ca ions in response 
to cell membrane depolarisation (voltage- or potential-dependent channels) or 
in response to stimulation of specific receptors (receptor-operated channels)22• 
Voltage- and receptor-operated channels are structurally closely related, but are 
activated seperately by their respective activators23 . Furthermore, small amounts 
of calcium can enter the cell passively via a membrane leak and via sodium 
channels. This Ca entry is compensated by Ca efflux mechanisms and does not 
cause activation of the contractile apparatus24. Ca entry mobilises a larger pool 
of Ca ions, that is bound to the sarcoplasmic reticulum. This Ca-induced 
intracellular calcium release may also be important in cell activation 24'25 . 
When the intracellular [Ca2j exceeds 10-6M, it binds to calmodulin, a 148-
amino acid peptide (MW:16.500 D) that has four Ca binding sites26. Saturation 
of calmodulin with Ca activates the molecule; active calmodulin binds to myosin 
light chain kinase, thereby in turn activating this enzyme17. 
Contraction results when Ca is released from intracellular stores, such as the 
sarcoplasmic reticulum27, and the inner surface of the cell membrane. The most 
active substances that release Ca intracellularly are Ca itself, inositol triphosphate 
and caffeine27. Various contractile agonists differ in their capacity to induce 
contraction by releasing intracellular calcium4: acetylcholine, for instance, con-
tracts airway smooth muscle independent of Ca influx in various species9' 12'28 , 
whereas histamine and serotonin are more dependent on extracellular calcium. 
The important role of intracellular calcium in human airway smooth muscle 
contraction to cholinergic stimulation has also been demonstrated29' 30. 
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DiacylglyceroVprotein kinase C pathway 
An alternative Ca-calmodulin independent path leading to smooth muscle 
contraction is the diacylglycerol/protein kinase C pathwal1• Stimulation of a 
receptor produces activation of the membrane-associated enzyme protein kinase 
C, which converts phosphorylated phosphatidylinositol in the cell membrane 
into inositol triphosphate and diacylglycerol. Inositol triphosphate functions as 
a second messenger and releases Ca from intracellular stores, thus producing 
contraction. Diacylglycerol activates the enzyme protein kinase C by increasing 
the sensitivity of this enzyme to Ca, but not via an increase in intracellular 
Ca21 ' 31 • Activated protein kinase C in turn activates myosin light chain kinase. 
This leads to contraction, independent of Ca-calmodulin, in the presence of 
a basally low Ca concentration. 
Sequence of biochemical processes 
After receptor occupation by a contracting agonist, the rise in intracellular Ca 
has a transient nature. Within a few seconds, the Ca level in the cell falls to 
almost basal values, in spite of a persisting high Ca influx rate21 • In this phase, 
the Ca-calmodulin-mediated response decreases, and the diacylglycerol pathway 
sustains the response when the stimulus is still present2' 32 • This part of the 
contraction response is highly effective, in that the response is sustained at a 
very low energy cost. The diacylglycerol/protein kinase C pathway probably 
activates slowly- or noncycling crossbridges, also called 'latch bridges'3, that 
will be discussed later in this chapter. 
Biochemistry of airway smooth muscle relaxation 
Two mechanisms cause relaxation of airway smooth muscle, the first being related 
to the Ca-influx rate, the other to activation of adenylate cyclase. 
Calcium clearing 
The muscle cell membrane contains ionic exchange systems that can remove 
Ca out of the cell in exchange for magnesium or sodium ions34• The Ca-Na 
exchanger extrudes Ca ions driven by the electrochemical gradient of Na over 
the cell membrane, and is probably sensitive to alterations in membrane potential. 
The Ca-Mg ATPase is activated by theCa-calmodulin complex34 and by activated 
protein kinase A. The Ca influx is therefore a self-limiting process which elevates 
intracellular Ca only transiently. Ca can also be removed from the cytoplasm 
by sequestration in intracellular stores, such as the sarcoplasmic reticulum, which 
have ATPases that are presumably different from those on the cell membrane4 • 
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Cyclic AMP 
The second relaxing mechanism, that acts more slowly, is activation of adenylate 
cyclase, which leads to the formation of cyclic AMP (cAMP). This cAMP activates 
protein kinases which remove Ca from the cytoplasm by stimulating ionic Ca 
efflux pumps in the smooth muscle cell membrane17' 34' 35 • In addition, cAMP 
dependent protein kinases can inhibit the breakdown of cell membrane phos-
phatidyl inositol. This reduces the contraction that is mediated by diacylglycerol 
and inositol triphosphate32• The main physiologic activator of adenylate cyclase 
is stimulation of /3-adrenergic receptors by circulating catecholamines32• Both 
relaxing mechanisms, acting via the Ca and cAMP messenger systems, are not 
independent but probably have many complex interactions36• 
Other biochemical events during relaxation 
When the Ca influx into the muscle cell decreases, and the intracellular Ca 
level has returned to a basal level, dephosphorylation of the myosin light chains 
occurs. This process is catalysed by the enzyme myosin light chain phosphatase. 
The activity of this enzyme is independent of the intracellular calcium concen-
tration, and its net effect on the phosphorylation state of the myosin light chains 
depends on the degree of activity of the counter-acting enzyme myosin light 
chain kinase18• Dephosphorylation of myosin light chains stops the cross-bridge 
cycling, which causes relaxation and elongation of the contractile elements, driven 
by passive elastic forces. 
Airway smooth muscle mechanics 
Isometric and isotonic functioning 
Excitation of a smooth muscle preparation results in shortening and stiffening 
of the tissue. Dependent on experimental conditions, two modalities of action 
can be defined: isometric activity, where the muscle is maintained at a fixed 
length and upon stimulation develops force, and isotonic shortening, where the 
contractile elements contract and, hence, the muscle performs work against a 
(constant) load. 
It is presently thought, that, in vivo, airway smooth muscle contracts quasi 
isotonically1• Isotonic shortening leads to airway narrowing. After the initial 
shortening, the muscle has to act against an increased load due to the elasticity 
of the non-contracting tissue surrounding the airways. This probably forces the 
airway smooth muscle to contract in a more isometric fashion with increased 
activation. The isometric stiffening of airway smooth muscle is the equivalent 
of tone development, which stabilises the airway. 
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Optimal length 
The maximum isometric force or tension that airway smooth muscle can generate 
(T max) is dependent on the initial length of the muscle, which determines the 
relative position of the myosin and actin filaments, according to a Frank-Starling 
type of curve. In canine trachea, the optimal length Lo is reached at a relatively 
small initial load of less than 10% of Tmax3• The maximal tension is similar 
to that of skeletal muscle. This is remarkable because striated muscle has a 
much higher myosin content than airway smooth muscle2 • 
It has been shown that airway smooth muscle, upon maximal activation, can 
shorten to even 10-20% of its optimal length, which is called 'supercontraction'3, 
whereas skeletal muscle shortens at most to 65%. The mechanism that enables 
airway muscle to supercontract may be related to the different organisation 
and length of the contractile elements as compared to striated muscle, but remains 
to be elucidated. At initial lengths shorter than Lo, airway smooth muscle cannot 
be activated maximalll7• This may be due to changed dimensions of the muscle, 
which impair activation of muscle cells that are localized centrally in the tissue. 
It is not known whether airway smooth muscle resting length in vivo is near 
Lo 1• 
Latch bridges 
The initial shortening of airway smooth muscle following electrical or phar-
macological excitation is probably caused by the activity of normally cycling 
cross-bridges. The tension that develops later on in the activation process is 
believed to result from the action of 'latch bridges', which are activated a few 
seconds later than the normally cycling cross-bridges3'33 • Latch bridges can 
efficiently sustain a contraction because of their low energy consumption33•38•39 • 
The existence of latch bridges has first been demonstrated in vascular smooth 
muscle40 and later in canine airway smooth muscle33• Their importance lies in 
their extreme efficiency, which results from a high load bearing capacity and 
a low energy consumption. 
Elastic forces 
Two types of passive elastic forces are important in the capacity of force 
maintenance of airway smooth muscle, ,(iS shown schematically in Figure 2. The 
'series elastic component' can be defined as the non-contracting tissue that is 
in series with the contractile element4• Its stiffness during isometric contraction 
is proportionate to the number of cycling.'cross-bridges3• The 'parallel elastic 
component' represents the non-contracting structures that are parallel to the 
contractile element. Compression of these elements during muscle shortening 
may constraint the cycling of cross-bridges, and decrease the velocity of 
shortening. 
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SEC= Series Elastic Component 
PEG= Parallel Elastic Component 
CE =Contractile Element. 
Figure 2. Schematic representation of the series - and parallel elastic components in the airway 
smooth muscle cell. 
Force-velocity relationship 
The rate of force development provides insight in the power that is produced 
by the muscle cells. Force-velocity relationships have only been examined in 
tracheal smooth muscle, because its measurement requires a pure muscle 
preparation with the cells oriented parallel to each other. Canine tracheal smooth 
muscle is a slow acting type of muscle, probably because of the slow rate at 
which energy-liberating reactions occur in this muscle2'42 • The force that can 
be developed is, however, relatively high. 
Relaxation 
Relaxation of airway smooth muscle is also a slow process which is determined 
by the rate of inactivation of the contractile elements' cross-bridge cycling. This 
is in contrast to relaxation of striated muscle, where the load determines the 
relaxation rate. The difference may be related to the sparsity of the sarcoplasmic 
reticulum in airway smooth muscle, which may delay the Ca clearing of the 
cytoplasm. After relaxation, cross-bridges do not cycle, but may be attached, 
thereby providing muscle resistance to stress43 • 
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Chapter 2 
Control of human airway smooth muscle: 
The autonomic nervous system 
Introduction 
The contractile state of airway smooth muscle under physiological conditions 
is controlled by the autonomic nervous system. This autonomic control is much 
more complex than previously thought. Not only a parasympathetic cholinergic 
system and a sympathetic adrenergic system, but also a non-adrenergic, non-
cholinergic (NANC) system is present, which innervates airway smooth muscle 
and other structures in the lungs, and has inhibitory and excitatory components1• 
The NANC system probably acts via a spectrum of peptide neurotransmitters. 
It is likely that complex interactions occur between the different components 
of the autonomic innervation of the airways. Furthermore, it has been shown 
that nerves terminate on mast cells that are in close contact with muscle cells 
in human airways. This suggests that mast cell mediator release is to some extent 
also controlled by the autonomic innervation, and has a regulatory role2• 
Unravelling the roles of these various components under physiological and 
pathological conditions is very difficult. There are wide differences between 
species3 and research on human tissue is still in its early years. Nevertheless, 
progress in the understanding of the autonomic innervation of human airways 
has been made 4• 
Cholinergic innervation 
Cholinergic excitatory nerves arise in the vagal nucle! in the brain stem and 
run in the vagus nerves to the lungs. Relatively few nerves supply smooth muscle 
and mucous glands in the central airways, where they enter from the adventitial 
side and synapse in ganglia in the tracheal and bronchial wall4- 7• Postganglionic 
unmyelinated cholinergic axons run between the smooth muscle bundles, but 
do not penetrate between individual muscle cells2' 5' 8 • Medium-sized bronchi 
(fourth to seventh generation) have a denser innervation than the trachea and 
second order bronchi, although close contacts between nerve endings and muscle 
cells are rare2' 8• Cholinergic fibers are scanty in bronchioles and absent in alveolar 
walls2'4 • This suggests that neural control is especially important in fourth to 
seventh order bronchi2 • Activation of cholinergic efferents releases acetylcholine 
from the cholinergic nerve terminals, which stimulates muscarinic receptors of 
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the M2 subtype on the muscle cells9 and causes muscle contraction. Muscarinic 
receptor density decreases from central to peripheral airways10, which confirms 
that the cholinergic system predominantly controls the central airways. 
In the guinea pig and the cat, muscarinic receptors, presumably of the MJ-
subtype, that are localized on the presynaptic membrane of postganglionic 
cholinergic fibers 1\ inhibit the release of acetylcholine12'13• This may represent 
a negative feedback mechanism. 
Adrenergic innervation 
Although the sympathetic nervous system innervates various structures in the 
lungs, such as the blood vessels and mucous glands, virtually no direct sympathetic 
innervation of human airway smooth muscle can be demonstrated histologically. 
Functional experiments on human central airways have failed to show an 
d . . . 6 14-16 N h 1 h . h 1 h a renerg1c mnervatwn ' . evert e ess, uman mrway smoot muse e as 
many adrenergic receptors on its cell membranes that are of the /32 subtype17'18. 
These /32 receptors increase in number from central to peripheral airways10• 
Stimulation of /32 receptors produces muscle relaxation. Circulating adrenalin, 
produced by the adrenal glands, may act as an endogenous bronchodilator19. 
Although the basal adrenalin concentrations in plasma are much too low to 
have an effect on airway smooth muscle, the peak levels during stress may cause 
bronchodilatation. The physiologic role of the /32 adrenoceptors on airway smooth 
muscle is not entirely clear; they certainly mediate the beneficial effect of /3-
agonists in asthma. In human lung, adrenergic fibers have been demonstrated 
that end in parasympathetic ganglia and that may modify ganglionic transmis-
sion20, probably by stimulating a:2 receptors21'22. Furthermore, adrenergic nerve 
varicosities have been found in close proximity to cholinergic nerve endings, 
that may modulate acetylcholine release via stimulation of presynaptic f3 
receptors23 . 
The role of a: adrenergic receptors on smooth muscle cells is obscure. They 
are mainly present in peripheral airways 10'24. Their stimulation has no consistent 
effects on normal human airway smooth muscle25 , but a: receptors may play 
a role in obstructive airway diseases4·7·28 . 
Non-adrenergic, non-cholinergic innervation 
The presence of this 'third nervous system' in the human lung has now been 
well documented1. The NANC system has inhibitory and excitatory components. 
NANC inhibitory nerves probably constitute the only direct inhibitory innervation 
of human airway smooth muscle14'15'27-29. NANC nerves reach the lungs via the 
vagus nerves and, like cholinergic nerves, synapse at ganglia in the tracheal 
and bronchial wall. The NANC inhibitory system is mainly present in central 
airways; NANC nerves become sparse in human peripheral airways28'30-32• There 
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is strong evidence that the neurotransmitters of this system are the 28-aminoacid 
polypeptide vasoactive intestinal peptide (VIP) and the related peptide histidine 
isoleucine (PHI)30- 35 • VIP has been shown to coexist with acetylcholine in 
parasympathetic nerve endings, and is therefore probably a co-transmitter of 
acetylcholine4• The elucidation of the importance of this system in humans awaits 
the development of specific blocking drugs. 
NANC excitatory nerves, containing subtance P and other tachykinins including 
neurokinin A, neuropeptide K, eledoisin-like peptide, and calcitonin gene-related 
peptide, have been identified in the airways of various animal species, and in 
humans4• Autoradiographic studies have localized substance P-receptors on 
human airway smooth muscle and submucosal glands36• The results of animal 
experiments on the effects of tachykinins on airway smooth muscle37' 38 , vascular 
permeabilitl7 , tracheal gland secretion39 ·and mast cells have led to speculations 
on their role in obstructive airway diseases32' 40 • Their release upon sensory nerve 
activation suggests a possible involvement in local axon reflexes4' 32• 
Ganglia 
Ganglia of the parasympathetic system are present in the bronchial wall, localized 
external to the smooth muscle layer. They contain several types of neuronal 
bodies and have a complex structure, including cholinergic, adrenergic and NANC 
elements20' 30• It seems likely that these components interact to integrate and 
coordinate the neural inputs to the airway smooth muscle. It has been shown 
that adrenergic stimulation of ferret and guinea pig paratracheal ganglia causes 
presynaptic inhibition of cholinergic neurotransmission20• This local ganglionic 
regulation process is still poorly understood; studies on human tissue are lacking. 
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Chapter 3 
Control of human airway smooth muscle: 
Indlammatorymediators 
Introduction 
During an inflammatory reaction, a large number of mediators is produced 
by inflammatory cells. Several mediators of inflammation are potent constrictors 
of human airways, and have other effects, e.g. stimulation of airway gland 
secretion, induction of capillary leakiness and chemotactic activity, that can 
contribute to airways obstruction. Because of their local release, mediators may 
reach levels that are high enough to cause smooth muscle contraction in the 
bronchial wall. Inflammatory mediators may therefore be important in the control 
of airway smooth muscle contraction, especially in inflammatory airways diseases 
such as chronic bronchitis and asthma. During the past decade, most research 
has focussed on the roles of histamine, prostanoids, leukotrienes and platelet 
activating factor, and these mediators will be considered in some detail in this 
chapter. 
Histamine 
Histamine is released from lung mast cells and causes airway smooth muscle 
contraction via stimulation of histamine receptors of the H1 subtypel-3. The 
presence of H2 receptors, which relax airway smooth muscle, has been de-
monstrated in monkey and rabbit trachea 4' 5 , but there is no valid evidence for 
relaxing H2 receptors on human airway smooth muscle6• Histamine contracts 
airways with a potency and efficacy comparable to those of acetylcholine, but 
is more potent in peripheral airways than in central airways4•7•8• 
Products of arachidonic acid metabolism 
Arachidonic acid is split from cell membrane phospholipids by the action of 
phospholipase A2. Arachidonic acid can be converted to prostaglandins and 
thromboxanes via the cyclo-oxygenase pathway, and to leukotrienes via the 
lip oxygenase pathway (Figure). 
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SYNTHESIS OF LEUKOTRIENES AND PROSTAGLANDINS 
Cell membrane 
Phospholipids 
I 
Arachidonic acid 
Lipoxygenase 
l 
f5-HPETE 1 
5-HETE LT~~ 
~ LTB4 
LTC4 
/ Diacylglycerol 
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Cyclooxygenase 
~ 6 keto PGF1a 
LTD4 
~ 
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Abbreviations: PL, phospholipase; HPETE, hydroxyperoxyeicosatetraenoic acid; 
HETE, hydroxy eicosatetraenoic acid; L T, leukotriene; PG, prostaglandin. 
Figure 1. Metabolism of arachidonic acid. 
Cyclooxygenase metabolites 
Human lung tissue homogenates and lung mast cell suspensions produce cyclo-
oxygenase metabolites spontaneously and after stimulation with calcium-iono-
phore, allergen or contracting agents like histamine or carbachol9-12. The main 
product is prostaglandin D2 (PGD2), followed by PGF2"', h, E2 and thromboxane 
(Tx) A2 and B/-14. In~ vivo, PGD2, PGF2a and TxA2 are bronchoconstrictors 
in man13'15-18, whereas PGE2 produces inconsistent effects15'19'20. In vitro, PGD2, 
PGF2"" and TxA2 contract human airway smooth muscle preparations3·14'21-25 , 
with a potency and efficacy that are equal or less than those of histamine. PGE2 
has produced paradoxical effects in vitro, and is not very effective21'22. PGh 
has no important direct effects on human airway smooth muscle25 , but may 
have a modulating role in the response to other agonists26, or on neuromuscular 
transmission27 . 
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PG's are released by canine, guinea-pig and human lung after smooth muscle 
contraction by acetylcholine or histamine25'28'29, which suggests that PG's mo-
dulate the effects of contracting agonists. Inhibition of this reactive PG synthesis, 
however, does not change the contractile response of human isolated air-
ways25'30'31. Therefore, PG's do not seem to have an important direct role in 
the control of human airway muscle contraction. 
In addition to their direct effects, prostaglandins and Tx analogues have a 
potentiating effect on cholinergic responsiveness in canine and guinea-pig central 
airways, either by increasing smooth muscle contractility or by enhancement 
of cholinergic neurotransmision32-35. PGE1 and Ez may inhibit cholinergic 
. . 32 36 37 c 1 b 1" h f 1 . fl neurotransm1ss10n ' ' . yc ooxygenase meta o 1tes may t ere ore a so m u-
ence airway smooth muscle responses by indirect presynaptic actions. Finally, 
PG's may have an effect on muscle cell-to-cell coupling, by changing the number 
and size of gap junctions39. PGE2 and PGiz increase the number of gap junctions 
in canine trachea, which could lead to an enhanced response to vagal stimulation 39. 
In vivo studies on the effects of PG synthesis inhibition on human bronchial 
responsiveness to histamine, however, have failed to show important changes 
in histamine-induced bronchoconstriction38. 
Lipoxygenase metabolites 
Leukotrienes (LT's), formerly known as SRS-A, are the lipoxygenase metabolites 
of arachidonic acid40,41. Several L T's are highly potent constrictors of human 
bronchus in vivo and in vitro42'49 • LTC4, D4, E4 and B4 are produced by human 
lung mast cells, alveolar macrophages, lung parenchyma and bronchus, and by 
eosinophils, after stimulation with e.g. calcium-ionophore or allergen, and can 
be recovered from the sputum of patients with obstructive lung diseases50'57 . 
Leukotrienes C4 and D4 are a 100-fold more potent than histamine in causing 
contraction of human airways in vitro42' 43 and a factor 1.000 - 10.000 more 
potent than histamine in causing bronchoconstriction in humans in vivo, whereas 
LTE4 is only 10 - 40 fold more potent than histamine47-49'58'59. The maximal 
effect of L T's is lower than that of acetylcholine or histamine in human airways 
in vitro, but not in vivo. LT's may be more potent in peripheral than in central 
airways60'61 . Apart from their effects on bronchial muscle, L T's can also contribute 
to airways obstruction by stimulating mucus secretion, inducing capillary 
leakiness, and attracting inflammatory cells60'62'63 . LTB4, that has only weak and 
indirect bronchoconstricting activity64, has a strong chemotactic effect53'65. In 
guinea-pigs and cats, part of the response of peripheral airway smooth muscle 
to L T's seems the consequence of synthesis of cyclooxygenase products, especially 
TxB2 66-71 . The effect of LT's on human airway smooth muscle is probably mainly 
a direct one60. Specific LT receptors have been demonstrated by radioligand 
binding studies and functional experiments on lung tissue from various animal 
species 72- 76. There is, however, no conclusive evidence for L T receptors on human 
airway muscle60'63'77' 78 • 
32 
In addition to their direct contractile effect on airway smooth muscle, L T's 
may have other actions that indirectly could influence airway smooth muscle 
responses. L T's may inhibit the formation of gap junctions in canine trachea39 , 
which might reduce the contractile response to vagal stimulation. Furthermore, 
experiments on guinea-pigs have suggested that L T's may reduce the response 
to ,B-adrenoceptor stimulation, and increase the effect of histamine79- 81 • These 
effects of L T's have only been reported for experimental animals, so their relevance 
for human bronchial hyperresponsiveness is still uncertain. Other lipoxygenase 
products, e.g. hydroxyeicosatetraenoic acid (HETE) may also have an effect 
on airway smooth muscle; there are, however, insufficient data to support a 
possible role in human airways smooth muscle control. 
Platelet activating factor 
Recently there has been interest in the role of platelet activating factor (P AF) 
in the pathogenesis of asthma82' 83 • PAF is a phospholipid mediator that can 
be released by platelets, leukocytes, mast cells and macrophages84• Although 
PAF produces bronchoconstriction and hyperresponsiveness in guinea-pig and 
man in vivo85' 86 , it has no direct effect on human airway smooth muscle in vitro2• 
It has been shown that PAP-induced airway obstruction in the guinea-pig in 
vivo is not due to muscle contraction86• Most evidence suggests that the actions 
of PAF on the lungs are mediated via its effects on microvascular permeability, 
its chemotactic potency and via the activation of inflammatory cells to produce 
other mediators, e.g. thromboxanes87- 89• 
Other mediators of inflammation 
Many more products of inflammatory cells are of interest for the pathophysiology 
of airways obstruction, e.g. major basic protein and eosinophilic cationic protein, 
superoxide radicals, proteolytic enzymes, bradykinin, adenosin and RETE's. 
Their effects on human airway smooth muscle, however, have not been examined 
in detail, or not at all. At present, there are insufficient data to support a direct 
action of most of these substances on human airway smooth muscle, although 
there may be important actions on other cell types in the lungs that may contribute 
to the development of obstructive lung disease90' 91 • 
References 
1. Hawkins DF, Schild HO. The action of drugs on isolated human bronchial chains. Br J 
Pharmacal 1951;6:682-690. 
2. Raffestin B, Cerrina J, Boullet C, Lebat C, Benveniste J, Brink C. Response and sensitivity 
of isolated pulmonary muscle preparations to pharmalogical agents. J Pharmacal Exp Ther 
1985;233:186-194. 
33 
3. Finney MJB, Karlsson JA, Persson CGA. Effects of bronchoconstrictors and bronchodilators 
on a novel human small airway preparation. Br J Pharmacoll985;85:29-36. 
4. Chand N, Dhawan BN, Srimal RC, Ramhani NH, Smukla RK, Altura BM. Reactivity of 
trachea, bronchi, and lung strips to histamine and carbachol in rhesus monkeys. J Appl Physiol 
1980;49:729-734. 
5. Kenakin TP, Beek D. A quantitative analysis of histamine H2-receptor mediated relaxation 
of rabbit trachea. J Pharmacal Exp Ther 1982;220:353-357. 
6. Vincenc K, Black J, Shaw J. Relaxation and contraction responses to histamine in the human 
lung parenchymal strip. Eur J Pharmacol1984;98:201-210. 
7. Armour CL, Black JL, Berend N. Histamine and carbachol contractile responses in proximal 
and distal airways of the rabbit. Clin Exp Pharmacal Physiol1985;12:19-23. 
8. Drazen JM, Schneider MW. Comparative responses of tracheal spirals and parenchymal strips 
to histamine and carbachol in vitro. J Clin Invest 1978;61:1441-1447. 
9. Steel J, Platshon L, Kaliner M. Prostaglandin generation by human and guinea pig lung tissue: 
comparison of parenchymal and airways responses. J Allergy Clin Immunol 1979;64:287-293. 
10. Adkinson NF, Newhall HM, Findley S, Adams K, Lichtenstein LM. Anaphylactic release 
of prostaglandins from human lung in vitro. Am Rev Respir Dis 1980;121:911-920. 
II. Schulman ES, Newhall HM, Demers LM, Fitzpatrick FA, Adkinson NF. Anaphylactic release 
of thromboxane Az, prostaglandin D2 and prostacyclin from human lung parenchyma. Am 
Rev Respir Dis 1981; 124:402-406. 
12. Peters SP, McGlashan DW, Schleimer RP, Hayes EC, Adkinson NF, Lichtenstein LM. The 
pharmacologic modulation of the release of arachidonic acid metabolites from purified human 
lung mast cells. Am Rev Respir Dis 1985;132:367-373. 
13. Robinson C, Holgate ST. The generation of prostaglandins by human lung and their effects 
on airway function in man. Bull Eur Physiopathol Respir 1986:22 (suppl 7):81-90. 
14. Zijlstra FJ, VincentJE, Bonta IL. The effects ofleukotrienes, thromboxaneA2 and phospholipase 
Az on human, porcine and guinea pig lung parenchyma. Agents Actions 1983;14:88-92. 
15. Smith AP, Cuthbert MF. Antagonistic action of aerosols of prostaglandins F2a and Ez on 
bronchial muscle tone in man. Br Med J 1972;III:212-213. 
16. Mathe AA, Hedqvist P, Holmgren A, Svanborg N. Bronchial hyperreactivity to prostaglandin 
F2a and histamine in patients with asthma. Br Med J 1973;1:193-196. 
17. Thomson NC, Roberts R, Bandouvakis J, Newhall H, Hargreave FE. Comparison of bronchial 
responses to prostaglandin F2a and methacholine. J Allergy Clin Immunol 1981;68:392-397. 
18. Fish JE, Newhall HM, Norman PS, Peterman VI. Novel effects of PGF2a on airway function 
in asthmatic subjects. J Appl Physiol1983;54:105-112. 
19. Smith AP. A comparison of the effects of prostaglandin E2 and salbutamol by intravenous 
infusion on the airways obstruction of patients with asthma. Br J Clin Pharmacol1974;1:399-
404. 
20. Walters EH, Davies BH. Dual effects of prostaglandin Ez on normal airways smooth muscle 
in vivo. Thorax 1982;37:918-922. 
21. Sweatman WJF, Collier HOJ. Effects of prostaglandins on human bronchial muscle. Nature 
1968;217:69-70. 
22. Gardiner PJ. The effects of some natural prostaglandins on isolated human circular bronchial 
muscle. Prostaglandins 1975;10:607-616. 
23. Ghelani AM, Holroyde MC, Sheard P. Response of human isolated bronchial and lung 
parenchymal strips to SRS-A and other mediators of asthmatic bronchospasm. Br J Pharmacal 
1980;71:107-112. 
24. Black JL, Armour CL, Vincenc KS, Johnson PRA. A comparison of the contractile activity 
of PGDz and PGF2a on human isolated bronchus. Prostaglandins 1986;32:25-31. 
25. Haye-Legrand I, Cerrina J, Raffestin B, Labat C, Boullet C, Bayol A, Benveniste J, Brink 
C. Histamine contraction of isolated human airway muscle preparations: role of prostaglandins. 
J Pharmacal Exp Ther 1986;239:536-541. 
26. Mugridge KG, Higgs GA, Moncada S, Prostacyclin modulates the responses to leukotrienes 
C4 and D4 of guinea-pig airway smooth muscle. Eur J Pharmacol1984;104:1-7. 
34 
27. Inoue T, Ito Y. Pre- and postjunctional actions of prostaglandin h, carbocyclic thromboxane 
A2 and leukotriene C4 in dog tracheal tissue. Br J Pharmacol1985;84:289-298. 
28. Yamaguchi T, Hitzig B, Coburn RF. Endogenous prostaglandins and mechanical tension in 
canine trachealis muscle. Am J Physioll976;230:1737-1743. 
29. Orehek J, Douglas JS, Lewis AJ, Bouhuys A. Prostaglandin regulation of airway smooth 
muscle tone. Nature 1973;245:84-85. 
30. Brink C, Grimaud C, Guillot C, Orehek J. The interaction between indomethacin and contractile 
agents on human isolated airway muscle. Br J Pharmacal 1980;69:383-388. 
31. Finney MJB, Berend N, Black JL. Cholinergic responses in the human lung parenchymal 
strip: a structure-function correlation. Eur J Respir Dis 1984;65:447-455. 
32. Nakanishi H, Yoshida H, Nakahata N, Suzuki T. Effects of prostaglandins on excitatory 
transmission in isolated canine tracheal muscle. Jpn J Pharmacal 1978;28:883-889. 
33. Chung KF, Evans TW, Graf PD, Nadel JA. Modulation of cholinergic neurotransmission 
in canine airways by thromboxane mimetic U-46619. Eur J Pharmacoll985;117:373-375. 
34. Omini C, Brunelli G, Daffonchio L, Mapp C, Fabbri L, Berti F. Prostaglandin D2 (PGD2l 
potentiates cholinergic responsiveness in guinea pig trachea. J Auton Pharmacal 1986;6:181-
186. 
35. Munoz NM, Shioya T, Murphy TM, Primack S, Dame C, Sands MF, Leff AR. Potentiation 
of vagal contractile response by thromboxane mimetic U-46619. J Appl Physiol1986;61:1173-
1179. 
36. Walters EH, O'Byrne PM, Fabbri LM, Graf PD, Holtzman MJ, Nadel JA. Control of 
neurotransmission by prostaglandins in canine trachealis smooth muscle. J Appl Physiol 
1984;57:129-134. 
37. Shaver-Madden K, Van der Kloot W. Indomethacin, prostaglandin E2 and transmission at 
the frog neuromuscular junction. J Pharmacal Exp Ther 1985;232:305-314. 
38. Walters EH. Prostaglandins and the control of airways responses to histamine in normal and 
asthmatic subjects. Thorax 1983;38: 188-194. 
39. Agrawal R, Daniel EE. Control of gap junction formation in canine trachea by arachidonic 
acid metabolites. Am J Physiol 1986;250: C 495-C505. 
40. Samuelsson B, Hammarstrom S, Murphy RC, Borgeat P. Leukotrienes and slow reacting 
substances of anaphylaxis (SRS-A). Allergy 1980;35:375-381. 
41. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow reacting substance 
of anaphylaxis: identification of leukotrienes C1 and D from human and rat sources. Proc 
Natl Acad Sci USA 1980;77:3710-3714. 
42. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors 
of human bronchi. Nature 1980;288:484-486. 
43. Hanna CJ, Bach MK, Pare PD, Schellenberg RR. Slow reacting substances (leukotrienes) 
contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981;290:343-
344. 
44. Holroyde MC, Altounyan REC, Cole M, Dixon M, Elliot EV. Bronchoconstriction produced 
in man by 1eukotrienes C and D. Lancet 198l;II:17-18. 
45. Holroyde MC, Altounyan REC, Cole M, Dixon M, Elliot EV. Leukotrienes C and D induce 
bronchoconstriction in man. Agents Actions 1981;11:573-574. 
46. Sirois P, Roy S, Tretrault JP, Borgeat P, Picard S, Corey EJ. Pharmacologic activity of 
leukotrienes A4, B4, C4 and D4 on selected guinea-pig, rat, rabbit and human smooth muscles. 
Prostaglandins Leukotrienes Med 1981;7:327-340. 
47. Weiss JW, Drazen JM, Coles N, McFadden ER, Weller PF, Corey EJ, Lewis RA, Austen 
KF. Bronchoconstrictor effects of leukotriene C in humans. Science 1982;216:196-197. 
48. Weiss JW, Drazen JM, McFadden ER, Weller P, Corey EJ, Lewis RA, Austen KF. Airway 
constriction in normal humans produced by inhalation ofleukotrine D. JAMA 1983;249:2814-
2817. 
49. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4, leukotriene 
D4 and histamine in normal human subjects. Thorax 1984;39:500-504. 
35 
50. McGlashan DW, Schleimer RP, Peters SP, Schulman ES, Adams GK, Newball HM, Lichtenstein 
LM. Generation of leukotrienes by purified human lung mast cells. J Clin Invest 1982;70:747-
751. 
51. Dahlen SE, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B. Allergen challenge 
of lung tissue from asthmatics elicits bronchial contraction that correlates with the release 
ofleukotrienes c., D., E •. Proc Nat! Acad Sci USA 1983;80:1712-1716. 
52. Borgeat P, Fruteau de Laclos B, Rabinovitch H, Picard S, Braquet P, Hebert J, Laviolette 
M. Generation and structures of the lipoxygenase products. J Allergy Clin Immunoll984;74:310-
315. 
53. Martin TR, Altman LC, Albert RK, Henderson WR. Leukotriene B. production by the human 
alveolar macrophage: a potential mechanism for amplifying inflammation in the lung. Am 
Rev Respir Dis 1984; 129:106-111. 
54. O'Driscoll BRC, Cromwell 0, Kay AB. Sputum leukotrienes in obstructive airways diseases. 
Clin Exp Immunol 1984;55:397-404. 
55. Bruynzeel PLB, Kok PTM, Vietor RJ, Verhagen J. On the optimal conditions of LTC. formation 
by human eosinophils in vitro. Prostaglandins Leukotrienes Med 1985;20:11-22. 
56. Sautebin L, Vigano T, Grassi E, Crivellari MT, Galli G, Berti F, Mezzetti M, Falco G. Release 
of leukotrienes, induced by the Ca++ ionophore A 23187, from human lung parenchyma in 
vitro. J Pharmacal Exp Ther 1985;234:217-221. 
57. Vigano T, Saute bin L, Magni F, Crivellari MT, Paganelli R, Galli G, Berti F, F oleo G. Stimulus-
related difference in the formation of leukotrienes and PGD2 after immunological and non-
immunological challenge of human lung parenchyma in vitro. Prostaglandins Leukotrienes 
Med 1986;23:109-115. 
58. Drazen JM. Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest 
1986;89:414-419. 
59. Davidson AB, LeeTH, Scanlon PD, Solway J, McFadden ER, Ingram RH, Corey EJ, Austen 
KF, Drazen JM. Bronchoconstrictor effects of leukotriene E. in normal and asthmatic subjects. 
Am Rev Respir Dis 1987;135:333-337. 
60. Lewis RA, Austen KF. The biologically active leukotrienes. J Clin Invest 1984;73:889-897. 
61. Hedqvist P, Dahlen SE, Gustafsson L, Hammarstrom S, Samuelsson B. Biological profile 
of leukotrienes c. and D •. Acta Physiol Scand 1980;110:331-334. 
62. Hammarstrom S, Lundberg JM, Hua XY, Dahlen SE, Hedqvist P. Action and metabolism 
of circulating leukotriene C. J Allergy Clin Immunol 1984;74:358-362. 
63. Feuerstein G. Autonomic pharmacology of leukotrienes. J Auton Pharmacoll985;5:149-168. 
64. Lawson C, Bunting S, Holzgrefe H, Fitzpatrick F. Leukotriene B. and 20-hydroxyleukotriene 
B. contract guinea pig trachea strips in vitro. J Pharmacal Exp Ther 1986;237:888-892. 
65. Bisgaard H. Leukotrienes and prostaglandins in asthma. Allergy 1984;39:413-420. 
66. Eichmann BH, Muccitelli RM, Osborn RR, Holden DA, Gleason JG, Wasserman MA. In 
vitro and in vivo mechanisms of leukotriene-mediated bronchoconstriction in the guinea-pig. 
J Pharmacal Exp Ther 1982;222:202-208. 
67. Zijlstra FJ, Vincent JE, Bonta IL. Separation of the two components of the contractile activity 
of leukotriene c. on the guinea-pig lung parenchymal strip. Prostaglandins Leukotrienes Med 
1983;11:385-389. 
68. Zijlstra FJ, Bonta IL, Vincent JE. Tachyphylaxis of leukotriene c.-induced release of 
thromboxane A2 from guinea-pig lung parenchyma and isoproterenol inhibition of this release. 
Adv Prostaglandin Thromboxane Leukotriene Res 1983;12:167-171. 
69. Creese BR, Bach MK, Fitzpatrick FA, Bothwell WM. Leukotriene- induced contraction and 
thromboxane production in guinea-pig lung parenchymal strips. Eur J Pharmacoll984;102:197-
204. 
70. Sirois P, Chagnon M, Borgeat P, Vallerand P. Role of cyclooxygenase products in the lung. 
Action of leukotrienes A., B., c., D. and E4• Pharmacology 1985;31:225-236. 
71. Graybar GB, Harrington JK, Cowen KH, Spannhake< EW, Hyman AL, McNamara DB, 
Kadowitz PJ. Cyclooxygenase mediated airway response to leukotriene D4 in the cat. 
Prostaglandins 1986;31:167-177. 
36 
72. Pong SS, Dehaven RN, Characterization of a leukotriene D. receptor in guinea-pig lung. Proc 
Nat! Acad Sci USA 1983;80:7415-7419. 
73. Kuehl FA, Dehaven R, Pong SS. Lung tissue receptors for sulfidopeptide leukotrienes. J Allergy 
Clin Immunol1984;74: 378-381. 
74. Snyder DW, Krell RD. Pharmacological evidence for a distinct leukotriene c. receptor in 
guinea-pig trachea. J Pharmacal Exp Ther 1984;231:616-622. 
75. Cheng JB, Lang D, Bewtra A, Townley RG. Tissue distribution and functional correlation 
of 3H leukotriene C4 and 3H leukotriene D 4 binding in guinea-pig uterus and lung preparations. 
J Pharmacal Exp Ther 1985;232:80-87. 
76. Mong S, Scott MO, Lewis MA, Wu HL, Hogaboom GK, Clark MA, Crooke ST. Leukotriene 
E. binds specifically to LTD. receptors in guinea-pig lung membranes. Eur J Pharmacal 
1985;109:183-192. 
77. Buckner CK, Krell RD, Laravuso RB, Coursin DB, Bernstein PR, Will JA. Pharmacological 
evidence that human intralobar airways do not contain different receptors that mediate 
contractions to leukotriene c. and leukotriene D •. J Pharmacal Exp Ther 1986;237: 558-562. 
78. Cheng JB, LTC. 'receptor': its demonstration using airway and non- airway tissues. Trends 
Pharmacal Sci 1986;477. 
79. Stewart AG, Thompson DC, Fenessy MR. Leukotriene D4 potentiates histamine-induced 
bronchoconstriction in guinea-pigs. Agents Actions 1984;15:146-152. 
80. Daffonchio L, Abbracchio MP, Hernandez A, Giani E, Cattabeni F, Omini C. Arachidonic 
acid matabolites induce j3-adrenoceptor desensitization in rat lung in vitro. Prostaglandins 
1985;30:799-809. 
81. Fennessy MR, Stewart AG, Thompson DC. Aerosolized and intravenously administered 
leukotrienes: effects on the bronchoconstrictor potenty of histamine in the guinea-pig. Br J 
Pharmacoll986;87:741-749. 
82. Morley J, Sanjar S, Page CP. The platelet in asthma. Lancet 1984; II:l142-1144. 
83. Morley J. Platelet activating factor and asthma. Agents Actions 1986;19:100-107. 
84. Beneveniste J. PAF-acether (platelet-activating factor). Bull Eur Physiopathol Respir 
1986;22(suppl 7):91-94. 
85. Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary 
function and bronchial responsiveness in man. Lancet 1986;II:l89-192. 
86. Barnes PJ, Grandordy BM, Page CP, Rhoden KJ, Robertson DN. The effects of platelet 
activating factor on pulmonary j3-adrenoceptors. Br J !'harmacoll987;90:709-715. 
87. Burhop KE, Garcia JGN, Selig WM, Lo SK, VanderZee H, Kaplan JE, Malik AB. Platelet-
activating factor increases lung vascular permeability to protein. J Appl Physiol 1986;61:2210-
2217. 
88. Chung KF, Aizawa H, Leikauf GD, Ueki IF, Evans TW, Nadel JA. Airway hyperresponsiveness 
induced by platelet-activating factor: role of thromboxane generation. J Pharmacal Exp Ther 
1986;236:580-584. 
89. Massmann H, Bamberger U, Velev BA, Gehrung M, Hammer DK. Effect of platelet-activating 
factor on human polymorphonuclear leukocyte enhancement of chemiluminiscence and an-
tibody-dependent cellular cytotoxicity. J Leukocyte Bioll986;39:153-165. 
90. Venge P. Inflammation and mediators in asthma. In: Kerrebijn KF, Sluiter MJ, eds. Nocturnal 
dyspnea, inflammation and reactivity. Astra Symposium 1986:93-105. 
91. Raphael GD, Metcalfe DD. Mediators of airway inflammation. Eur J Respir Dis 1986;69(suppl 
147):44-56 .. 
Chapter 4 
Bronchial hyperresponsiveness 
Introduction 
Bronchial hyperresponsiveness is defined as an exaggerated bronchoconstrictor 
response to physical, pharmacological and chemical stimuli, such as inhaled 
histamine, sulphur dioxyde or cold, dry air, that do not have this effect in normal 
subjects1'2 • Bronchial hyperresponsiveness is a characteristic of asthma, is common 
in chronic bronchitis with airflow limitation, and is sometimes present in patients 
with allergic upper airway disease1'3• There is a clear correlation between the 
degree of bronchial responsiveness and the severity of asthmatic symptoms2 , 
and hyperresponsiveness is regarded as a risk factor for the development of 
chronic airflow limitation4• 
In vivo, bronchial responsiveness is assessed by measuring a lung function 
index that reflects airway caliber (e.g. the forced expiratory volume in 1 sec, 
FEV1, or the specific conductance, sGA W) before and after inhalation of a 
bronchoconstricting agonist such as histamine or methacholine. The agonist is 
administered repeatedly in doubling doses, and the test is continued until a 
certain degree of airflow limitation has occurred. From ·the measured values, 
the provocative dose (PD) of the agonist that produced a defined fall in FEV1 
or sGA W, is interpolated5• 
In many asthmatic patients, airway obstruction can be provoked to a degree 
that causes severe respiratory distress, even when starting the test with a normal 
baseline lung function. It is not possible, therefore, to measure a maximal effect, 
or a response plateau, in vivo in those subjects. In some normals, most subjects 
with chronic bronchitis and airflow limitation, and in patients with mild asthma, 
the induced bronchoconstriction reaches a plateau response after relatively high 
agonist doses6- 8• In patients with chronic bronchitis, but not in most asthmatics, 
the degree of bronchial hyperresponsiveness is correlated with baseline airway 
caliber9' 10• 
The different characteristics of the response to inhaled bronchoconstrictors 
in patients with asthma and chronic bronchitis have suggested that there may 
be fundamental differences in the pathophysiology of bronchial hyperrespon:-
siveness between these two groups3' 6' 11 • The mechanisms that cause either type 
of hyperresponsivenes& are, however, not clear. This is reflected by the large 
number of hypotheses that try to explain bronchial hyperresponsiveness1·2·12·13 • 
In this chapter, the various possible mechanisms of bronchial hyperresponsiveness 
will be reviewed. 
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Endogenous factors in bronchial hyperresponsiveness 
Genetic factors 
Family studies, studies in monozygotic twins, and animal experiments have 
indicated that bronchial hyperresponsiveness in asthma, chronic bronchitis and 
allergic upper airway disease is a heritable trait14-17 • A considerable genetic 
heterogeneity seems present, and environmental factors, such as cigarette smo-
king, exposition to allergens, and viral infections, will determine the outcome 
in a given individual to an important extent16. It has been suggested that asthma 
and chronic bronchitis have a common genetic base: the 'Dutch Hypothesis' 18. 
This concept awaits confirmation from long-term follow-up studies19. 
Autonomic dysbalance 
The possibility of an abnormal control of airway caliber by the autonomic nervous 
system has drawn attention for many years20'21 . An increased activity of the 
cholinergic system22, impaired relaxation to, or secretion of circulating cate-
cholamines23-26 or an increased a-receptor-mediated bronchoconstriction27•30, a 
decreased inhibition by the NAI system31'32 or an enhanced activity of local 
..reflexes with release of neuropeptides33'34 have been put forward. Several of these 
theories are not yet supported by findings in humans, or do not explain the 
c f if' b h' 1 h . 21 35-37 ~eatures o nonspec 1c ronc 1a yperresponstveness ' . 
Inflammatory mediators 
Asthmatics are hyperresponsive in vivo to a number of inflammatory mediators, 
including PGD2, PGF2"' and severalleukotrienes38-45 . LTB4 and PAF have been 
shown to induce bronchial hyperresponsiveness in experimental animals and 
humans, respectively46'47 and LTC4 enhances methacholine responsiveness in 
man48. The release of prostaglandins, leukotrienes, histamine, chemotactic factors 
and platelet activating factor during the course of an asthmatic attack has been 
documented in man 49-52. 
In asthmatics, mediator releasing cells (basophils, neutrophils, eosinophils, 
macrophages and mast cells) may have an increased ability to release mediators 
and oxygen radicals53-60. Animal experiments have suggested, that different classes 
of mediators may augment the response to cholinergic nerve stimulation, modulate 
ganglionic transmission, enhance smooth muscle contractility, decrease fi-receptor 
function or inactivate relaxing peptide transmitterl1'61-66 • Interaction of mediator 
classes further complicates this picture64. 
The inflammatory reaction that is caused by the released mediators will produce 
mucosal swelling due to extravasation of plasma and accumulation of inflam-
matory cells67 . Increased mucosal thickness and epithelial disruption may further 
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contribute to bronchial hyperresponsiveness68'69. The direct and indirect effects 
of inflammatory mediators, their release in asthmatics, and their capacity to 
produce airway wall thickening make them likely candidates to play a role in 
the pathogenesis of bronchial hyperresponsiveness70-76. It is unlikely, however, 
that any single mediator will play a key role. 
Airway epithelium 
It has been speculated that an increased permeability of the bronchial epithelium, 
or a decreased production of smooth muscle relaxing factors by the epithelium, 
might cause bronchial hyperresponsiveness77- 81 . Epithelial damage results from 
exposure to cigarette smoke or viral infections, and has been demonstrated in 
vivo in man 82•83 . An intrinsically abnormal structure of the epithelium seems 
to be present in asthmatics84'85 . It seems unlikely, however, that bronchial 
hyperresponsiveness in man is due to the increased permeability of airway 
epithelium82'86. In guinea-pigs and dogs, but not yet in man, bronchial epithelium 
has been shown to produce a muscle relaxing factor77'87'88. In man, the epithelium 
of central airways can produce lipoxygenase and cycloxygenase metabolites of 
arachidonic acid89'90 that, however, have bronchoconstricting activities. 
Abnormal airway mechanics 
Airway smooth muscle contraction in vivo and in vitro is different in that the 
maximal shortening to 20% of the initial length that is possible in vitro certainly 
does not occur in vivo. In stead of trying to explain bronchial hyperresponsiveness, 
which can be predicted from the shortening capacity of normal airway smooth 
muscle cells, the question should be answered why normals do not respond 
or develop only a mild bronchoconstriction during bronchoprovocation tes-
ting91'92. The most likely explanation for this seems, that elastic forces from 
the surrounding structures prevent maximal muscle contraction in vivo. A 
decreased tethering effect of the lung tissue opposing the contractile force of 
airway smooth muscle could then lead to bronchial hyperresponsiveness69 . 
Alternatively, if in hyperresponsive subjects the resting muscle length were 
more near optimal length compared to the resting length in normals, an increased 
contractility could result. It has been shown in dogs that hyperinflation, i.e. 
stretching of the muscle, increases bronchial responsiveness93. This suggests that, 
at resting lung volume, the muscle was not at its optimal length. 
Finally, a given degree of smooth muscle contraction will produce an increased 
airflow resistance dependent on the thickness of the mucosa69'94. Small increases 
in mucosal thickness can therefore enhance the effect of muscle contraction 
considerably. 
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Abnormal airway smooth muscle cells 
The non-specificity of bronchial hyperresponsiveness suggests an end organ 
abnormality. An intrinsic defect of airway smooth muscle may therefore underly 
bronchial hyperresponsiveness. This possibility will be discussed in the next 
chapter. 
Exogenous factors in bronchial hyperresponsiveness 
Allergy 
A high percentage of asthmatics is allergic to airborne allergens. Allergic 
provocation leads to a direct, and often also a late asthmatic reaction, initiated 
by t ne release of mediators from mast cells and, perhaps, other cell types in 
the airways95 • During late phase reactions, eosinophil numbers in the blood 
are elevated96 and increased numbers of eosinophils are present in the airway 
lumen97 • Activation of eosinophils may play a role in the pathogenesis of the 
late reaction by the release of toxic substances such as major basic protein98 • 
There is also evidence of neutrophil activation during late phase allergic 
reactions99 • In rabbits it has been shown that, for the development of a late 
phase reaction, neutrophils are already required at the time of the allergen 
challenge100• In humans, it is likely that the early reaction to allergen results 
from direct effects of mediators, whereas the late phase is the consequence of 
an inflammatory reaction of the bronchial mucosa 101 • In asthmatics, bronchial 
hyperresponsiveness increases shortly after the early reaction, and may remain 
elevated for days or even weeks102' 103 • The mechanism of this increase is therefore 
possibly related to the inflammatory reaction 104• 
Infection 
Viral respiratory tract infections can induce or worsen bronchial hyperrespon-
siveness for days or weeks105- 109• Inflammation of the bronchial mucosa may 
play an important role in virus-induced hyperresponsiveness. It has been shown 
that influenza virus causes inflammation of the bronchial mucosa in normals 
. . 110 
without pulmonary symptoms . 
If mediator release is exaggerated in asthmatics, this would give rise to a 
more severe inflammatory reaction in asthmatic airways, and this might cause 
an increased bronchial responsiveness as discussed previously104' 111 • It has been 
suggested that viral infections of small airways (bronchiolitis) may predispose 
d. f h . 112 to or pre 1ct uture ast mat1c symptoms . 
It is not clear why in man bacterial infections usually do not lead to bronchial 
hyperresponsiveness, despite massive infiltration of the airways with neutrophils, 
and extensive epithelial damage. In guinea-pigs; bronchial hyperresponsiveness 
41 
has been evoked by administering haemophilus influenzae113• Tliis effect might 
be due to hydroxyl radical production by alveolar macro phages, which attennuates 
/3-receptor function 114. 
Occupational stimuli, air pollution, ozone and cigarette smoke 
Chronic exposure to noxious gases, such as toluene diisocyanate (TDI) or sulphur 
dioxyde, leads to bronchial hyperresponsiveness and symptoms of asthma. These 
effects are probably mediated by airway inflammation115-117, although direct 
effects on airway smooth muscle may also play a role118• 
Administration of ozone to dogs, guinea-pigs or humans leads to in vivo 
bronchial hyperresponsiveness that lasts for several days 119-121 • This is associated 
with inflammation of the mucosa, and may be mediated by synthesis of 
arachidonic acid metabolites 122-124. 
Cigarette smoking has been reported to increase bronchial responsiveness in 
some subjects, but not in others125'126• The effect is dose-related, and is also 
related to changes in baseline airway caliber11 . Bronchial hyperresponsiveness 
in smokers differs from that in asthmatics because smokers do not respond 
to a-agonist provocation, are more reactive to histamine than to methacholine, 
and usually have a maximal response plateau in their response to inhaled 
histamine 11 . Inflammation is probably also an important determinant of smoking-
induced hyperresponsiveness 127• The degree of cigarette smoke-induced epithelial 
permeability does, however, not correlate with the degree of bronchial hyper-
responsiveness82'86. Finally, smoke may produce bronchoconstriction via stimu-
lation of vagal reflex activity and by stimulation of ganglionic nicotinic recep-
tors128. 
Summary 
From the literature it seems likely that endogenous and exogenous factors interact 
in an complex fashion to produce bronchial hyperresponsiveness. The various 
putative mechanisms that may lead to hyperresponsiveness are depicted sche-
matically in the Figure. 
An important feature in bronchial hyperresponsiveness is airway wall inflam-
mation. Most exogenous factors seem to have their effect on bronchial respon-
siveness by inducing or enhancing airway wall inflammation. Most of the proposed 
'intrinsic defects' might not be the cause, but the result of the inflammatory 
reaction, because mediators may modify the autonomic balance, smooth muscle 
function, and epithelial structure. Theoretical calculations and preliminary 
experimental data suggest that mechanical factors may well be important. 
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BRONCHIAL HYPERRESPONSIVENESS 
Figure 1. Mechanisms in bronchial hyperresponsiveness. 
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Chapter 5 
Airway smooth muscle and airway responsiveness 
Aims of the studies 
Introduction 
The function of airway smooth muscle in normal subjects is not evident. Possible 
physiological roles include maintenance of optimal regional ventilation/perfusion 
ratios, reduction of anatomic dead space, stabilisation of cartilaginous bronchi, 
defense against impurities and, less likely, squeezing mucus out of mucous glands 
and pulling open the alveoli next to the airways1. Any role of airway smooth 
muscle is necessarily limited, because an important degree of contraction will 
lead to airway narrowing and to an increased work of breathing. There is, however, 
no doubt that in asthma the acute bronchoconstriction following exposure to 
nonspecific or allergic stimuli is due to airway smooth muscle contraction. Most 
research on airway smooth muscle function has therefore concentrated on 
clarifying its role in bronchial hyperresponsiveness, airway obstruction and 
allergy. 
From the foregoing chapters it can be concluded that many factors may be 
involved in the pathogenesis of the abnormal responsiveness of airway smooth 
muscle in patients with asthma or chronic bronchitis. One of these factors is 
an intrinsic abnormality of the airway smooth muscle cells. In order to examine 
this, several animal models have been developed, most of which have features 
in common with human allergic bronchoconstriction2• Because of important 
differences between species, and because there is no satisfactory animal model 
of spontaneous, non-allergic asthma, it is crucial to study human airway smooth 
muscle from subjects with and without airway hyperresponsiveness. The research 
on human lung tissue in vitro has been limited by the supply, and by difficulties 
in obtaining stable and reproducible responses of airway smooth muscle in vitro. 
Moreover, it is very difficult to obtain lung tissue from asthmatic subjects. 
This chapter will give a summary of the research on airway smooth muscle 
hyperresponsiveness in experimental animals and man. From these data, the 
aims of the studies to be presented in parts II and III will be derived and briefly 
outlined. 
Hyperresponsiveness as a smooth muscle abnormality 
Airway smooth muscle cells can be hyperresponsive by being more sensitive 
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Figure 1. Types of smooth muscle hyperresponsiveness. Curve A: normal. Curve B: Increased sensitivity 
(deviation supersensitivity, prejunctional supersensitivity, type I); Curve C: Increased maximal 
response (non-deviation supersensitivity, postjunctional supersensitivity, type II); Curve D: com-
bination of B and C. 
to contracting agents, i.e. responding at lower agonist concentrations; by having 
a greater maximal response to 'normal' agonist concentrations, or by a com-
bination of these two possibilities (Figure 1 ). The first possibility is a consequence 
of changes in agonist-receptor interaction, and has also been called 'deviation 
supersensitivity' 'prejunctional supersensitivity' 'or 'type I supersensitivity'. The 
second type of hyperresponsiveness is due to post-receptor changes in the 
excitation-contraction coupling or in the contractile apparatus, and has also 
been called 'non-deviation supersensitivity' 'postjunctional supersensitivity' or 
'type II supersensitivity'3' 4 • Abnormalities of virtually all processes, described 
in chapter 2, that are involved in the contractile response of airway smooth 
muscle might produce hyperresponsiveness. 
An increased sensitivity could result from increased numbers or affinities of 
receptors for contracting agonists or, conversely, from a decrease in the number 
or affinity of relaxing receptors 5• Partial depolarisation of the cell membrane 
could also increase smooth muscle sensitivitl. 
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Increased maximal responses of muscle cells might result from abnormalities 
in the excitation-contraction coupling, e.g. an enhanced release of Ca7 , or from 
an abnormal structure or quantity of the contractile proteins or the enzymes 
necessary for their activation 1• Increased activity of cross-bridges, a decreased 
parallel elastic component or abnormal length-active tension relationships could 
also favour an increased contractile response1• When we consider not individual 
cells, but muscle tissue, several other putative mechanisms may cause an increased 
maximal response, such as an increased cell-to-cell coupling by gap junctions, 
which could lead to single unit behaviour8 • The net effect of an increase in 
the number or size of gap junctions is not necessarily hyperresponsiveness, 
however, beacause this will depend on the balance between excitatory and 
inhibitory influences. Finally, an increased amount of muscle cells will lead to 
a higher maximal response. Muscle hypertrophy is a characteristic of human 
asthmatic bronchi9• 
Before these putative mechanisms can be examined, the question needs to 
be answered whether there is a primary smooth muscle abnormality in human 
bronchial hyperresponsiveness or airway obstruction. 
The guinea-pig model 
In guinea-pigs with spontaneous variations in histamine responsiveness of the 
airways, no relation was found between the histamine response in vivo and the 
histamine sensitivity of tracheal smooth muscle in vitro 10 • Several authors have 
reported that guinea-pigs that had been sensitized to egg-albumen have a decreased 
sensitivity and maximal contractility of their tracheal smooth muscle to histamine 
and methacholine in vitro 11' 12• Others, however, have reported an increased 
maximal responsiveness in this model13 • 
The maximal effect of /3-receptor stimulation in sensitized guinea-pig trachea 
appeared to be reduced 11 in a similar fashion as in the Haemophilus- inoculated 
guinea-pig14• There is some indirect evidence that in sensitized guinea-pig trachea 
the effect of stimulation of the NAI system is also less than in control tissue15• 
Measurement of the membrane potential of tracheal smooth muscle cells from 
sensitized guinea-pigs has shown that repeated allergen challenge causes a slight 
hyperpolarization of the cell membrane, that may be due to potentiation of 
the electrogenic sodium pump6•16• 
The dog model 
The trachealis muscle of dogs that are allergic to Ascaris relaxes less to iso-
proterenol than non-allergic control tissue, and has an increased maximal response 
to methacholine17 • These changes have been attributed to a basally low con-
centration of cAMP in the muscle cells 18• In this same model, however, others 
have found no in vivo hyperresponsiveness to histamine, acetylcholine or 
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serotonin 19, whereas a selectively enhanced response of sensitized dog trachealis 
muscle to serotonin, but not to acetylcholine, has also been reported20. 
The tracheal muscle from dogs allergic to egg albumen is also hyperresponsive 
to histamine in vitro, both with respect to sensitivity and maximal effece1. In 
this model, subtle changes have been demonstrated in the mechanical response 
to electric field stimulation in vitro22• An increased velocity of shortening, 
myogenic responses after a quick stretch and an increased capacity to shorten 
have been reported, and these changes might be due to an increased activity 
of rapidly cycling cross-bridges23 . 
Dogs sensitized to ragweed have hyperresponsiveness to histamine and metha-
choline in vivo24• In vivo studies on dogs allergic to ragweed have shown that 
a cyclo-oxygenase product, probably thromboxane, may be involved in the 
pathogenesis of allergic airway hyperresponsiveness25 . 
The sheep model 
Sheep that are allergic to Ascaris are hyperresponsive to H1-receptor stimulation 
with histamine in vivo, probably because of a functional depression of relaxing 
H2-receptors26. Isolated tracheal smooth muscle from this animal model, however, 
has no increased response to histamine and other contracting agonists27 . Lung 
parenchymal strips of sheep allergic to Ascaris showed an increased response 
to histamine and other contracting agonists27. Lung parenchymal strips of sheep 
allergic to Ascaris showed and increased maximal response to a thromboxane 
analogue and to histamine, but not to PGF2" and methacholine27• 
Studies on human airway smooth muscle 
In 1951, Schild et al concluded that histamine was of major importance in human 
allergic asthmatic bronchoconstriction28 on the basis of an experiment with 
bronchi from a single asthmatic. More than 30 years later, Dahlen et al did 
similar experiments on human lung tissue from two asthmatic patients and 
concluded that leukotrienes, but not histamine, were important in human allergic 
asthma29. Since then, functional studies on asthmatic human airways in vitro 
have produced evidence of an increased maximal contractility to histamine, L TC4 
and carbachol, and of a decreased sensitivity and maximal response to iso-
proterenol and other sympathomimetics30-35. There are however many discre-
pancies in the results of this relatively small number of reports, that clearly 
illustrate the confusion that has resulted from examining small numbers of 
asthmatic human airways in vitro with large differences in methodology and 
patient selection. 
More work has been done on airway smooth muscle from better defined 
populations of non-asthmatic humans with and without bronchial hyperrespon-
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siveness, who were operated for bronchial carcinoma. These studies have mainly 
concentrated on the sensitivity of isolated airways to constricting agents, and 
not on their maximal effect, because of a troublesome variability of maximal 
responses within- subjects. None of the studies has shown a significant correlation 
between the degree of bronchial hyperresponsiveness in vivo and the sensitivity 
of airway smooth muscle to histamine or methacholine in vitro33' 36- 41 • Also, no 
differences were found in the relaxation responses of non-asthmatic airways to 
sympathomimetics or forskolin35' 41 and to stimulation of the NAI system 41 • Only 
small numbers of patients were studied, however. There are few reports on the 
responsiveness of passively in vitro sensitized non-asthmatic human airways. It 
has been shown that house-dust mite- or ragweed-induced contractions of 
sensitized human airways in vitro were due to release of prostaglandins, leu-
kotrienes and histamine42'43 , but, unfortunately, the effects of the sensitization 
procedure on smooth muscle function has not been examined. 
Aims of the studies 
From the data in the literature we can conclude, that: 
1. Animal models have not been very helpful, due to the many differences between 
species with respect to airway smooth muscle function and its control, and 
the effects of sensitization. Different investigators have produced contradictory 
results. 
2. Calculations on the reproducibility of the in vitro studies on human airways 
are lacking, especially regarding the within- subjects variation. This makes 
interpretation of previous studies difficult. Moreover, most studies have been 
done using isometric transducers. This provides no insight in the shortening 
capacity of the muscle, which may be more relevant than force. 
3. It is not possible to draw conclusions from studies on asthmatic human airways 
in vitro, because of the small number of patients and important methodological 
differences between the studies. 
4. There has not been much interest in the relaxation responses of human isolated 
airways in relation to airway obstruction and hyperresponsiveness. 
5. Structure-function correlation studies on human airways and studies on 
mechanics of human airway smooth muscle contraction are virtually lacking. 
The studies presented in this thesis were undertaken to clarify the role of human 
airway smooth muscle and its autonomic control in airway obstruction and 
hyperresponsiveness. The following questions were addressed. 
1. Is it possible to obtain reproducible and accurate measurements of the 
sensitivity and contractility of human isolated airway smooth muscle pre-
parations to contracting and relaxing agonists? 
2. Is airway smooth muscle function abnormal in patients with chronic bronchitis 
or asthma and bronchial hyperresponsiveness? Specifically: is the response 
to contracting agonists increased or the response to relaxing agonists decreased? 
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3. Is the function of human airway smooth muscle related to the degree of 
airway inflammation? 
4. Are there abnormalities in the autonomic innervation of the airways in patients 
with asthma or chronic bronchitis and bronchial hyperresponsiveness? 
For this purpose, we have developed a technique to measure the mechanical 
responses of human isolated airways reproducibly, with sufficient accuracy to 
detect differences between subjects. In part II, these methods and their repro-
ducibility are described in detail. In part III, the results are reported of studies 
on human airway smooth muscle function in relation to clinical signs and 
symptoms of chronic bronchitis and airflow limitation, asthma, bronchial 
hyperresponsiveness and airway inflammation, followed by a summary and 
general discussion. 
Note on terminology 
The terms 'chronic obstructive bronchitis' and 'chronic obstructive pulmonary 
disease', or COPD, have been used depending on whether a study has been 
published in, or submitted to, a British or an American journal, respectively. 
'Chronic bronchitis' is defined as proposed by the Medical Research Council44 
as a syndrome of chronic cough and sputum production on most days during 
at least three consecutive months each year, for more than two successive years. 
The term 'obstructive' indicates chronic airflow limitation, and is usually defined 
as an FEV1/VC ratio lower than 70% or more than 1.64 standard deviations 
below mean predicted values45 . 'Chronic obstructive pulmonary disease' is defined 
according to criteria of the American Thoracic Society, and is synonymous with 
chronic obstructive bronchitis46• 
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Measurement of human airway smooth muscle 
function in vitro 

Chapter 6 
Measurement of human small airway smooth muscle function 
in vitro with the bronchiolar strip preparation 
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Summary 
The technique by which human bronchiolar strips are prepared is described 
in detail. The biological viability of the preparations after storage at 4°C overnight 
and the reproducibility of contractile responses to KCl and methacholine were 
examined in lung tissue from six patients. Measurements were performed on 
the first and second day after surgical resection. On both days, most bronchioles 
showed an increase in contractility. The responses on the first day were not 
different from those on the second day. No significant changes in time were 
found for EC5o and slope of the methacholine concentration- response curves. 
The variability of responses between-patients was significantly larger than 
between-strips within-patients. The ECso was the best reproducible parameter. 
Key words: human bronchiolar strip, airway smooth muscle, methacholine, KCL 
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Introduction 
Attempts to measure human airway smooth muscle function in vitro have been 
made by using slices of lung tissue\ bronchial chains2, tubes and spirals3, and 
strips of lung parenchyma4• Lung tissue is usually obtained from autopsies up 
to 14 hours post mortem5 and from thoracotomies performed because of bronchial 
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carcinoma6• We have developed a technique to prepare human bronchioles under 
standardised conditions using lung tissue obtained from thoracotomies to avoid 
the influence of hypoxia, which is present in autopsy tissue. 
Little information is available on the reproducibility of contractile responses 
from different comparable sized airway preparations obtained from the same 
specimen of human lung tissue. We therefore compared within-patient variability 
of bronchiolar responsiveness and between-patient variability. Furthermore, we 
studied the reproducibility of contractile responses within a 55 h postoperative 
period including two episodes of storage in cooled buffer. 
Methods 
Human lung tissue was obtained from thoracotomies, usually performed because 
oflung cancer. Immediately after surgical resection, a specimen of macroscopically 
normal lung tissue, containing airways of 1-2 mm in diameter, was obtained. 
The tissue was immediately submerged in Krebs buffer at 0°C (composition 
in mM: NaCl 118, KCl 4.7, CaCh 2.5, MgS04 1.2, KH2P04 1.2, NaHC03 25, 
glucose 5.55), which was aerated with carbogen (95% 02, 5% COz). 
After rapid transport to the laboratory, the tissue was washed several times 
to remove the blood. In the cut surface, bronchioles with a diameter of 1-2 
mm were identified and cannulated while the tissue remained in buffer. To 
ascertain that these were really airways, air was inflated gently into the cannula 
with a 5 ml syringe, to obtain tissue inflation. The cannulae were left in place 
to indicate the direction of the bronchiole, which facilitates its preparation. After 
cannulation, all bronchioles were cut from the tissue, leaving a rim of parenchyma 
in place to avoid damage. Care was taken not to squeeze or stretch the bronchiole. 
Subsequently, the bronchioles were placed over a stainless steel rod by positioning 
the cannula, which was still in place, end-to-end to the rod and then moving 
the airway segment over the rod. A small segment of the bronchiole was cut 
off for histological examination. 
Under a binocular preparation microscope (magnification 20 x) the bronchioles 
were then prepared as free as possible from blood vessels, lymphatic tissue, 
and parenchyma using iris scissors. The tissue remained in fresh buffer. The 
bronchiolar tube was spiralised to obtain a strip measuring 20x2 mm. Utmost 
care was taken to avoid applying any force to the tissue as this is deleterious 
for its contractile function. Thin surgical silk threads were tied to both ends 
of the strip. 
From most lung tissue specimens, at least 4 to 6 strips of similar size could 
be prepared. After completion, which takes about a quarter of an hour for 
each preparation, the strips were stored overnight in cooled (4°C) Krebs buffer 
containing penicillin (3xl0-5 g/1) and tobramycin (5xl0-3 g/1). Carbogen was 
bubbled through the buffer, and a perfusion pump changed the total bath volume 
every hour continuously in order to wash out substances possibly liberated during 
the preparation procedure and the narcotics (see below). 
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The following day, 20 hours postoperatively, the bronchioles were mounted 
in 10 ml double-jacketed organ baths containing Krebs buffer at 37°C, aerated 
with carbogen (pH 7.35, Pc02 4.6 kPa, P02 71.8 kPa). One thread was fixed 
to a glass hook in the bottom of the organ bath and the other to a Grass 
FT03D isometric force transducer, which could be moved vertically with a 
micrometer screw (Figure 1). The transducers were coupled via a carrier wave 
amplifier (Peekel instruments, The Netherlands) to a digital voltmeter and to 
a Rikadenki multichannel pen recorder. Before the measurements were started, 
the bronchioles were allowed to equilibrate for 2 h under an isometric tension 
of 500 mg, which was restored every 15 min when necessary. Preliminary 
experiments had shown that this resting tension resulted in optimal contractile 
force. 
The bath fluid was changed every 15 min during this period. Pharmacological 
Figure 1. Bronchiolar strip (B) mounted in the organ bath. The strip is attached to an isometric 
transducer (T) which can be moved vertically with a micrometer screw. 
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stimulation was carried out by adding agonists in small (50 ,ul or less) volumes. 
In this way, cumulative concentration-response curves (CCRC) were obtained. 
After each complete curve, the bath fluid was changed four times with 2 min 
intervals. 
Results were expressed as mg force per mg dry weight of the bronchiole and 
also as mg force per mg of protein present in the strip. For this purpose the 
bronchioles were dried for 48 hat room temperature and weighed after completion 
of all measurements. Subsequently the amount of protein in each strip was 
determined colorimetricalll. 
The viability of the bronchioles after storage and the reproducibility of 
responses thus obtained is illustrated by a study in which 18 bronchioles from 
6 patients (three bronchioles from each patient) were stimulated repeatedly over 
a 55 h period. Lung tissue was obtained from six consecutive thoracotomies. 
The patients' ages ranged from 57 to 72 years; five had bronchial carcinoma 
and one had a bronchopleural fistula (patient 2). Premedication and anesthetics 
were the same for all patients: atropine, thiopentone, fentanyl, Oz/NzO, halothane, 
and pancuronium. Each bronchiole was examined on the first and second day 
after thoracotomy. On both days, two complete methacholine CCRC (10-8 to 
10-4M) were made, preceded and followed by a single contraction evoked by 
adding high-potassium Krebs buffer that contained 118 mM KCl instead of 
NaCl (Figure 2). After completion of the measurements on the first day, the 
strips were transferred to the storage vessel for storage overnight and were 
remounted in the organ baths the next morning, followed by 2 h of equilibration 
at 37°C as described above. Before each drug exposure, the resting tension was 
readjusted to 500 mg. 
The following parameters were measured: -log EC5o: the negative logarithm 
of the methacholine concentration that caused 50% of the maximal contraction; 
T max: the maximal tension corrected for dry weight or for protein content of 
the bronchiole; and the slope of the linear part of the CCRC, expressed as 
0 3 46 48 so 52 54 
time( hours) 
Figure 2. Design of the study. K = KCJ response. M =Methacholine concentration-response curve. 
Table 1. Statistical model of the various sources of variation 
Source of variation 
1 Between patients 
2 Between strips/within patients 
3 Between days 
4 Order of measurement per day 
5 Days x measurement order 
6 Days x patients 
7 Measurement order x patients 
8 Days x measurement order x patients 
9 Residual variation 
10 Total variation 
Degrees of freedom 
5 
12 
I 
5 
5 
5 
36 
71 
63 
Statistical model of possible sources of variation. The factors patients and strips/within patients 
were considered as random, whereas the factors days and measurement order per day were considered 
as fixed. 
the increase in tension (as a percentage of maximal response) resulting from 
a tenfold increase in agonist concentration. 
For both contractile agents, the various contributions to the total variation of 
72 measurements were quantified through analysis of variance according to the 
statistical model shown in Table 18• This model determined the testing procedure 
for evaluating the statistical significance of the mean squares by means of the 
F-test. Therefore the F-ratios (of two mean squares) were computed as follows: 
items 2, 6, 7 and 8 were compared to 9, 5 to 8, 4 to 7, 3 to 6 and 1 to 2. 
In addition, the net components of variance were calculated for between-patients 
and between-strips/within-patients variability as well as for residual variation. 
These net variance components were then transformed to relative standard 
deviations as a percentage of the overall mean. 
Results 
The values for each patient of -log ECso, Tmax, and slope are summarised in 
Table 2. Each figure represents the mean response of three bronchiolar strips 
from one patient. The contractility to KCl and methacholine increased signi-
ficantly over the first postoperative day. On the second day, only the KCI-response 
increased, while methacholine T max was constant and was comparable to the 
second measurement on the first day. No significant changes in time for -log 
ECso and slope were found (Figure 3). Examination of CCRC after 48 h of 
storage without intervening exposure to KCl or methacholine indicated no 
difference from CCRC made on the first day. 
The outcomes of the analyses of variance are displayed in Table 3 as F-ratios, 
being indicators of the statistical significance of the various contributions to 
the total variation, and relative standard deviations as a percentage of the overall 
mean. 
Table 2. Methacholine and KCl-responses of six patients 
-log ECso Tmax slope 
Ml M2 M3 M4 Ml M2 M3 M4 Kl K2 K3 K4 Ml M2 M3 M4 
Patient 1 6.10 6.08 6.05 5.91 257 331 270 244 208 214 221 185 42 41 36 36 
Patient 2 5.62 5.54 5.27 5.28 78 83 75 81 130 170 169 159 72 65 69 68 
Patient 3 6.42 6.49 6.57 6.47 172 214 205 223 83 121 45 162 58 47 42 61 
Patient 4 6.35 6.46 6.91 6.50 150 192 173 181 91 180 84 150 45 43 43 47 
Patient 5 5.50 5.93 5.95 5.87 40 69 99 114 47 101 58 112 54 45 46 47 
Patient 6 6.61 6.47 6.58 6.43 101 113 140 143 62 110 76 102 50 51 49 52 
Mean 6.10 6.16 6.22 6.08 133 167 160 164 103 149 109 145 53 49 48 52 
Each figure represents the mean of three bronchiolar strips from one patient. 
Abbreviations: M 1-4=methacho1ine response 1-4 (see Figure 1); K 1-4= KCl response 1-4 (see Figure 1); Tm,=maximal contraction expressed 
as mg force per mg dry weight; slope= percent increase in contractile force resulting from a ten-fold increase in methacholine concentration. 
0\ 
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Table 3. Results of analysis of variance 
F-RATIOS 
Tmox (M) Tmox (M) Tmox (K) 
Sources of variation -log ECso corrDW corr prot Slope (M) corrDW 
1 Between patients 8.45* 4.53* 4.93* 3.67* 5.50* 
2 Between strips/within patients 6.45* 14.31* 9.15* 5.22* 5.10* 
3 Between days 0.04 0.93 2.16 2.86 0.02 
4 Order of measurement per day 0.72 21.66* 18.50* 0,03 7.67* 
5 Days x measurement order 3.91 4.12 1.58 3.65 0.26 
6 Days x patients 3.02* 2.68* 2.45 0.33 0.45 
7 Measurement order x patients 0.92 0.27 0.60 0.57 3.96 
8 Days x measurement order x patients 1.04 0.90 1.16 1.48 1.67 
NET COEFFICIENTS OF VARIATION' 
Between-patients 26% 171% 162% 69% 132% 
Between strips/within patients 9% 80% 73% 36% 56% 
Residual variation 4% 21% 24% 16% 25% 
Abbreviations: T max (M) corr DW =methacholine T mox corrected for dry weight of the preparation. T mox (M) corr prot= methacholine T mox corrected 
for the amount of protein in the preparation. Ohter abbreviations: see legend of Table I. 
*p<0.05 
'Coefficients of variation are expressed as percentage of the overall mean response and pertain to net components of variation for single measurements. 
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Figure 3. In vitro contractile responses to methacholine of human bronchioles (n = 18), repeatedly 
measured at 25, 27, 50 and 52 h after surgical resection. The bronchioles were stored at 4°C overnight 
twice (see Figure 1 ). The vertical axis depicts the contractile response to methacholine as a percentage 
of the maximal response in each preparation. 
For all parameters, overall variability was determined to a large extent by 
between-patients differences. However, a considerable within-patient variability 
was present. Individual T max- and -log ECso-values differed slightly between the 
first and second pair of methacholine CCRC, but this difference showed no 
consistent direction. The precision of T max measurements was not increased by 
correcting for the protein content of the bronchiole (Table 3). 
Discussion 
The study of human airways in vitro is of importance for answering questions 
related to properties and pharmacological modification of responses of airway 
omooth muscle3' 5' 6' 9- 11 , Furthermore, bronchial responsiveness in vivo can be 
compared to in vitro airway responsiveness 12- 15 • Bronchiolar strips have several 
advantages over other airway smooth muscle preparations. The responses of 
these strips are not influenced by vascular smooth muscle contractions, as is 
the case with parenchymal strips4' 16' 17' 18 • Bronchioles have a relatively homogenous 
structure comp·ared to larger bronchi, so that irregularly distributed cartilage 
plates cannot influence smooth muscle function. Finally, almost all lung tissue 
specimens removed surgically contain enough macroscopically normal bronchi-
oles to allow multiple measurements, which is often not the case with respect 
67 
to bronchi. Reproducible measurements of -log ECso, and, to a lesser degree, 
of Tmax and slope of methacholine CCRC can be obtained within 55 h post-
operatively without a loss in sensitivity or contractility. Tmax to KCl and 
methacholine showed a significant increase on the first day, and, for KCl only, 
on the second day postoperatively; -log ECso and slope remained constant with 
time. This indicated a vertical shift of the CCRC. The increase in T max is most 
likely not due to a change in muscarinic receptor function, as KCl induces a 
contraction without receptor activation. The increase in T max in time could also 
be due to a gradual fall in baseline tone. This was apparently not the case, 
as the resting tension was consistently adjusted to 500 mg before commencing 
each curve. After cooling, responsiveness was unchanged and this confirmed 
earlier observations6• 
Differences between patients could be shown for -log ECso, Tmax and slope. 
All these parameters showed significant additional between-patients variability, 
which is therefore not merely a reflection of between-strips/within-patients 
variation (Table 3). 
The relatively large within-patients variability of maximal contractile force in 
strips can have several causes. The most probable explanation of this variability 
seems to be that it is mainly caused by the mechanical forces applied to different 
bronchioles during the operative removal and the preparation procedure. Slight 
differences in preparative technique, for instance the angle of spiral cutting, 
can have important consequences. However, real differences may also be present. 
Because automation of the delicate preparation procedure seems virtually 
impossible, it is important that the cutting of the bronchioles is always done 
by the same experienced person. 
We have tried to improve the reproducibiliby of Tmax by correcting contractile 
force for the amount of protein in the bronchiolar strip. This, however, resulted 
in a similar coefficient of variation (Table 2). Armour et al, likewise, did not 
find any benefit from correction for smooth muscle volume, determined histo-
metrically14, so further attempts to relate contractile force oLbronchiolar strips 
to the amount of protein or muscle seem of little value compared to correction 
for the weight. 
Our results show that it is possible to demonstrate significant differences 
between-patients by measuring bronchiolar responses in vitro. The sensitivity 
(-log EC5o) can be accurately measured and is the best reproducible parameter. 
The contractility (T max) and slope showed a much larger variability; multiple 
measurements were necessary because of a relatively large within-patient va-
riability and one should be very careful in interpreting differences between 
patients. Whether the present results, using methacholine and KCl, have general 
validity needs to be established in further studies with other contracting agents. 
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Chapter 7 
Human small airway smooth muscle responses in vitro: 
actions and interactions of methacholine, histamine and 
leukotriene c4 
J.C. de Jongste, H. Mons, R. van Strik, I.L. Bonta and K.F. Kerrebijn. 
Departments of Paediatric Respiratory Diseases, Biostatistics (R.S.) and Pharma-
cology (LL.B.), Erasmus University and University Hospital Rotterdam/Sophia 
Children's Hospital, Rotterdam, The Netherlands. 
Summary 
The in vitro contractile responses to methacholine, histamine and leukotriene 
C4 (LTC4) were measured in human bronchiolar strips obtained after surgery. 
LTC4 was approximately 100 times more potent than both methacholine and 
histamine (mean -log EC5o values were 8.01, 6.18 and 5.87 respectively). All 
three agonists produced a similar maximum contractile response (Tmax) and no 
difference was found in the time course of methacholine, histamine and LTC4-
induced responses. When methacholine, histamine and L TC4 were applied in 
succession on a single airway preparation, no interactions between these agonists 
were demonstrated for -log EC5o. However, interactions were found concerning 
T max· The -log EC50 could be measured accurately and reproducibly and showed 
a relatively small within-patients variation (coefficients of variation 4-5% ). In 
contrast, Tmax showed a considerable within-patients variation (coefficients of 
variation 47-91%), which limits its usefulness when small numbers of airway 
preparations are studied. 
Key words: human airway smooth muscle, bronchiolar strip, methacholine, 
histamine, leukotriene c4. 
De Jongste JC, Mons H, Van Strik R, Kerrebijn KF. Human small airway smooth muscle responses 
in vitro: actions and interactions of methacholine, histamine and leukotriene c •. European J Pharmacal 
1986;125:29-35. Reprinted with permission of Elsevier Science Publishing Company. 
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Introduction 
Recently, a number of studies has been published in which in vitro findings 
concerning human airway tissues were related to in vivo parameters, such as 
bronchial hyperresponsiveness, chronic bronchitis and airway inflammation 1-7. 
Various types of airway preparations were used by the different authors and 
it is often not clear how accurately single responses represent the contractile 
properties of a given tissue sample. In a previous study, we calculated the between-
and within-patients variation of methacholine responses of human bronchiolar 
strips. We found that this preparation was stable for 55 h post thoracotomy 
and that prolonged storage at 4°C did not influence contractile properties8. We 
used the same technique in the present study to analyse the responses to 
methacholine, histamine and leukotriene C4 (LTC4) and estimated the relative 
contributions of various sources of error (i.e. between-patients and between-
strips/within-patients) to the total variation of sensitivity (expressed as -log ECso) 
and maximum contraction (T max). 
For this type of study, ideally only one agonist should be applied to a single 
airway preparation and one single response curve should be made unless 
tachyphylaxis or interactions are studied. However, due to the limited amount 
of human lung tissue that can be obtained for pharmacological experiments, 
it is advantageous to apply several agonists to one airway preparation. This 
is only justified if the agonists do not interact. Until now, indirect evidence 
for interactions between cholinergic agonists, histamine and leukotrienes is only 
available for dog and guinea pig airways9- 11 • To examine the feasibility of testing 
the effects of methacholine, histamine and LTC4 on a single bronchiolar strip, 
we applied these agents in succession to each of 90 preparations from 30 patients 
and evaluated the possible occurrence of interactions. 
Methods 
Human lung tissue was obtained from thoracotomies performed because of 
carcinoma. Within a few minutes after resection, a piece of macroscopically 
normal lung tissue was submerged in ice-cold Krebs-Henseleit buffer (composition 
in mM: NaCl 118, KCl 4.7, CaCh 2.5, MgS04 1.2, KH2P04 1.2, NaHC03 25, 
glucose 5.55) which was aerated with 95% 02, 5% C02. After rapid transport 
to the laboratory, bronchioles (approximately 10 to 13th generation) were 
carefully dissected free from parenchyma and blood vessels as described pre-
viousll. The tissue was stored overnight at 4°C in a slow, continuous flow 
of aerated Krebs-Henseleit buffer. We and others previously have shown that 
this storage procedure does not influence tissue sensitivity and contractile 
function8- 12• The extensive washing of the tissue will remove anesthetics (pen-
tothal, atropine, fentanyl, halothane, pancuronium and 0 2/N20) and substances 
liberated during the dissection. Measurements were performed on the first day 
following thoracotomy. Three bronchiolar strips from each patient were mounted 
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in 10 ml double-jacketed organ baths containing aerated buffer at 37°C. They 
were allowed to equilibrate for 2 h under an isometric tension of 500 mg which 
was adjusted every 15 min when necessary. Preliminary experiments had shown 
that a resting tension of 500 mg resulted in optimal contractility. The contractile 
responses were measured using Grass FT03D isometric force transducers coupled 
to a Rikadenki pen recorder and a digital voltmeter via a carrier wave amplifier 
(Peekel instruments). 
After baseline stabilisation, all strips were pretreated with methacholine (10-8 
to 10-4 M increasing in 10-fold concentration steps followed by washing) in 
order to ensure a stable contractility during the rest of the dal' 13• Cumulative 
concentration-response curves (CCRC) were made by adding agonists in small 
volumes (less than 50 ~1). The tissue was washed 4 times with 2 min intervals 
after completion of each CCRC and subsequently the bath fluid was changed 
every 15 min until a stable baseline was obtained. Successive CCRC were separated 
by 2 h intervals. Before starting a new measurement, the baseline tone was 
readjusted to 500 mg whenever necessary. The following parameters were derived 
from each CCRC: -log ECso: the negative logarithm of the concentration of 
agonist which produced 50% of maximal contraction, and T max: maximal tension, 
expressed as mg isometric force per mg dry weight of the bronchiole. The dry 
weight was determined after drying for 48 h at room temperature. 
The following drugs were used: methacholine hydrobromide, histamine hy-
drochloride (Janssen Pharmaceuticals, Belgium) and synthetic LTC4, (a kind 
gift of Dr. J. Rokach, Merck Frosst Laboratories, Canada). All agonist solutions 
were prepared freshly on the day of the experiment and kept on ice. Three 
bronchioles from one patient were studied simultaneously. Each strip received 
methacholine (10-8 to 10-4 M), histamine (10-8 to 10-4 M) and LTC4 (10-10 to 
10-7 M). The order in which these substances were applied was determined by 
randomised 3x3 latin squares. All 3x3 latin squares can be reduced to only 
two possible configurations (Figure 1) by interchanging the rows, which is justified 
because strip selection can be considered as random. In this study we included 
15 experiments according to the first latin square (group 1) and 15 according 
to the second (group 2), both randomised over 3 strips as rows. 
Statistical analysis 
The mean -log ECso values for each agonist were compared between the two 
groups and within-patients by Student's t-test (two tailed), since -log EC50 values 
could be considered as normally distributed. The average Tmax values were 
compared by distribution-free tests because of apparent skewness of the dis-
tribution; paired Wilcoxons signed rank test (two tailed) for comparison of within-
patients responses and Mann-Whitney U-test (two tailed) for comparison of 
responses for each agonist between the 2 groups. 
We estimated the various components of the total variation of the 270 CCRC 
through analysis of variance according to the statistical model shown in Table 
114. This model determined the testing procedure for evaluation of the statistical 
significance of the mean squares by means of the F-test. Assuming that patient 
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GROUP GROUP 2 
( n=15) ( n =15) 
STRIP A M H L H M L 
STRIP B L M H L H M 
STRIP C H L M M L H 
2 3 1 2 3 
ORDER OF MEASUREMENT 
Figure 1. Design of the study. Three bronchioles (strip A, B and C) from each patient were stimulated 
with methacholine (M), histamine (H) and leukotriene c. (L). The sequence of agonists was determined 
by randomised latin squares. All latin squares could be reduced to one of the two confi~urations 
shown by changing the rows, because strip selection can be considered as random. 
Table 1. Statistical model of the various sources of variation 
Sources of variation 
1 Between patients 
2 Between strips/within patients 
3 Order of measurement 
4 Between agonists 
5 Measurement order x patients 
6 Agonists x patients 
7 Residual variation 
8 Total variation 
Degrees of freedom 
14 
30 
2 
2 
28 
28 
30 
134 
Sources of variation when 3 agonists are tested on 3 preparations according to a 3 x 3 latin square 
within each patient, for n= 15 patients (1 group). The factors 1 and 2 were considered as random, 
3 and 4 as fixed. 
and strip selection were random factors, and measurement order and agonists 
were fixed factors, the F-ratios (of two mean squares) were computed as follows: 
item 1 was compared to 2, items 2, 5 and 6 to 7, item 3 to 5 and item 4 to 
6. Components of variance were calculated for between-patients and between-
strips/within-patients variability as well as for residual variation. These variance 
components were transformed to relative standard deviations (coefficients of 
variation) as a percentage of the overall means. 
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Results 
The mean CCRC's for methacholine, histamine and LTC4 are shown in Figure 
2A-C; the corresponding -log ECso values are given in Table 2. LTC4 was 100 
times more potent than both methacholine and histamine. Methacholine was 
slightly more potent than histamine. The -log ECso values were 6.18 ± 0.06 and 
5.88±0.04 respectively, P<O.OOl (mean±S.E.M., n=30). Figure 2A-C shows 
that the order of measurement had no influence on -log EC5o and that the responses 
in both groups were almost identicaL It can be seen from Figure 2C that the 
mean L TC4-CCRC did not reach their plateau within the 10-9 to 10-7 M 
concentration range. A plateau, defined as a less than 5% increase in tension 
after the final concentration step, was only reached in 33 out of the 90 bronchioles. 
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Figure 2. Mean concentration-response curves for methacholine, histamine and leukotriene C4 • Results 
are expressed as a percentage of maximal contraction in each curve versus the agonist concentration 
(-log M) and are the. mean± S.E.M. (n = 15). Responses in groups 1 and 2 are shown separately 
for each agonist, and are given for the curves from the three separate preparations as indicated 
by the numbers in brackets (=measurement order). Note the arrangement of the horizontal axis: 
three different calibrations correspond to the respective CCRC (in<;iicated by the numbers in brackets). 
Filled circles, dashed lines= group 1; open circles, continuous lines= group 2. 
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Table 2. -log EC5o values for methacholine, histamine and LTC4 in group 1 and 2 
-log ECso 
HISTAMINE METHACHOLINE LEUKOTRIENE c. 
group 1 group 2 group 1 group 2 group 1 group 2 
Curve 1 5.86±0.07 5.88±0.08 6.09±0.08 6.23±0.12 7.89±0.06 7.91 ± 0.06 
Curve 2 5.92±0.09 5.84±0.06 6.05±0.11 6.28±0.10 8.03±0.07 8.00±0.07 
Curve 3 5.92±0.09 5.85±0.08 6.10±0.10 6.31 ±0.09 8.09±0.05 8.11±0.06 
Results are expressed as mean± S.E.M., n= 15 in each group. No significant differences were found 
between curves 1, 2, and 3 and between corresponding measurements in the two groups for each 
agonist. 
Table 3. Analysis of variance 
Item Sources of variation F-ratiosb 
no.a 
-log EC,o -log ECso Tmax Tmax 
(group 1) (group 2) (group 1) (group 2) 
Between patients 2.71* 5.54*** 4.92** 1.84 
2 Between strips/within patients 3.17** 4.54*** 5.70*** 14.32*** 
3 Order of measurement 1.54 2.70 17.82 31.02* 
4 Between-agonists 482.04*** 472.05*** 3.23 12.22 
5 Measurement order x patients 1.54 1.83 2.59** 1.48 
6 Agonists x patients 3.74*** 7.22*** 1.77 1.14 
Coefficients of variation' 
Between-patients 8% 10% 105% 124% 
2 Between strips/within patients 5% 4% 47% 91% 
7 Residual variation 3% 2% 20% 20% 
"Items are numbered according to the statistical model shown in Table 1. 
b Results of analysis of variance, expressed as F-ratios, calculated seperately for -log ECso and T ma> 
in both groups. The F-ratios were computed as follows: item 1 was compared to 2, items 2, 5 
and 6 to 7 (residual variation), item 3 to 5 and item 4 to 6. 
' Coefficients of variation are expressed as a percentage of the overall means. 
Significances:*P<0.05; **P<O.Ol; ***P<O.OOL 
These 33 bronchioles were distributed equally in both groups. In a small number 
of preparations we extended the LTC4-CCRC to 10-6M, which always resulted 
in a plateau. However, the limited amount of LTC4 that was available made 
it impossible to complete all LTC4 curves. The submaximal values were ne-
vertheless included in the statistical calculations for reasons of completeness. 
The _results of the analysis of variance, expressed as F-ratios, are :shown in 
Table 3. The -log ECso measurements for the three agonists showed a significant 
between-patients variability, which was greater than the betwee!hstrips/within-
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Figure 3. Individual values for maximum contractile force (Tmax) for histamine, leukotriene C4 and 
methacholine in groups 1 and 2, according to measurement order (numbered 1, 2 and 3 in the 
graphs). Median values are indicated by the horizontal bars. Filled circles= group 1, closed 
circles =group 2. 
Horizontal bar: median. *P<0.02; * *P<0.01 
patients variability. The latter also contributed significantly to the total variation. 
The small coefficients of variation indicate a high reproducibility of -log EC50 
in both groups. The Tmax showed a significant between-patients variation 
compared to between-strips/within-patients variation only in group 1. No 
significant between-patients variation in T max was found in group 2 due to a 
relatively large between-strips/within-patients variation in some patients in this 
group. Coefficients of variation were large for T max, with a considerable residual 
variation. The mean values of Tmax are not useful because of a non-normal 
distribution. The individual Tmax values are shown in Figure 3, and the median 
values are indicated. Despite the wide range, there were significant differences 
between the first and second histamine responses in both groups, between second 
and third methacholine responses in group 2 and between first and second L TC4 
responses in group 1. No significant differences were found between corresponding 
values for group ·1 and 2, or in the maximal forces in the first curves, i.e. the 
maximum contractile response produced by methacholine, histamine and LTC4 
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was similar. Contraction and relaxation time following washout of LTC4 followed 
a time course which was comparable to that of the other two agonists. 
Discussion 
Our findings show that the sensitivity of human bronchioles in vitro to metha-
choline, histamine and L TC4 can reproducibly and accurately be measured with 
minimal within-patients variation. The maximal contractile force however showed 
a much larger variability, and the within-patients variation was almost as large 
as the between-patients variation. The F-test may be somewhat unreliable due 
to the non-normal distribution of Tmax values. However, this test is fairly robust 
against departures from normal distribution in balanced designs such as this 
one. In addition, we found a non-specific tendency for contractility to increase 
with time as appears from Figure 3. This may be the result of an increase in 
function of the contractile apparatus beyond the receptor level. Another possible 
explanation is that an inhibitory substance, for instance a prostaglandin (PG), 
is produced by the preparation initially, and that this production decreases with 
time. This speculation is supported by preliminary data from our laboratory, 
indicating that PGE2 and 6-keto-PGF1, the stable product of PGI, are produced 
by human bronchioles in the organ bath and depress smooth muscle tone. 
However, Brink et al12 and Finney et al 15 have found no effect of indomethacin 
on methacholine and carbachol responses of human bronchi. 
Finally, a fall in baseline tone could influence Tmax, but this was apparently 
not the case as the baseline was stable in most preparations and was always 
adjusted to 500 mg before the start of each curve. 
The opposite finding by Black et al of a decrease in carbachol contractility 
upon repetitive stimulation16 might be related to differences in preparative or 
storage techniques: we stored the bronchioles in a continuous flow of cooled 
gassed buffer8, while in the study by Black et al the tissue was left overnight 
in a sealed storage vessel with previously gassed buffer at 4°C, which might 
influence the viability of the preparation, e.g. due to the action of proteolytic 
enzymes. 
Our observations on the magnitude and time course of LTC4 responses are 
not in agreement with previous observations by Ghelani et al and Hanna et 
al, who concluded that L TC4 is only a partial agonist, the mechanism of action 
of which was not closely linked to the contractile apparatus, because of a delayed 
onset of action and slowly developing response17' 18• This discrepancy may have 
resulted from the use of different airway preparations (bronchioli versus bronchi) 
and different sources of the agonist (synthetic LTC4 versus rat or guinea-pig 
LTC4). 
The inclusion of submaximal LTC4-responses in the statistical calculations 
has introduced a bias in variance and LTC4-mean values. However, because 
a plateau was invariably reached in a number of preparations when the LTC4-
CCRC was extended to 10-6 M, and because the first LTC4-CCRC of both groups 
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were similar (Figure 2C), it can be speculated that this bias has not essentially 
influenced the interpretation of our results. 
The statistical evaluation indicated that -log ECso values, measured conse-
cutively on one preparation, are equivalent to single measurements, because 
no influence of the order of measurement could be demonstrated and identical 
mean -log EC50 values were found for first, second and third curves in both 
groups for all three agonists (Table 3). This increases the amount of reliable 
data three-fold, which is of advantage when studying small numbers of pre-
parations. The same is not true for T max· Apart from an apparent non-specific 
increase in contractility with time, the outcomes of the analysis of variance point 
to the presence of interactions between the agonists. Although this type of study 
can only demonstrate the presence of interactions without precisely defining 
them, it seems that LTC4 Tmax is increased after histamine pretreatment (Figure 
3, right panel). Despite a wide range, this increase was significant in group 
1 and nearly so in group 2, suggesting that histamine induces an increase in 
airway smooth muscle responsiveness to leukotrienes. 
In conclusion we found that methacholine, histamine and LTC4 cause dose-
dependent contraction of human bronchioles. LTC4 was 100 times more potent 
than methacholine and histamine; the three agents induced maximum contractions 
of similar magnitude. When these substances were applied in succession to a 
single preparation, no interactions occurred regarding the -log ECso, and this 
finding can be used to increase the information that can be obtained from a 
limited number of airway preparations. T max showed a nonspecific increase during 
the day and, in addition, interactions occurred when agonists were added in 
succession. Therefore only singleT max measurements should be taken into account. 
These appeared to be of limited value in human bronchioles due to the large 
within-patients variation. We recommend that -log EC50 should be considered 
mainly as a measure of human small airway function in vitro when small numbers 
of airway preparations are studied. 
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Chapter 8 
Comparison of isometric and isotonic responses of human 
small airway smooth muscle in vitro 
J.C. de Jongste, H. Mons, R. van Strik, I.L. Bonta and K.F.Kerrebijn. 
Departments of Paediatric Respiratory Diseases, Biostatistics (R.S.) and Pharma-
cology (LL.B.), Erasmus University and University Hospital Rotterdam/Sophia 
Children's Hospital, Rotterdam, The Netherlands. 
Summary 
The difference between isometric and isotonic responses of human small airway 
smooth muscle to a number of pharmacological agonists was studied. The 
isotonically measured sensitivity to methacholine was 1.4 times less than the 
isometrically measured value (p < 0.05) and similar small discrepancies were found 
for histamine, leukotriene C4, prostaglandin F2a, isoproterenol and theophylline. 
Maximal isometric force and isotonic shortening after methacholine were linearly 
related (p < 0.01 ). The between-methods difference is relatively small. Because 
the difference was of similar magnitude and in the same direction in all tissues 
studied, it is of little practical importance for conventional pharmacological 
experiments. 
Key words: airway smooth muscle, human bronchiolar strip, isotonic, isometric. 
De Jongste JC, Mons H, Van Strik R, Bonta IL, Kerrebijn KF. Comparison of isometric and 
isotonic responses of human small airway smooth muscle in vitro. J. Pharmacol Methods 1987;17:165-
171. Reprinted with permission of Elsevier Science Publishing Company. 
Introduction 
It has been corrunon practice to use isometric force transducers to perform in 
vitro pharmacological experiments on airway smooth muscle. However, airway 
smooth muscle in vivo probably contracts semi-isotonically, causing airway 
narrowing. This seems especially true for small airways (bronchioles) as their 
walls lack cartilage, which could hinder isotonic functioning. 
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There are numerous reports that compare isometric and isotonic responses 
of various types of striated and smooth muscle, and differences in contraction 
kinetics have been shown. However, in pharmacological studies measurements 
are usually performed when a contraction has reached its plateau, and it has 
not been determined to what extent such concentration-response curves produced 
isometrically and isotonically differ. The present study was undertaken to 
quantitate the possible difference between isometric and. isotonic measurements 
of human small airway smooth muscle responses to pharmacological stimulation. 
Methods 
Human lung tissue was obtained at surgery for lung cancer. Macroscopically 
normal tissue specimens were collected immediately after surgical resection and 
submerged in ice-cold Krebs-Henseleit buffer (composition, in mM: NaCl 118; 
KC14.7; CaCh 2.5; MgS04 1.2; KHzP04 1.2; NaHC03 25; glucose 5.55) aerated 
with 95% Oz and 5% COz. After rapid transport to the laboratory, bronchiolar 
strips were prepared and, after storage overnight, cumulative concentration-
response curves (CCRC) were made according to a technique described pre-
viously1. From each of 10 patients, 6 bronchiolar strips were studied simul-
taneously: 3 isometrically using Grass FT03D force transducers and 3 isotonically 
using Harvard model 386 heart-smooth muscle transducers. Isometric CCRC 
always started from 500 mg initial tension, and isotonic measurements were 
performed employing a 500 mg load because preliminary findings indicated that 
this load .produced optimal contractions. From each CCRC the following 
parameters were derived: -log ECzo and -log EC5o: the concentration of agonist 
that produced 20% and 50% of the maximal effect; Tmax for isometric measu-
rements: the maximal contractile force expressed as mg isometric force per mg 
of dry weight of the bronchiole (determined after 48 h of drying at room 
temperature) and Smax for isotonic curves: the maximal shortening expressed 
in JLm (because all strips were approximately 20 mm long correction for length 
was not carried out). All strips were primed by adding methacholine (10-8 to 
10-4M) in 10-fold concentration steps followed by washout, because this ensured 
a stable function for the rest of the day. After return to baseline, a second 
methacholine CCRC was generated in all strips. Finally, a third CCRC was 
made using histamine (10-8 to 10-4 M), Prostaglandin Fza (PGFz00) (10-8 to 10-5 
M), leukotriene C4 (LTC4) (10-10 to 10-7 M), isoproterenol (10-9 to 10-5 M) or 
theophylline (10-5 to 2x10-3 M) on one isotonically and one isometrically 
functioning strip. For each of the latter 5 agonists, 5 paired observations were 
obtained; each of these drugs was applied to only one pair of strips from a 
given tissue sample. Relaxing agents were applied after raising baseline tone 
with the methacholine EC5o of that preparation. After relaxation with either 
theophylline (2x10-3 M) or isoproterenol (10-5M), 'zero tone' or 'maximal length' 
was determined inCa-free buffer containing EDTA (4x10-3 M) and isoproterenol 
(10-5 M). The maximal response of both isometric and isotonic measurements 
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for relaxing agonists was expressed as a percentage of the difference between 
methacholine ECso-induced contraction and maximal relaxation. 
Drugs 
Methacholine hydrobromide, histamine dihydrochloride and d,l-isoproterenol 
were obtained from Janssen (Belgium); PGF2a and EDTA from Sigma; theo-
phylline monohydrate from Brocacef; and synthetic LTC4 was a gift from Dr. 
J. Rokach, Merck Frosst Laboratories (Canada). 
Statistical methods 
For all agonists, the values of -log EC2o and -log ECso for isotonic and isometric 
measurements were compared by paired t-tests (two tailed). The linear correlation 
of Smax and Tmax was determined for each agonist separately. Methacholine 
triplicate measurements were analysed by three-way analysis of variance. For 
the other agonists, pairs of measurements were analyzed by two-way analysis 
of variance. The level of significance was a= 0.05. 
Results 
All airway smooth muscle preparations responded in a dose-dependent fashion 
to all agonists. Mean values for -log ECso and -log EC2o are given in Table 
1. The mean methacholine CCRC resulting from isometric and isotonic mea-
surements are shown in Figure 1. A small but significant difference was present 
Table 1. Sensitivity of human bronchiolar strips measured isotonically and isometrically 
Agonist" method -log ECso -log EC2o 
Methacholine isotonic 5.97±0.06* 6.64±0.07 
isometric 6.12± 0.08* 6.76±0.06 
LTC. isotonic 7.92±0.12 8.62±0.29 
isometric 8.08±0.10 8.70±0.17 
PGF2a isotonic 5.46 ± 0.09 5.87±0.18 
isometric 5.66±0.12 6.12±0.13 
Histamine isotonic 5.37± 0.12 6.03±0.23 
isometric 5.56±0.13 6.02±0.15 
d, I Isoproterenol isotonic 7.00±0.24 7.56±0.20 
isometric 7.50±0.33 7.94±0.29 
Theophylline isotonic 3.55 ± 0.12 3.95±0.13 
isometric 3.69 ± 0.12 4.35±0.20 
an= 10 paired triplicate measurements for methacholine; for the other agonists, n=5 paired 
measurements. 
* p < 0.05 for comparison between methods. 
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Figure 1. Mean methacholine concentration-response curves of 60 bronchiolar strips from 10 patients. 
Triplicate measurements were performed isometrically (open circles) and isotonically (closed circles). 
The vertical axis depicts the percentage of maximal response for each strip. Mean -log ECso values 
were significantly different (p < 0.05). *: p < 0.05. 
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Figure 2. Relation between methacholine (10-4 M)-induced maximal isometric force (Tmax) expressed 
as mg of force per mg of dry weight (DW) of the bronchiole, and maximal isotonic shortening 
(Smax), expressed as J..Lm of absolute shortening, measured in 60 bronchiolar strips from 10 patients 
(each dot represents the mean of 3 isometric and 3 isotonic responses within a patient). 
in -log ECso of the two curves (p < 0.05) corresponding with a potency difference 
of approximately 1.4. Analysis of variance showed that this difference was in 
the same direction and of similar magnitude in all tissues studied, and that 
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Figure 3. Mean isometric (open circles) and isotonic (closed circles) concentration-response curves 
for histamine, PGF2, and LTC4 (n =five pairs of bronchiolar strips from five different patients 
for each agonist). No significant difference was found between isometric and isotonic -log EC,o 
(* :p<0.05). 
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Figure 4. Mean isometric (open circles) and isotonic (closed circles) concentration-response curves 
for d,l-isoproterenol and theophylline (n = five pairs of bronchiolar strips from five different patients 
for each agonist). There was no significant difference between isometric and isotonic -log EC5o 
(* : p<0.05). 
no significant within-patients/within-methods variation existed. For -log EC20 
methacholine the difference between methods did not reach significance. A 
significant (p < 0.01) relation was found between mean T max and Smax values of 
methacholine responses (Figure 2). In Figure 3, the mean CCRC for LTC4, 
PGF2a and histamine are shown. Although no significant differences in -log 
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EC5o and -log EC2o were found by paired t-test, and two-way analysis of variance 
indicated no significant contribution of the between-methods variation for each 
agonist separately, the mean isotonic curves always tended to be shifted towards 
higher agonist concentrations compared to the isometric curves. The statistical 
significance of this consistent tendency could not be assessed because several 
pairs of strips from the same tissue samples were used to examine the effects 
of the various agonists (see: Methods). Similar results were obtained with the 
relaxing agents isoproterenol and theophylline (Figure 4). Maximal relaxation 
(percentage reversal of methacholine-induced tone) in the isometric and isotonic 
mode were 98,8 ± 4,9% and 86,0 ± 6,6%, respectively, for isoproterenol and 
81,4±3,7% and 77,4±3,8%, respectively, for theophylline (mean±SEM, 
p>0.05). 
Discussion 
The present results indicate that a small, but significant, difference exists between 
isometric and isotonic measurements of pharmacological responses of human 
small airway smooth muscle in vitro. The sensitivity to methacholine, measured 
isometrically, was increased by a factor 1.4 compared to the isotonically 
determined sensitivity. A similar trend was observed for the responses to 
histamine, LTC4 and PGF2a as well as for the relaxant agents isoproterenol 
and theophylline, although no level of significance was reached, probably due 
to the limited number of observations. 
Differences in isometric and isotonic responses have been examined in detail 
in various types of striated and smooth muscle among which tracheal smooth 
muscle2-5. These studies were mainly concerned with length-tension relationships 
and contraction kinetics, and have shown that isometric responses develop more 
rapidly and usually occur at a higher stimulus level than isotonic responses. 
It has been suggested that isotonic responses represent incomplete activation 
of the contractile apparatus due to the concurrent shortening and thickening 
of the muscle, which might hinder diffusion of the agonist and cause changes 
in the arrangement of the contractile elements ('folding'), which can also impair 
optimal functioning4'5. However, it has not been determined how important these 
physiological considerations are for the outcome of conventional pharmacological 
experiments. This is especially relevant for the type of study that links in vitro 
data to clinical data, such as bronchial responsiveness to inhaled methacholine6' 7 • 
Several studies have failed to demonstrate a relation between isometric in vitro 
responses and in vivo airway responsiveness and it is possible that such a relation 
would have been found had in vitro responses been measured isotonically instead 
of isometrically. The present findings suggest that this probably is not the case, 
because the difference betwe~n both methods is small and consistent between 
different lung tissue specimens. The magnitude of the between-methods discre-
pancy may become larger when initial tension or length is increased3'5. However, 
pharmalogical experiments are commonly performed starting from 'optimal' 
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tension or length as we have done. Our results are unexpected with regard to 
the relative positions of the isometric and isotonic curves. Michelson and 
Shelkovnikov showed that isotonic curves were shifted to a varying degree towards 
lower agonist concentrations compared to isometric curves4, whereas we found 
the reverse. This means that in human small airway smooth muscle some tension 
develops before shortening occurs, which suggests that intrinsic mechanical 
resistance has to be overcome. 
In conclusion, isometric and isotonic pharmacological responses of human 
small airway smooth muscle show significant but small differences in sensitivity 
to methacholine and probably also to a number of other agonists. Maximal 
force and shortening are linearly related. The observed discrepancies seem of 
little practical importance for conventional pharmacological experiments. 
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Chapter 9 
Non-neural components in the reponse of fresh human 
airways to electric field stimulation in vitro 
J.C. de Jongste, H. Mons, I.L. Bonta and K.F. Kerrebijn 
Departments of Paediatric Respiratory Diseases and Pharmacology (LL.B.), 
Erasmus University and University Hospital Rotterdam/Sophia Children's 
Hospital, Rotterdam, The Netherlands. 
Summary 
Fresh human bronchi, obtained at thoracotomy and maintained at 37°C, were 
studied in vitro to investigate their response to electric field stimulation (EFS). 
We found complex responses that were not only composed of a rapid initial 
nerve-mediated cholinergic contraction and a non-adrenergic nerve-mediated 
relaxation, but, in 80% of preparations, also of a tonic contraction with a sustained 
time course. This sustained phase was not blocked by the nervous conductance 
blocker tetrodotoxin (TTX), and was therefore not neurally mediated. Controlled 
transient cooling to 4°C in the organ bath reduced this sustained phase selectively 
for several hours. The leukotriene-antagonist FPL-55712, dexamethasone, which 
inhibits phospholipase Az, and the anti-asthma drug disodium cromoglycate, 
all reduced the sustained phase significantly. In 20% of strips, an additional 
TTX-resistant contraction was seen directly following the cholinergic phase. This 
contraction could be inhibited by indomethacin. A similar small peak sometimes 
appeared after selective blocking of either the cholinergic or the sustained phases. 
Experiments in which the epithelium was removed from the strips suggested 
that this indomethacin-sensitive response, but not the sustained phase, was 
dependent on the presence of epithelium. These results show that EFS of fresh 
human bronchi stimulated cholinergic and non-adrenergic inhibitory nerves, and 
gave rise to a partly epithelium-dependent synthesis of arachidonic acid me-
tabolites, which caused contractile responses that interfered with the neurally 
mediated responses. 
Key words: human airway smooth muscle, bronchial strip, electric field stimu-
lation, cholinergic nerves, non-adrenergic inhibitory nerves, arachidonic acid 
metabolites, leukotrienes, prostaglandins. 
De Jongste JC, Mons H, Bonta IL, Kerrebijn KF. Non-neural components in the response of 
fresh human airways to electric field stimulation in vitro. J Appl Physiol 1987, in press. Reprinted 
with permission of the American Physiological Society. 
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Introduction 
It has been shown that human bronchus responds to electric field stimulation 
(EFS) in vitro with a fast, cholinergic;_ nerve-mediated contraction followed by 
a slow relaxation that results from stimulation of non-adrenergic inhibitory (N AI) 
nerves1- 5. Previous studies were performed on human lung tissue, obtained at 
thoracotomy or autopsy. It has been common practice to collect tissue specimens 
in cold buffer. It cannot be excluded that prolonged hypoxia (in the case of 
autopsy) or cooling change the responsiveness of the tissue to EFS in vitro. 
In order to elucidate this, we studied the responses to EFS of human bronchi 
which were collected with minimal hypoxic delay and were maintained at 30-
370C after surgical removal. We found that fresh human bronchus that had 
not been cooled exhibited not only the biphasic nerve-mediated contraction/ 
relaxation responses, but also, in 80%, a large, sustained contraction phase. 
In 20% of all preparations studied, another smaller contractile phase was present 
with its peak immediately following the cholinergic response. We examined the 
frequency-response characteristics, the effect of controlled cooling and of epi-
thelium removal on the response to EFS, and applied various blocking drugs 
in order to characterise the nature of these additional contractile phases. 
Methods 
Human lung tissue was obtained from 40 patients at thoracotomies performed 
because of carcinoma. Within a few minutes after surgical removal, a piece 
of macroscopically normal lung tissue was submerged in Krebs-Henseleit buffer 
(composition, in mM: NaCL 118, KCl 4.7, CaCh 2,5, MgS04 1.2, KH2P04 1.2, 
NaHC03 25, glucose 5.55) gassed with carbogen (95% 02, 5% C02) at 37°C. 
After rapid transfer to the laboratory, cartilaginous bronchi (approx. 5th to 
7th generation) were dissected free from parenchyma and blood vessels and 
were cut helically at a 45° pitch to obtain bronchial strips measuring 20 x 2 
mm, as we have described previousll, while the tissue remained in oxygenated 
warm buffer. One to 6 bronchial strips were dissected from each specimen. 
Bronchial strips were suspended in 10 m1 double-jacketed organ baths containing 
Krebs-Henseleit buffer, aerated with carbogen, at 37°C (pH: 7.35, Pc02: 4.6 kPa, 
P02: 71.8 kPa). The time from surgical resection until mounting in the organ 
bath was less than 1 h. Contractile responses were measured isotonically using 
high-precision angular displacement transducers 7 and employing an isotonic load 
of 1 gram. Field stimulation took place via platinum plate electrodes measuring 
40 x 5 mm which were glued to the organ bath wall on both sides parallel 
to the bronchial strip (electrode distance 15 mm). 
Electrical stimuli were delivered by a custom made tissue stimulator which 
produced voltage-constant rectangular pulses of alternating polarity. 
Bronchial strips were equilibrated for 1-2 h in the organ bath while the buffer 
was changed every 15 min. When a stable baseline was obtained, EFS was carried 
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out, employing 30 sec tetani of supramaximal voltage (50V) and a short pulse 
duration (0,3 ms) at a frequency of 30 Hz. These stimulus parameters caused 
optimal contractions and relaxations, which were inhibited by the nerve con-
ductance blocker tetrodotoxin (TTX, 3 ,ug/ml) indicating that nerves were 
stimulated selectively (preliminary findings). After completion of the experiments, 
a number of strips was maximally relaxed in calcium-free buffer containing d,l-
isoproterenol (10-4 M) and EDTA (4xl0-3 M). The difference between baseline 
and maximal relaxation was considered to reflect active baseline tone: the part 
of the intrinsic tone that is caused by spontaneous smooth muscle activity. 
Frequency-response curves were made by applying 30 sec. pulse trains (50 
V, 0.3 msec) with increasing frequencies (1 to 100 Hz), separated by 30 min 
intervals. 
The effect of controlled transient co0ling of the tissue was studied in two 
ways. First, bronchi were exposed in the organ bath to a temperature of 4°C 
for 30 min. and the responses to EFS before and 1 h after cooling were compared. 
Secondly, strips were stimulated at hourly intervals during two 8-hour periods 
before and after storage in aerated cold buffer overnight (12 h at 4°C). This 
was done to evaluate the duration of the effect of cold, and furthermore to 
examine possible tachyphylaxis of the response to EFS. Cooling was accomplished 
by changing the thermostat setting of the circulation pump that perfused the 
organ baths' double jackets. Changing the temperature of the organ bath content 
took 20 min. 
The effect of pharmacological blockers was tested by adding blocking drugs 
to the organ bath content when strips had reached a stable baseline and had 
a reproducible response to EFS. Drug incubations lasted for 20 min, except 
in the case of dexamethasone (2 h) because of the mode of action of this drug, 
which entails protein synthesis8• Control experiments were done in which EFS 
was repeated under identical conditions, but without a blocker being present. 
Only one blocking drug was tested on a given strip. 
To estimate a possible role of the airway epithelium in the response of bronchial 
strips to EFS, we removed the epithelium from the strips by gently rubbing 
the mucosal surface with a small piece of cotton gauze. The effectiveness of 
this procedure was confirmed by histological examination. We compared the 
responses of paired strips with and without epithelium. 
Data analysis 
The relatively high intrinsic variability of the absolute contractile responses of 
human airways6 makes normalisation imperative. Therefore, we expressed all 
responses of a given strip as a percentage of its cholinergic contraction to maximal 
EFS. All data are presented as mean values± S.E.M. The significance of the 
differences between means was determined by Student's t-test for paired or 
unpaired data, as appropriate (two tailed, a= 0.05). 
Drugs 
The following drugs were used: histamine dihydrochloride, methacholine hy-
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drobromide and d.l-isoproterenol sulphate (Janssen), TTX and EDTA (Sigma), 
atropine sulphate (Brocacef), mepyramine maleate and methysergide maleate 
(Rhone-Poulenc), hexamethonium bromide (Fluka), timolol maleate (Merck, 
Sharp & Dhome) disodium cromoglycate (DSCG, Fisons), indomethacin and 
dexamethasone (Duchefa) and the leukotriene antagonist FPL 55712 (a gift from 
Fisons). 
All drug solutions were freshly prepared daily in 0,9% NaCl or, in the case 
of indomethacin and FPL 55712, in methanoL Dilutions were chosen so that 
drugs could be added to the organ baths in volumes of 5 to 50 tiL In preliminary 
experiments, equivalent amounts of methanol had no effect on baseline tone 
or airway smooth muscle function. 
Results 
Effects of EFS on fresh airways maintained at 37'C 
After EFS, 78 out of 98 bronchial strips from 40 patients (80%) exhibited responses 
that consisted of a rapid initial contraction followed by a sustained, tonic 
contraction (Figure 1a), which reached a maximum approximately 10 min after 
onset of EFS. The mean amplitude of this sustained phase was 56,2 ± 5.0 % 
of the initial response. In 35 preparations, both contractile phases were separated 
by a relaxation below baseline (Figure 1 b). In 9 of the 78 strips with a sustained 
contractile phase, another smaller contraction could be seen that had its peak 
approximately 1 min. after onset of EFS (Figure lc). This small peak was also 
present in 11 strips without a sustained phase (Figure ld). The mean amplitude 
of this contractile peak was 62.1 ± 9.6 % of the cholinergic response. The 
remaining 9 strips showed either only the initial rapid contraction (n = 3) or 
a biphasic contraction-relaxation response (n = 6) without a sustained contraction 
(Figure le). Following elevation of baseline tone by histamine 10-6M a biphasic 
contraction-relaxation response to EFS was seen in the 3 preparations that initially 
showed no relaxation. 
These findings contrasted with our previous (unpublished) observations in 
39 bronchi from 32 subjects, that had been collected at surgery in ice-cold buffer. 
All these strips responded to EFS with biphasic contraction-relaxation responses, 
but a sustained contraction was found in only 5 (13%). 
Thus, it appeared that the initial response to EFS of fresh human airways, 
that had not been cooled previously, was composed of a rapid initial contractile 
phase (100%), a second, smaller contraction (20%), a relaxation phase (45%) 
and a tonic sustained contraction (80%), numbered according to peak latency 
after EFS (Figure 2). Phases 1 and 3 corresponded to the nerve-mediated 
cholinergic and NAI response described previously1- 5' 9 • Nerve mediation was 
apparent from the inhibition of both phases by the nervous conductance blocker 
TTX (3xl0-6 g/ml). The non-adrenergic nature of the relaxation phase 3 was 
confirmed because it was not inhibited by the j3-receptor blocker timolol 10-6M. 
Atropine (1.2x10-6M) blocked phase 1 completely (Figure 3)(Table 1). Neither 
TTX nor atropine affected the sustained phase 4 and phase 2 (Figure 3). 
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Figure 1 Representative response patterns of fresh human bronchi, maintained at 37°C after resection, 
to electric field stimulation in vitro. Arrows indicate the onset of a 30 sec pulse train (30 Hz, 0.3 
msec, 50 V). A: initial rapid cholinergic contraction (phase I) followed by a sustained contraction 
(phase 4). B: phases I and 4, separated by a deflection below the baseline, that is due to stimulation 
of non-adrenergic inhibitory nerves (phase 3). C: phases I, 2 and 4. D: phase 1, only followed 
by phase 2. E: phase 1 and phase 3. Response pattern A and B were seen initially in 7Q%, C 
in 9%, D in 11% and E in 9% of all preparations (n = 98 strips from 40 patients). 
We have attempted to relate the presence or amplitude of phase 2 and 4 
responses to clinical variables such as chronic bronchitis or airflow limitation. 
No correlations were found, however. 
We also analysed phase 4 responses as a % of maximal cholinergic contraction 
of 30 strips (3 strips from each of 10 tissue specimens) by means of analysis 
\0 
Table 1. Effects of cooling and pharmacological blockers upon the 4 phases of the response of isolated fresh human bronchus to electric field N 
stimulation 
Drugs (concentration) Number of patients Phase 1 Phase 2 Phase 3 Phase 4 
Cold (30 min, 4° C) 5 B 100 (5) N.D. -79.6 ± 19.6 (5) 64.1 ± 10.1 (5) 
A 130 ± 11.6 -55.9± 17.5 11.5± 5.7 *** 
Atropine (1.2x 10-6 M) 5 B 100 (5) N.D. N.D. 41.9 ± 18.3 (5) 
A 0 ± 0*** 47.5 ± 16.2 
FPL-55712 (11.5x10-6 M) 7 B 100 (7) 13.8 ± 13.8 (5) -16.7 ± 7.5 (5) 37.7± 9.7 (7) 
A 105.7 ± 8.3 28.2± 11.8 -11.2± 5.1 3.3 ± 2.9*** 
Dexamethasone (l 0-4 M) 5 B 100 (5) N.D. N.D. 38.7 ± 8.5 (5) 
A 93.8± 9.0 6.5± 2.5* 
Disodiumcromoglycate (10-4 M) 8 B 100 (8) N.D. - 9.4 ± 4.3 (5) 61.0 ± 12.6 (8) 
A 93.3± 4.3 -27.3 ± 5.7* 25.1± 6.1** 
Indomethacin (6x10-6 M) 10 B 100 (10) 68.2 ± 11.1 (6) - 8.4 ± 2.9 (5) 32.0 ± 10.8 (9) 
A 80.5 ± 4.2*** 10.2± 4.7*** -30.5 ± 8.9* 40.9± 10.0 
Mepyramine (2.8x10-6 M) 4 B 100 (4) N.D. N.D. 52.3± 12.6 (4) 
A 101.8± 12.1 60.4±29.0 
Methysergide (2x10-6 M) 3 B 100 (3) N.D. N.D. 88.8 ± 22.9 (3) 
A 87.2± 6.7 79.5± 17.5 
Hexamethonium (1.4xl0-5 M) 3 B 100 (3) N.D. N.D. 86.8 ± 22.0 (3) 
A 101.4± 1.4 81.3± 18.9 
Control 23 B 100 (23) 57.1 ± 11.3 (5) -21.5 ± 6.3 (10) 49.8 ± 6.4 (20) 
A 103.3± 2.3 48.6± 11.2 -13.6± 2.3 52.2± 6.6 
Abbreviations: B, before; A, after; ND, not done. 
All responses are expressed as a percentage of the cholinergic response to maximal EFS before incubation. 
Means± S.E.M. are given. Numbers between brackets refer to the number of strips in which that phase was present. 
Statistical significances: *p < 0.05; **p < 0.005; ***p < 0.001 (paired Students' t-test, two tailed). 
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Figure 2. Schematic representation of time course, peak latency and amplitudes of the 4 phases 
that constitute the response of fresh human bronchus to electric field stimulation (EFS) in vitro. 
Phases are numbered according to peak latency after EFS; 1: cholinergic nerve-mediated, rapid 
contraction. 3: non-adrenergic inhibitory nerve-mediated relaxation. 2 and 4: non-neural contraction. 
of variance and the F test. It appeared that the between-subject variation did 
not contribute significantly to the total variation in phase 4 responses (p > 0.10). 
Characterisation of the sustained phase 
Frequency- and voltage-response curves were performed on airways that had 
a phase 1 and phase 4 response (4 patients). Frequency-response curves showed 
that phase 1 was maximal at 20 to 50 Hz, and that phase 4 gradually reached 
a maximum at 50 to 100 Hz (Figure 4). Voltage-response experiments on 3 
strips are shown in Figure 5. Phase 1 was already maximal at 30 V, whereas 
phase 4 still increased between 40 and 50 V in some strips (50 V was the maximal 
voltage that our tissue stimulator could deliver). These tracings illustrate that 
the sustained response can interfere with NAI relaxations, which leads to an 
apparent amplitude decrease of both phases 3 and 4 (Figure 5). 
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Figure 3. Effect of tetrodotoxin (3xl0-6 g/ml) and of atropine (1.2xl0-6 M) on the response of 
2 fresh human bronchial strips from 2 different patients to electric field stimulation in vitro. Small 
arrows indicate the onset of a 30 sec pulse train (30 Hz, 0.3 msec, 50 V). Note the appearance 
of a phase 2 (indicated by the asterisk) after inhibition of phase 1 by atropine; phase 4 is not 
influenced by TTX or atropine. 
Effect of transient cooling 
Five strips (5 patients) were exposed in the organ bath to a temperature of 
4°C for 30 min. After rewarming, EFS responses showed a significant reduction 
of phase 4 (p < 0.005) compared to pre-cooling values (Table 1 ). Furthermore, 
phases 1 and 3 tended to be increased and decreased, respectively, after cooling. 
This was probably the consequence of a reduction of spontaneous muscle tone 
during the cooling. 
The responses to repeated EFS during an 8 h period before and after cooling 
overnight were studied on 9 strips (5 subjects), 6 of which had a phase 4 response. 
The mean results are depicted in Figure 6. On the day of surgery, phases 1 
and 4 were relatively stable and showed no tachyphylaxis. On the second day, 
phase 1 was initially reduced to 82.3 ± 8.8% of the maximal cholinergic response 
on the previous day, but returned to the pre-cooling level within 3 h. Phase 
4 was reduced much more from 61.5 ± 20.9% to 11.2 ± 4.8%, and increased slowly 
to 46.3 ± 6.1% after 7 h, which was considerably below the maximum of the 
preceding day (Figure 6). 
Effects of drugs 
Because the slow time course and TTX resistance of phase 4 suggested that 
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Figure 4. Frequency-response curves of phases 1 (closed circles) and 4 (open circles). Electric field 
stimulation (30 sec of 50 V, 0.3 msec pulses) was applied on 4 bronchial strips (4 patients) at 
intervals of 30 min. Responses are expressed as a % of the maximal amplitude of that phase in 
a given strip. 
this phase was caused by endogenous release or synthesis of a contracting 
substance, we examined the effects of a number of pharmacological 'blockers'. 
The mean results of these experiments are given in Table 1. FPL-55712, a 
leukotriene antagonist, caused a selective pronounced reduction of phase 4 from 
37.7±9.7% to 3.3±2.9% (P<0.001), but had no significant effect on phases 
1, 2 and 3 (7 strips from 7 patients). A small phase 2 response, that was not 
visible initially, appeared in 4 of the 10 strips after treatment with FPL-55712. 
In another strip that initially had a prominent phase 2 response, no change 
in phase 2 was observed after FPL-55712. Dexamethasone, that interferes with 
arachidonic acid metabolism by inhibiting phospholipase (PL)Az, also caused 
a selective inhibition of phase 4 (P<0.05) in 5 strips (5 patients) with phase 
1 and 4 responses. The anti-asthma drug DSCG, that inhibits mediator release 
by an essentially unknown mechanism, reduced phase 4 moderately but sig-
nificantly from 61.0± 12.6% to 25.1 ±6.1% (P<0.005, 8 strips from 8 patients). 
In these strips, that also had phase 3 relaxation responses, the decrease of phase 
4 resulted in a more negative phase 3, as could be expected from the experiments 
shown in Figure 5. The cyclooxygenase inhibitor indomethacin, the antihistamine 
mepyramine, the serotonin antagonist methysergide and the ganglionic blocker 
hexamethonium had no effect on the sustained contraction (Table 1). 
Because of its peak latency, the contractile phase 2 reminded to the so-called 
'rebound contraction', which is characteristic for the response of ferret and guinea-
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Figure 5. Repetitive field stimulation of three human bronchi with increasing voltages (5 to 50 
V, 0,3 msec, 30 Hz for 30 sec). Arrows indicate the onset of field stimp1ation. At the lowest voltage 
the relaxation phase 3 appears first, followed by the cholinergic contraction phase 1 at 10 V. At 
20 V, phase 4 is visible as a hump interfering with the relaxation phase (especially clear in panel 
A, third response) and with increasing voltage the sustained contraction phase 4 appears above 
the baseline (panels A and B). In some cases a phase 4 response which does not appear as a second 
contraction (panel C) seems to be present; it then only distorts the appearance of the relaxation 
phase 3. The phase 2 response is only visible in panel B (sixth response, small peak following 
phase 1). At the end of each experiment preparations were maximally relaxed (dots indicate addition 
of calcium-free buffer containing EDTA and isoproterenol) to estimate active spontaneous baseline 
tone (see: methods). It appears that the presence of a relaxation response in preparations with 
considerable spontaneous tone can be masked by the phase 4 sustained contraction (panel B). 
pig intestinal tract to EFS 10- 12 . This rebound contraction has been reported to 
be indomethacin sensitive. Therefore, we examined the effect of indomethacin 
on strips that had a prominent phase 2 response. Indomethacin reduced phase 
2 significantly from 68.2± 11.1% to 10.2±4.7% (P<0.005, 6 strips from 6 
subjects), and concomitantly caused a significant reduction of phase 1 and an 
increase of phase 3 (P < 0.005 and P < 0.05, respectively). This was most likely 
due to the partial superposition of the phases 1, 2 and 3, so that changes in 
phase 2 also caused changes in phases 1 and 3. Although no significant effect 
of indomethacin on phase 4 was found, we observed that indomethacin treatment 
of 2 strips that initally only had a phase 1 and 2 response, resulted in development 
of a phase 4 response (Figure 7). 
Effect of epithelium removal 
Because bronchial epithelium is a potential source of contracting substances13, 
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Figure 6. Effect of repeated electric field stimulation (30 sec trains of 50 V, 0.3 msec, 30 Hz pulses) 
on the amplitudes of the cholinergic phase 1 (closed circles) and the sustained phase 4 (open circles) 
during two periods of 8 h at 37°C, before and after storage overnight for 12 h at 4°C. Each point 
represents the mean±S.E.M. of 9 (phase 1) or 6 (phase 4) separate experiments. Contractions are 
expressed as a percentage of the maximal cholinergic (phase 1) response of a given strip. It is 
shown that cooling had only a minor and transient effect on phase 1, but profoundly depressed 
the amplitude of phase 4, that did not return to pre-cooling values even after 8 ·h. 
INDOMETHACIN 
t 
10 min 
Figure 7. Tracing of one of two bronchial strips that initially showed a phase 1 and 2 response, 
but developed a sustained phase 4 after treatment with indomethacin. Arrows indicate onset of 
a 30 sec train of 0.3 msec, 50 V pulses at 30 Hz. 
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Table 2. Effect of removing the epithelium on the response of isolated human bronchus to electric 
field stimulation. 
After 2 h After 4 h 
epithelium epithelium epithelium epithelium 
present removed present removed 
Phase 1 100 100 115.0± 13.9 112.7±8.8 
Phase 2 27.4±20.1* 8.6±5.6* 41.3 ± 16.0* 4.4±2.7* 
Phase 3 6.7±5.1 13.2±8.1 2.4± 2.1 8.0±3.7 
Phase 4 35.3± 18.8 15.8 ±8.6 33.0± 14.2 23.0±9.9 
EFS responses were elicited 2 and 4 h after mounting the bronchial strips in the organ baths. 
All values are expressed as a % of the initial cholinergic response to maximal EFS. Means± S.E.M. 
of 7 paired experiments (7 patients) are given. 
*p <0.05 (paired Student's t-test, two tailed), comparison of paired strips with and without epithelium. 
we examined the effect of epithelium removal on the EFS response in paired 
strips with and without epithelium (14 strips from 7 patients). Responses to 
EFS were elicited 2 and 4 h after mounting the strips in the organ bath. Of 
the 7 intact strips, 6 had a phase 4 and 3 a phase 2 response. Of the 7 denuded 
strips, 4 had a phase 4 and 3 a phase 2 response. These phase 2 responses 
had a significantly lower amplitude than in the intact strips (Table 2). Paired 
analysis showed no significant differences, both at 2 and 4 h after mounting, 
in the amplitudes of phase 4. 
Discussion 
In this study, we present evidence that EFS of isolated fresh human bronchi, 
that were maintained at 37°C, not only produced a nerve-mediated cholinergic 
contraction and a NAI relaxation response, but also gave contractile responses 
that were the result of endogenous release of contracting substances. Two distinct 
non-neural response components were defined, one with a sustained time course 
that was present in 80% and the other, with its peak 1 min after onset of EFS, 
in at least 20% of all airways that we have examined. We numbered these phases 
1-4 according to their peak latency after EFS. The tonic phase 4 was blocked 
by FPL-55712, which acts as a leukotriene receptor antagonist in the concentration 
we have used14' 15• Phase 2 was inhibited by the cyclo-oxygenase inhibitor 
indomethacin. This suggested that phase 2 and 4 resulted from synthesis of 
cyclo-oxygenase metabolites (prostaglandins or thromboxanes ), and L T -like 
substances, respectively. This is further supported by the observation that 
indomethacin not only inhibited phase 2, but in some tissues also induced phase 
4 responses (Figure 7), which suggested deviation of the substrate (arachidonic 
acid) from the cyclo-oxygenase to the lipoxygenase pathway. 
Mobilisation of arachidonic acid from the cell membrane by activation of 
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PLA2 is an early step in the synthesis of both prostaglandins and leukotrienes. 
Therefore, the significant inhibition of phase 4 by dexamethasone may have 
resulted from the PLA2 inhibitory action of the corticosteroid. It seems likely 
that the effect of DSCG on the sustained phase 4 reflects the capacity of DSCG 
to prevent mediator release. This may be mediated via an effect on calcium 
influx16' 17• 
We have shown that the sustained phase 4 was selectively attenuated by transient 
cooling, an effect that lasted for several hours (Figure 6). This explains why 
sustained responses have not been found more often, as in most previous studies 
lung tissue was allowed to cool prior to organ bath experiments. The mechanism 
by which cold depresses these responses is not clear; it may be speculated that 
cold depresses the membrane excitability or the mediator generating capacity 
of certain cells in the bronchial strips. However, in vitro experiments have shown 
that temperature-induced membrane changes follow a much faster time course 
than the changes we have observed18 • 
The release of AA-metabolites by human and animal lung tissue has been 
documented extensively. It can be stimulated by addition of specific antigen, 
calcium ionophore, histamine, carbachol or by mechanical stimulation and also 
occurs spontaneously19- 25 • However, the release of AA metabolites by human 
bronchus after field stimulation has not been described before. It remains to 
be determined which cells produce these AA metabolites. The most likely 
candidates are the mast cell26' 27 , which can release mediators after field stimulation 
in vitro (J. Bienenstock, personal communication) or the bronchial epithelium, 
which is an active site of AA metabolism13 . Both cell types are present in the 
bronchial strip. 
We examined the possible role of the bronchial epithelium in a series of 
experiments on paired strips with and without epithelium (Table 2). Phase 2 
contractions were significantly reduced in strips without epithelium. This suggests 
that, after EFS, the epithelium synthetises the prostaglandin-like substance that 
leads to the contractile response phase 2. No difference was found, however, 
between the sustained phase 4 responses of intact and denuded strips, which 
indicates that the LT-like substance that is responsible for the sustained phase 
4 contractions was not produced by the epithelium. 
Our findings show a number of similarities to results of smooth muscle research 
in experimental animals. Sustained responses similar to our phase 4 after EFS 
have been reported by Ordog and coworkers in guinea pig trachea28, without 
demonstration of the underlying mechanism. Lundberg et af9 have reported 
tonic responses of guinea pig main- and hilar bronchus, but not of trachea, 
to EFS, that were blocked by a substance P antagonist. In previous unpublished 
experiments, we have never observed the sustained responses of guinea pig trachea 
to EFS described by Ordog. The sustained contraction of guinea-pig bronchi 
to EFS29 is, however, easily reproducible but different from the human phase 
4 reponses because it has a different time course, is not cold-sensitive and can 
not be blocked by FPL-55712 (unpublished observations). 
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In a recent paper, Nielsen-Kudsk et ae0 reported biphasic contractile responses 
of guinea-pig trachea to high potassium (K} concentrations, with a time course 
that closely mimicked the phase 4 response of the human bronchi. This tonic 
response was Ca ++-influx dependent and coincided with the production of 
inhibitory prostaglandins30• These findings may, however, be fundamentally 
different from what we found in the human tissue, because K+ will depolarize 
airway smooth muscle cells, which leads to Ca++-inf1ux by opening of voltage-
dependent Ca ++ channels, whereas EFS pulses of 0.3 msec will certainly not 
depolarize the muscle cells because of their strong current rectifying properties 
and large electric time- and space constants31 • The K+ effect, therefore, may 
largely be a direct one, whereas EFS acts indirectly via mediator synthesis to 
produce a sustained response. Thus, although in experiments on animal airways 
sustained contractile responses have been found, these may not share a common 
mechanism with the human bronchial phase 4 response. In several airways that 
initially only had a phase 1 and phase 4 response, FPL-55712 not only blocked 
phase 4 but also. revealed a phase 2, that may have been masked by a prominent 
phase 4 initially. This effect of FPL-55712 suggests that phase 2 responses may 
have occurred more often than in the 20% of all preparations in which they 
were seen initially. Like the 'rebound contraction' of ferret and guinea pig 
gastrointestinal smooth muscle, phase 2 was indomethacin sensitive10• It can 
be speculated, therefore, that comparable mechanisms underly the human phase 
2 response and the 'rebound contraction' in tissues that have a common 
embryological origin. There are, however, arguments against this: the rebound 
contraction was considered to be initiated by cessation of EFS and to occur 
only during active NAI relaxation, whereas phase 2 had its onset at the beginning 
of EFS, and was not dependent on the presence of an active relaxation response. 
The present finding of AA-metabolite synthesis by human bronchi after EFS 
in vitro stresses the importance of standardizing procedures and baseline con-
ditions in the study of neural response patterns of human airways. If only the 
nerve-mediated responses are to be examined, inhibitors of AA metabolism seem 
necessary to avoid these interfering response phases 2 and 4, that may otherwise 
distort the neurally mediated responses to an unknown degree. 
L T's are thought to be important in the pathogenesis of obstructive lung 
disease32- 34• Experimental data suggest that LT's are at least partly responsible 
for the bronchoconstriction that follows allergen challenge in asthmatic patients22 • 
The time course of our sustained response, which is probably the consequence 
of L T synthesis, is reminiscent of the course of the early phase of the in vivo 
bronchoconstriction after allergen challenge35 and is also similar to the time 
course of the bronchoconstriction that follows exercise. Furthermore, the 
clinically effective anti-asthmatic drugs dexamethasone and DSCG blocked the 
phase 4 sustained response in vitro. Corticosteroids protect against late allergic 
bronchial responses and also attenuate the immediate bronchoconstriction that 
follows allergen challenge in asthmatics36' 37• Both DSCG and, to a lesser degree, 
corticosteroids protect against exercise-induced bronchoconstriction38• It can 
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therefore be speculated that the presently described sustained in vitro responses 
share a common mechanism with the bronchoconstriction produced by allergen 
challenge or excercise in vivo. It may be worthwile to define the nature of these 
in vitro observations more precisely. 
In conclusion, two mechanisms produce the response of fresh human bronchus 
which has not been cooled to field stimulation: selective stimulation of post-
ganglionic cholinergic and non-adrenergic nerves in the bronchial wall, which 
produces a fast initial contraction (phase 1) followed by a slow relaxation (phase 
3), and stimulation of mediator releasing cells to produce AA-metabolites which 
cause a second rapid (phase 2) and third sustained (phase 4) contraction. The 
latter process appeared selectively sensitive to transient cooling to 4°C, which 
abolished these responses for several hours. 
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Part III 
Human airway smooth muscle function in health 
and disease 

Chapter 10 
Increased in vitro histamine responses in human small airway 
smooth muscle from patients with chronic obstructive 
pulmonary disease 
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Summary 
We tested the hypothesis that abnormal responses of airway smooth muscle 
contribute to the pathogenesis of airway obstruction in chronic obstructive 
pulmonary disease (COPD). For this purpose, lung tissue from 10 patients with 
and 10 patients without COPD was obtained during thoracotomies. Lung function 
was measured preoperatively. The in vitro responses of isolated bronchioles were 
measured using histamine, leukotriene (LT) C4 and methacholine as contracting 
agents, and the results of the in vitro measurements were compared between 
patients with and without COPD. Histamine efficacy (maximal isometric force, 
Tmax) in vitro of bronchioles from patients with COPD was significantly greater 
than the histamine Tmax of the bronchioles from patients without COPD (P 
< 0.01). This difference was probably not due to histamine tachyphylaxis or 
the production of relaxing prostaglandins by airways without COPD, as neither 
mechanism could be detected in separate experiments on airways without COPD. 
No differences were found between in vitro bronchiolar responses to LTC4 and 
methacholine in patients with and patients without COPD. Increased histamine 
responses of small airways may be one of the determinants of airway obstruction 
in COPD. 
Key words: human airway smooth muscle, histamine, methacholine, leukotriene 
C4, chronic obstructive pulmonary disease, bronchial hyperresponsiveness. 
De Jongste JC, Mons, H, Block R, Bonta IL, Fredriksz AP, Kerrebijn KF. Increased in vitro histamine 
responses in human small airway smooth muscle from patients with chronic obstructive pulmonary 
disease. Am Rev Respir Dis 1987;135:549-553. Reprinted with permission of the American Review 
of Respiratory Disease. 
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Introduction 
Increased bronchial responsiveness to nonallergic stimuli is common in patients 
with chronic obstructive pulmonary disease (COPD)1. Although baseline airway 
caliber is considered as an important determinant of this increased responsi-
veness2'3, additional mechanisms may be involved. A number of recent studies 
have compared in vivo bronchial responsiveness in COPD with in vitro responses 
of isolated human airway smooth muscle (ASM). These studies have failed to 
show a relation between in vivo and in vitro bronchial responsiveness4-11 • In 
vitro, human ASM appeared to exhibit a rather constant sensitivity to histamine 
or methacholine, regardless of the degree of bronchial responsiveness in vivo5- 11 • 
However, a possible role of ASM in bronchial hyperresponsiveness in patients 
with COPD has not been excluded. Data ·on absolute responses (isometric force 
development or isotonic shortening) as a measure of efficacy are scanty and 
show no differences between responses of ASM from subjects with and without 
bronchial hyperresponsiveness5' 6• This may, however, be due to the large 
variability of these absolute responses. An increased efficacy of ASM responses 
might well cause in vivo bronchial hyperresponsiveness because small increases 
in ASM shortening can lead to large increases in airways resistance12 • Another 
flaw of previous studies is that airways of different generations have been studied 
together5- 11 , which will have introduced an extra source of variability because 
of differences in contractile properties of central and peripheral ASM. The present 
study was undertaken to test the hypothesis that abnormal responses of ASM 
contribute to the pathogenesis of COPD. We used established in vitro techniques 
with known reproducibility13' 14 to measure the sensitivity and efficacy of human 
small airway ASM responses to contractile agonists (histamine, leukotriene (LT) 
C4 and methacholine) and used only airways of similar caliber (tenth to thirteenth 
generation) in order to limit the variability that will result from taking central 
and peripheral airways together. In vitro ASM responses from airways obtained 
from patients who had no chronic respiratory disease were compared with 
responses of airways from patients with COPD. 
Methods 
Patients 
Twenty patients who were scheduled for pneumonectomy or lobectomy were 
included in the study. Lung resection was indicated because of bronchial 
carcinoma. Preoperatively, all patients underwent lung function studies, including 
measurements of inspiratory vital capacity (VC) and forced expiratory volume 
in 1 sec(FEV 1). To assess reversibility of air-flow limitation, the effect of nebulised 
isoproterenol on baseline airway caliber was determined. According to the criteria 
proposed by the American Thoracic Society, patients were included in the group 
with COPD when there was a history of at least 3 yr of chronic or recurrent 
cough with expectoration (at least 3 months each year) together with air-flow 
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limitation, defined as a FEV1/VC of less than 70%. Patients were classified 
as without COPD when there had been no respiratory symptoms (apart from 
the recent symptoms caused by malignancy) in the past and when lung function 
studies were within normal limits. The smoking habits and recently taken 
medication were recorded. Patients were regarded as non-smokers when they 
had ceased smoking at least 5 yr previously. The study protocol was approved 
by the ethical committee of the University HospitaL 
In vitro measurements 
Immediately after surgical resection, a piece of macroscopically normal lung 
tissue was submerged in ice-cold Krebs-Henseleit buffer (composition, in mM: 
NaCl 118, KCl 4.7, CaCh 2.5, MgS04 1.2, KH2P04 1.2, NaHCO 25, glucose 
5.55) previously gassed with carbogen (5% C02, 95% 02)- The hypoxic delay 
was kept to a minimum (usually well within 15 min). After rapid transportation 
to the laboratory, bronchioles (approximately tenth to thirteenth generation) 
were carefully dissected as described in detail before13 and were cut helically 
at a 45-degree pitch to obtain thin bronchiolar strips measuring approximately 
2 x 20 mm. The preparations were stored overnight in a slow, continuous flow 
of aerated, cooled (4°C) Krebs-Henseleit buffer containing penicillin (3x10-5 g/ 
L) and tobramycin (5xl0-3 g/L). This procedure should provide a thorough 
washout of narcotics (thiopentone, fentanyl, pancuronium, atropine, 02/N20, 
halothane) and of substances possibly lib era ted during the dissection. We formerly 
demonstrated that our storage procedure did not influence the contractile function 
of the preparations 13 • 
The next morning, bronchiolar strips were mounted in 10 ml organ baths 
containing Krebs-Henseleit buffer of 37°C, aerated with carbogen (pH: 7.35; 
Pc02: 4.6 kPa; P02: 71.8 kPa). 
Isometric force was measured using force-displacement transducers (Model 
FT03D; Grass Instruments, Quincy, MA), which were connected via a carrier 
wave amplifier (Peekel instruments, The Nether lands) to a Rikadenki pen recorder 
and a digital volt meter. After 2 h of equilibration with changing of the bath 
fluid every 15 min, a resting tension of 500 mg was applied; preliminary 
experiments had shown that this tension resulted in optimal isometric force 
development by bronchiolar strips. Cumulative concentration-response curves 
(CCRC) were made by adding agonists in small (less than 50 ,ul) volumes. 
Methacholine hydrobromide and histamine hydrochloride (Janssen pharmaceu-
ticals, Belgium) were dissolved in saline. Synthetic LTC4 (a gift of dr. J. Rokach, 
Merck Frosst Laboratories, Canada) was kept on stock in saline at -70°C and 
was diluted before the experiments. Drug solutions were freshly prepared daily 
and kept on ice for the duration of the experiments. 
The CCRC were made using the following concentration ranges: histamine, 
10-8 to 10-4 M; methacholine, 10-8 to 10-4 M; LTC4, 10-Io to 10-7 M. Before 
the measurements were started, each strip was pretreated with methacholine 
(10-8 to 10-4 M in 10-fold concentration steps followed by washout). This was 
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done because we previously found that the first response of a given strip was 
always considerably lower than all subsequent responses, which then showed 
a good reproducibility over a period of at least 55 h 13 • After a maximal response 
was reached, drugs were washed out by changing the bath fluid 4 times at 2 
min intervals, and thereafter every 15 min until return to baseline. Most 
preparations had a stable baseline tension throughout the day; incidentally, 
preparations required minor adjustments in order to restore a 500 mg resting 
tension before starting a new CCRC. Successive CCRC were separated by 2 
h intervals. 
From a CCRC, the following parameters were derived: ECso, (the molar 
concentration of an agonist that causes 50% of its maximal effect on a given 
strip) as a measure of sensitivity, and Tmax (the maximal isometric force expressed 
in milligrams of force per milligram of dry weight of the bronchiole), as a measure 
of efficacy. Dry weight was determined after completion of an experiment by 
weighing the bronchiole after 48 h drying in ambient air at room temperature. 
Three bronchioles from each patient were studied and the three different agonists 
were applied to each preparation in a sequence determined by randomised (3x3) 
latin squares. In this way, triple CCRC for each agonist were obtained in all 
patients. We previously showed that this procedure did not result in interactions 
between agonists with regard to the sensitivity of the tissue14• Therefore, the 
geometric mean of triplicate (logarithmically transformed) ECso measurements 
was calculated for each agonist in each patient. Because we found that Tmax 
was influenced by subsequent exposition of bronchiolar strips to the various 
agonists14, only the first CCRC of each strip was used to calculate Tmax· 
In a separate set of experiments, we examined whether histamine tachyphylaxis 
and/or the production of endogenous prostaglandins modulate the bronchiolar 
response to histamine. Three sequential histamine CCRC were carried out with 
an interval of 1 h between curves on two bronchioles from each of 7 patients 
without COPD, indomethacin (3x10-6 M), a prostaglandin synthesis inhibitor, 
being present in 1 of the 2 organ baths. Also, on a third strip from each of 
the 7 tissue specimens, two successive non-cumulative histamine curves (NCCRC) 
were made. 
Statistical methods 
All data of the two patient groups were compared using Student's t-test (two 
tailed) as within the groups the data were normally distributed. Successive 
histamine CCRC, histamine CCRC with and without indomethacin as well as 
histamine CCRC and NCCRC were compared using Student's paired t-tests 
(two tailed, a= 0.05). 
Results 
Clinical and lung function data are given in Table 1. Twenty patients were divided 
in 2 groups according to the absence or presence of COPD. All patients with 
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Table 1. Patient characteristics 
Subject Age Sex vc FEV1/VC ~FEV1" Current Medication' 
no. (yr) (% pred) (%) (%) Cigarette 
smokinl 
Patients without COPD 
1 63 M 90 78 
2 74 M 79 70 4 
3 58 M 100 70 0 + 
4 55 M 102 77 0 
5 53 M 119 73 
6 58 M 94 78 ++ 
7 49 M 110 90 0 + 
8 45 M 117 73 ++ 
9 69 M 108 75 pipe 
10 67 M 116 76 
mean±SEM 59±3 104±4 75±2 
Patients with COPD 
11 69 M 100 53 10 + ster 
12 55 M 94 67 0 ++ 
13 68 M 91 38 
14 76 M 78 49 ++ ipr 
15 57 M 113 60 6 
16 69 M 89 59 2 + 
17 56 M 115 45 4 ++ 
18 64 M 56 65 12 ++ 
19 63 M 95 44 ster, ipr, sal 
20 61 M 83 45 0 ++ ster, ipr 
mean±SEM 64±2 91±5 53±5 
Abbreviations: VC, vital capacity; FEV1, forced expiratory volume in 1 sec; 
a ~FEVJ:% increase in baseline FEVI after inhalation of isoproterenol. 
b Cigarette smoking: minus sign= no smoking for 5 yr of more; plus sign= current smoking 20 
cigarettes per day or less; double plus sign= more than 25 cigarettes per day for more than 1 
yr. 
' Medication regularly used before the operation: ster =corticosteroids (prednisolone or dexametha-
son e); ipr·= ipratropiumbromide; sal= salbutamol. 
COPD had a history of recurrent or chronic cough with expectoration of (usually 
non-purulent) sputum and had had airflow limitation for more than 3 yr. None 
had a history suggestive of asthma. The mean age of the two groups was similar. 
Current cigarette smoking was more frequent in patients with COPD. Heavy 
smoking, defined as smoking more than 25 cigarettes per day for more than 
1 yr, was reported by 2 subjects without and 5 with COPD. The lung function 
measurements indicated that the baseline VC was not significantly different 
between the 2 groups, although it tended to be lower in the COPD group. By 
definition, all patients with COPD had airflow limitation (FEVJVC ratio below 
70%). In 7 patients with COPD, the effect of nebulised isoproterenol on baseline 
FEV1 was determined. Most patients showed only minor improvement. 
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In vitro studies 
Histamine, L TC4 and methacholine caused concentration-dependent responses 
in all bronchioles. The mean CCRC for histamine, methacholine and LTC4 are 
shown in Figures 1, 2 and 3, respectively; the -log ECso and Tmax values for 
each patient separately are given in Table 2. From Figure 1 it can be seen 
that histamine efficacy was significantly greater in patients with COPD from 
5x10-7 M to 10-4 M. Histamine Tmax was twofold higher in the patients with 
COPD than in those without (P<O.Ol), but methacholine and LTC4 efficacy 
were similar (Figures 2 and 3). The ECso values were comparable to our previous 
results in a random group of patients14 in that LTC4 (-log ECso: 8.09±0.07 
and 7.95±0.06 in airways without and with COPD, respectively) was 100 times 
more potent than both histamine and methacholine, and that methacholine 
(-log EC5o: 6.24±0.14 and 6.05 ±0.12 in airways without and with COPD, 
respectively) was slightly more potent than histamine (-log ECso: 5.85 ± 0.08 
and 5.85 ± 0.11 in airways without and with COPD, respectively). No differences 
in EC5o were found between the 2 patient groups. There was no consistent effect 
of smoking on in vitro responses. The use of medication was not associated 
with changes in in vitro responses. The results of the experiments on histamine 
tachyphylaxis and the effect of prostaglandin synthesis inhibition are shown 
in Table 3. No tachyphylaxis to histamine was found in experiments with and 
without indomethacin. In accordance with our earlier findings 14 , most bronchioles 
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HISTAMINE CONCENTRATION (M) 
Figure 1. Mean histamine concentration-response curves of airway smooth muscle preparations from 
10 patients with COPD (filled circles) and 10 patients without COPD (open circles). * p<0.05 
* * p<O.Ol. The vertical axis depicts isometric force, expressed in mg force per mg dry weight 
(D W) of the airway preparation. 
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showed some increase of T max with time. There were no differences m ECso 
and Tmax of CCRC with or without indomethacin and NCCRC. 
100 ISOMETRIC FORCE 
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0 no C.O.P.D. (nolO) 
' C.O.P.D. (nolO) 
mean±S.E.M. 
lo- 10 10-9 10-8 10-7 
LTC 4 - CONCENTRATION (M) 
Figure 2. Mean LTC. concentration-response curves of airway smooth muscle preparations from 
10 patients with COPD (closed circles) and 10 patients without COPD (open circles). DW=dry 
weight. 
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100 
80 
60 
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20 0 no C.O.P.D. (nolO) 
' C.O.P.D. (nolO) 
mean± S.E.M. 
METHACHOLINE CONCENTRATION (M) 
Figure 3. Mean methacholine concentration-response curves of airway smooth muscle preparations 
from 10 patients with COPD (closed circles) and 10 patients without COPD (open circles). DW= dry 
weight. 
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Table 2. In vitro responses of bronchiolar strips 
Subject -log ECso' Tm.x (mg force/mg dry weight) 
no. 
Histamine LTC. Methacholine Histamine LTC4 
Patients without COPD 
1 5.71 8.22 6.65 59 114 
2 5.96 7.86 6.13 48 40 
3 5.37 7.87 5.65 37 32 
4 6.03 7.84 6.04 34 46 
5 5.95 8.35 6.53 54 71 
6 6.11 8.18 6.20 70 73 
7 6.07 8.15 6.78 67 56 
8 6.10 8.42 6.81 48 45 
9 5.68 8.21 5.77 44 79 
10 5.55 7.83 5.81 55 185 
mean± S.E.M. 5.85 ± 0.08 8.09±0.07 6.24±0.14 2±4* 74±14 
Patients with COPD 
11 6.18 8.22 6.24 121 121 
12 6.19 8.02 6.58 104 104 
13 6.03 8.04 5.70 89 75 
14 5.88 7.95 6.16 107 63 
15 5.84 8.15 6.31 54 138 
16 5.51 7.79 6.05 57 60 
17 6.01 8.06 6.00 53 61 
18 5.84 7.68 5.78 212 71 
19 5.96 7.89 6.39 99 124 
20 5.04 7.67 5.24 124 17 
mean± S.E.M. 5.85 ± 0.11 7.95±0.06 6.05±0.12 102± 15* 83± 12 
a -logEC5o values are the mean of 3 measurements (see: Methods) 
* p<0.01 (comparison ofnon-COPD with COPD). 
Table 3. Sequential histamine responses of human bronchioles 
-log ECso' 
CCRC, without indomethacin 
CCRC, with indomethacin 
NCCRC 
Tmaxb 
CCRC, without indomethacin 
CCRC, with indomethacin 
NCCRC 
first 
response 
5.98±0.13 
6.13 ± 0.16 
5.87±0.09 
100 
100 
100 
second 
response 
5.95±0.13 
5.90±0.11 
5.87±0.06 
112±6% 
93±6% 
135±21% 
Definition of abbreviations: CCRC =cumulative concentration- response curves; 
Methacholine 
132 
84 
108 
103 
52 
92 
24 
53 
90 
260 
100±20 
79 
75 
123 
124 
73 
55 
12 
76 
90 
113 
82± 11 
third 
response 
5.87±0.14 
5.86±0.10 
104±5% 
120± 14% 
NCCRC =noncumulative curves; T max= maximal isometric force expressed in milligrams of force 
per milligram of dry weight. 
' All values are mean± S.E.M. of 7 experiments. 
b Tm.x is expressed as % of the first CCRC T max in each strip (mean± SEM, n = 7). 
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Discussion 
The present results suggest that the histamine efficacy in ASM of patients with 
COPD is greater than that in ASM of patients without COPD. This was not 
found in earlier studies5' 7'9'11 • Furthermore, our findings show that smoking does 
not influence in vitro ASM responsiveness in subjects with or without COPD. 
No significant differences were found regarding the in vitro responses to 
methacholine, which is in agreement with previous studies6'8' 10, and to LTC4, 
which has not been reported before. By selection, both patient groups differed 
significantly in baseline airway caliber, which could be responsible for the altered 
histamine efficacy. This seems unlikely, however, because FEV1/VC and Tmax 
were not linearly correlated in the COPD group. 
A number of methodologic factors may be responsible for the discrepancy 
between our results and those of other investigators. Measuring abnormalities 
in efficacy requires a strictly standardized technique, such as applied by us; 
otherwise the within-subjects variability will be so large that it would be virtually 
impossible to detect differences between patients. Although in our hands this 
variability is still considerable13, the present results show differences that exceed 
the expected random variation. 
Furthermore, our results regarding histamine responses may be determined 
by the fact that we studied bronchioles only, whereas other investigators have 
also or exclusively used larger airways. From functional and autoradiographic 
studies it is known that histaminergic and cholinergic responses and receptor 
numbers in central and peripheral airways differ, histamine being more effective 
in peripheral airways15-19. Therefore, an increased histamine efficacy in vitro 
may be limited to the small airways and will not be detected when central airways 
are also included. This is supported by the findings by Roberts et al9 and Cerrina 
et al11 , who studied larger airways only, using a technique similar to ours. These 
investigators did not find differences in histamine responses of airways from 
patients with and without chronic bronchitis, although T max values were only 
mentioned in the study by Roberts et al9• 
It can be argued that human ASM functions isotonically in vivo and that 
our method measured isometric force, which may not be entirely relevant. 
However, we have shown that isometric and isotonic responses of human ASM 
to various agonists (including histamine, LTCr and methacholine) show only 
a very small and consistent difference with respect to ECso and that maximal 
shortening and force are linearly related20 • This makes it unlikely that different 
results would have been obtained had responses been measured isotonically. 
Others have compared the results of in vivo bronchial challenges with in vitro 
responsiveness of airways and were unable to demonstrate a relation between 
the two5-11 • This may not be surprising because bronchial responsiveness in vivo 
is variable in time and is modified by a number of internal factors (baseline 
airway caliber, vagal nerve activity, infection, smoking, antigen provocation)2 \ 
which probably do not act by changing ASM function. Such a comparison is 
further complicated by the fact that in vivo challenges almost never produce 
116 
complete dose-response curves. Sensitivity could be determined in vivo by 
measuring the threshold doses, even admitting that measurement errors are a 
problem. Incomplete curves do not allow accurate measurements of efficacy. 
Receptor theories should therefore not be used to explain in vivo data. 
An increased specific histamine efficacy of isolated human ASM has been 
described once before in a single bronchus from an asthmatic patient22• Although 
the few reports that exist on in vitro responses of human asthmatic airways 
do not confirm this finding9' 11' 23' 24, this may well be due to large differences 
in the applied techniques. Asthma and COPD or chronic bronchitis may be 
different expressions of the same genetic abnormalitl5• If this hypothesis is 
true, it would be logical to find similar abnormalities in ASM from asthmatics 
and 'bronchitics', which supports the idea that this abnormality has genetic 
determinants. 
Our results do not allow conclusions regarding the mechanism that produces 
the difference in histamine efficacy. The similarity of the in vitro responses to 
both methacholine and LTC4 in patients with and without COPD argues against 
nonspecific mechanisms such as ASM hyperplasia or an increased cell-to-cell 
coupling of the smooth muscle cells26. From the present findings it cannot be 
determined whether the histamine response is increased in subjects with COPD 
or suppressed in those without. Several possible explanations for the observed 
difference can therefore be put forward. Histamine may give rise to the production 
of arachidonic acid metabolites by cells in the bronchiolar preparation, e.g., 
the airway epithelial cells. It has been shown that human respiratory epithelium 
is active in producing arachidonic acid metabolites and that stimulation of muscle 
contraction in human bronchus causes the selective synthesis of the relaxant 
prostaglandin (PG)E27' 28 ; preliminary results from our laboratory have shown 
that the bronchiolar strip can release PGEz and prostacyclin spontaneously into 
the organ bath. Inhibitory prostaglandins may depress the ASM histamine 
response to a lesser degree in patients with COPD. Our findings indicate, however, 
that indomethacin does not enhance the response of human small airways to 
histamine, which is in accordance with earlier findings by Brink et al on central 
human airways29 • It seems, therefore, that inhibitory prostaglandins are not the 
cause of the difference in histamine efficacy. 
Alternatively, histamine tachyphylaxis in ASM from patients without COPD 
could explain a decreased response in the course of a CCRC. Selective histamine 
tachyphylaxis, probably caused by endogenous PG synthesis, has been de-
monstrated in isolated canine ASM30• We found, however, that histamine 
tachyphylaxis did not occur during 3 successive CCRC on human small airway 
preparations, and that cumulative and noncumulative CRC were not different. 
Thus, it seems unlikely that the observed difference is a consequence of histamine 
tachyphylaxis in airways without COPD. 
Finally, the difference may be caused by an altered histamine receptor 
activation-contraction coupling, or non-COPD ASM may have less histamine 
receptors, which would result in a sub-optimal activation by a given histamine 
concentration. These two possibilities cannot be excluded at this moment. Further 
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studies should be done to confirm our findings and to investigate the various 
mechanisms that may be involved. 
In summary, we found a significantly increased efficacy of histamine in 
bronchioles from patients with COPD compared with subjects without COPD. 
In vitro responses to L TC4 and methacholine were not different. We speculate 
that an increased histamine response contributes to the pathogenesis of airflow 
limitation in COPD. 
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Summary 
Airflow limitation and bronchial hyperresponsiveness in chronic bronchitis may 
result from an increased contractility or a decreased relaxability of airway smooth 
muscle (ASM). To elucidate this, we obtained ASM from 10 subjects with and 
10 without chronic obstructive bronchitis at thoracotomies, and measured 
contractile and relaxation responses to the cholinergic agonist methacholine, 
to !.:.isoproterenol, which stimulates ,8-adrenoceptors, and forskolin, which relaxes 
ASM via stimulation of intracellular cAMP production. Furthermore, we applied 
electric field stimulation (EFS) in orderto stimulate non-adrenergic inhibitory 
(NAI) nerves in the bronchial wall, the main direct inhibitory nerve supply to 
human ASM. Methacholine was equipotent in bronchiolar ASM from subjects 
with and without chronic obstructive bronchitis, but its maximal effect in 
bronchitic ASM was significantly lower than in normal ASM (p < 0.05). The 
mean relaxation responses to !-isoproterenol and forskolin were not different 
in the two groups, but 3 of the 10 patients with chronic obstructive bronchitis 
had a maximal relaxation response to !-isoproterenol that was significantly smaller 
than the control values obtained in normal ASM. EFS relaxed airways from 
subjects with and without chronic obstructive bronchitis to a similar degree. 
NAI nerve-mediated responses were relatively ineffective compared to !-iso-
proterenol- and forskolin- induced relaxations. The present findings suggest that 
airflow limitation and hyperresponsiveness in chronic bronchitis are not due 
to abnormal (cholinergic) contractile-, or (adrenergic) relaxation responses of 
bronchiolar ASM, nor to an impaired functioning of the NAI system. A decreased 
,8-receptor function, that is not related to the use of sympathomimetic bron-
chodilator drugs, may however exist in a subgroup of bronchitics. 
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proterenol, forskolin, electric field stimulation, non-adrenergic inhibitory system, 
chronic bronchitis, chronic airflow limitation. 
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Introduction 
Airflow limitation and an increased bronchial responsiveness to nonallergic 
stimuli are frequent findings in chronic bronchitis1. Possible mechanisms that 
underly both the obstruction and the hyperresponsiveness include an increased 
contractility or a decreased relaxability of airway smooth muscle (ASM). The 
sensitivity and maximal contractile response to pharmacological stimulation of 
isolated ASM from subjects with or without chronic bronchitis, airflow limitation 
and bronchial hyperresponsiveness have been compared2- 7• The results of these 
studies indicated that ASM from subjects with airflow limitation or hyperres-
ponsiveness is not hypersensitive to contracting agonists such as histamine or 
methacholine. The maximal response is more difficult to assess accurately in 
vitro than the sensitivity, due to a relatively large intrinsic variability of the 
maximal contractions of human ASM8• We have recently reported increased 
maximal responses to histamine, but not methacholine and leukotriene C4, in 
small airways smooth muscle from subjects with chronic bronchitis and airflow 
limitation7• This finding does not explain, however, why in vivo some subjects 
are hyperresponsive to a wide variety of stimuli. Hypothetically, this could be 
due to defective counteracting mechanisms. Bronchodilatation is probably 
mediated by circulating catecholamines that stimulate a homogenous population 
of /32 adrenergic receptors on ASM9' 10. There is also direct inhibitory innervation 
of ASM, which is non-adrenergic9• Few studies have compared the relaxability 
of human airways in relation to airflow limitation or bronchial hyperrespon-
siveness5'6'11-13. Animal experiments have suggested that {3-adrenoceptor numbers 
and function 14'15 and non-adrenergic inhibitory (NAI) nerve-mediated relaxa-
tions16 are reduced in experimental bronchial hyperresponsiveness. Decreased 
{3-adrenergic responses of ASM from patients with severe airflow limitation and 
hyperresponsiveness have been found by Cerrina et al6 but not by Taylor et 
al5. Studies on ASM from subjects with asthma have produced contradictory 
results 11-13• NAI nerve-mediated relaxation responses of airways from subjects 
with and without airflow limitation and hyperresponsiveness were compared 
in only two reports, suggesting that NAI function is normal in non-asthmatic 
hyperresponsiveness, but may be reduced in asthma5•13. The small number of 
observations and the lack of data on intraindividual reproducibility of in vitro 
findings make it impossible to draw conclusions from the available data. In 
the present study, we measured relaxation responses of isolated ASM from subjects 
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with and without chronic bronchitis and airflow limitation, using the .B:-agonist 
!-isoproterenol and forskolin, a diterpene, which stimulates cyclic adenosine 
monophosphate (cAMP) production independent of receptors. This was done 
to differentiate between defective ,B-receptor function and possible defects in 
intracellular cAMP generation, which both may cause reduced relaxation res-
ponses after ,B-receptor stimulation14. Furthermore, we measured the relaxation 
responses to electric field stimulation (EFS), which activates NAI nerves in the 
bronchial wall. 
Methods 
Lung tissue was obtained from 20 subjects who underwent surgery for bronchial 
malignancies. Prior to thoracotomy, the medical history was taken, and patients 
underwent a physical examination, bronchoscopy and lung function measure-
ments, including the inspiratory vital capacity (IV C), the forced expiratory volume 
in 1 sec (FEV1) before and after 10 mg of inhaled isoproterenol and the total 
lung capacity (TLC), determined with the helium dilution method. Chronic 
obstructive bronchitis was diagnosed according to criteria proposed by the 
Medical Research Council17 when subjects reported chronic cough and sputum 
production for at least two years, and during 3 or more months each year, 
and in case of airflow limitation, defined as an FEV 1/VC ratio that was 2 standard 
deviations or more below predicted mean values (reference values were from 
reference18). Control subjects had no history or symptoms of chronic bronchitis 
or asthma, and a normal lung function. 
In vitro studies 
Immediately after surgical resection, a macroscopically normal piece of lung 
was removed from the resected specimen and transported to the laboratory in 
Krebs-Henseleit buffer (composition in mM: NaC1118, KC14. 7, CaCh 2.3, MgS04 
1.2, KH2P04 1.2, NaHC03 25, glucose 5.55) aerated with 95% 02 and 5% C02. 
Tubular segments of bronchioles (lOth to 13th generation, internal diameter 
0.8 to 1.2 mm, length 2mm) were carefully dissected free from adhering 
parenchyma and blood vessels, using a modification of the technique described 
previously19 and were mounted between two stainless steel wires in 10 ml organ 
baths. Furthermore, cartilaginous airways (5th to 7th generation) were dissected 
and cut spirally to obtain bronchial strips measuring 20 x 2 mm. Bronchiolar 
segments were stored overnight in a slow flow of cold (4°C) aerated buffer19. 
The next day, the segments were equilibrated for 2 h at 37°C while the buffer 
was changed every 15 min. We have previously documented that bronchiolar 
ASM function does not change after this storage procedure19. Isotonic responses 
to pharmacological stimulation were recorded with high-precision angular 
position transducers20, using an isotonic load of 0.5 g. This load stretched the 
segments to their optimal length, as determined in preliminary experiments. All 
segments were primed with methacholine (10-5 M) followed by washout and 
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return to baseline. Subsequently, a full methacholine cumulative concentration-
response curve (CCRC) was made, and the effective concentration that produced 
50% of the maximal response (ECso) was determined. After washout, this EC50 
was applied to induce a baseline contraction plateau from which relaxation 
experiments could be carried out. Relaxation CCRC to either 1-isoproterenol 
or forskolin were made; only one of the two agonists was administered to a 
given segment. After maximal relaxation with 1-isoproterenol (5xl0-6M) or 
forskolin (5xl0-6M), full relaxation was obtained in calcium-free buffer containing 
EDTA (4xl0-3M). The relaxation responses to 1-isoproterenol and forskolin were 
expressed as a percentage of the difference between methacholine EC5o-induced 
contraction and full relaxation in _Ca free buffer. The spontaneous baseline 
contractile state of the ASM was defined as the difference (in ,urn) between 
the initial stable baseline and full relaxation in Ca-free buffer. From each CCRC, 
the ECso was calculated using a computerised iterative curve fitting method, 
and the maximal shortening (Smax) or relaxation (Rmax) were determined. 
Cartilaginous bronchi were used to measure the neurally mediated NAI 
relaxation to EFS, because the NAI system is mainly present in central airways9• 
Bronchial strips were mounted in the organ baths and equilibrated at 37°C in 
aerated buffer under an isotonic load of 1 g. The Krebs-Henseleit buffer that 
was used in EFS experiments contained atropine (1.2xl0-6M) to inhibit cholinergic 
nerve-mediated contractions to EFS, indomethacin (6xl0-6M) and the leukotriene 
antagonist FPL-55712 (11.5xl0-6M), because we have previously found that 
human bronchi can produce bronchoconstricting prostaglandin- and leukotriene-
like substances after EFS21 • In separate strips from 18 subjects, we examined 
the effect of the nervous conductance blocker tetrodotoxin (TTX, 3xl0-6 g/ 
1), to assess the role of nervous conduction in the response to EFS. After an 
equilibration of 2 h, with frequent changing of the buffer, histamine (5xl0-6M) 
was added to induce a contraction plateau. EFS was applied via platinum plate 
electrodes parallel to the bronchial strips, and rectangular pulses of alternating 
polarity were delivered by a voltage-constant custom made tissue stimulator. 
Frequency-response curves to EFS were made by applying graded EFS as 
described previously13, using 0.3 msec, 50 V pulses at frequencies of 1 to 50 
Hz. After maximal relaxation to EFS, full relaxation of the strips was obtained 
in Ca-free buffer with EDT A and l-isoproterenoll0-5M. Responses to EFS were 
expressed as a percentage of full relaxation. The frequency that produced 50% 
of the maximal effect of EFS (EFso) was determined by linear interpolation. 
Data analysis 
Mean values of the negative logarithms of ECso, the EFso, and the maximal 
responses to methacholine, 1-isoproterenol, forskolin and EFS, obtained in 
airways from patients with and without chronic obstructive bronchitis, were 
compared, and the significance of the differences between means was determined 
with Students t-test for unpaired samples (two tailed, a= 0.05). Duplicate or 
triplicate measurements were avaraged before inclusion in the statistical analysis. 
All values are given as means ± 1 S.E.M. 
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Drug sources 
Methacholine hydro bromide, !-isoproterenol and histamine dihydrochloride were 
purchased from Janssen pharmaceuticals, Belgium; indomethacin from Duchefa, 
The Netherlands; and TTX from Sigma, U.S.A. Forskolin was a gift from Hoechst 
Pharma, Holland, and FPL-55712 was provided by Fisons, U.K .. Buffer chemicals 
were analytical grade from Merck, F.R.G. 
Results 
The clinical, anthropometric and lung function data of the 20 subjects are given 
in Table 1. Ten subjects had chronic bronchitis and significant airflow limitation, 
and 10 were without symptoms and had a normal lung function. In both groups, 
7 subjects currently smoked cigarettes; heavy smoking (more thans 25 cigarettes 
per day for more than 1 year) was more common in bronchitics. Five patients 
with chronic obstructive bronchitis used bronchodilator drugs: theophylline 
(no.l4) and ,8-agonists (no.16,17 and 19), and three were treated preoperatively 
with oral dexamethasone (no.ll, 12 and 17). None ofthe control subjects received 
bronchoactive drugs. None of the subjects had central airway obstruction by 
tumor, as judged by preoperative bronchoscopy, and none had a clinical history 
suggestive of asthma. 
In vitro measurements 
All bronchiolar segments contracted dose-dependently to methacholine and 
relaxed to !-isoproterenol and forskolin. The mean values of -logECso, Smax and 
Rmax in each subject are given in Table 2. The contractions induced by 
methacholine in normal bronchiolar ASM were significantly greater than in ASM 
from bronchi tics (Smax: 1121 ± 146 ~m and 718 ± 112 ~m, respectively; p < 0.05). 
The mean -logECso was, however, similar (Figure 1). No differences were found 
between controls and bronchitics with respect to the mean -logECso and Rmax 
to !-isoproterenol and forskolin (Table 2, Figures 2 and 3). Three bronchitics 
(cases no.15, 16 and 20) had a low Rmax to !-isoproterenol that was outside 
the 95% confidence limits of the control group. The response to !-isoproterenol 
was not systematically reduced in the subjects that regularly used ,8-agonists, 
and no differences in in vitro responses were found in subjects that received 
dexamethasone. Forskolin was slightly less potent than !-isoproterenol (overall 
mean -logECso: 6.88 and 7.43 respectively), but always caused more relaxation 
(Rmax 97% and 87% respectively). 
Central airways were obtained from 9 controls and 10 bronchitics. No differences 
between the groups were found in the relaxation responses of bronchial strips 
to EFS, with or without TTX (Table 2, Figure 4). Relaxation responses to EFS 
were only 10-20% reduced in the presence of TTX, especially at lower stimulus 
frequencies (Figure 4). EFS was relatively ineffective, producing a mean maximal 
relaxation of 61,5%. All preparations had an intrinsic spontaneous baseline 
Table 1. Patient characteristics 
-N 
.j:>. 
Lung functiond 
case sex age current medicationb tumor IVC IVC FEVI FEVI/IVC% TLC TLC 
no (yr) smoking' location' (ml) % pred. (ml) before after (ml) % pred. 
bronchodilator 
Normals 
1 F 23 - - RL 3470 92 2860 82 ND 4940 99 
2 M 45 + RU 3580 112 2890 75 77 5080 102 
3 M 60 ++ - RL 4500 102 3200 72 ND 6900 99 
4 M 62 + RU 3440 114 2435 71 ND 5230 100 
5 M 63 + - RU 3400 102 2700 79 ND 5540 97 
6 F 54 + RU 4320 119 3400 79 ND 6920 119 
7 M 71 + - LL 3760 88 2680 71 ND 6430 89 
8 M 65 ex LU 3750 100 2780 74 ND 6050 93 
9 M 77 pipe - RL 4000 116 2870 72 ND ND ND 
10 M 58 ex RU 4900 123 3600 73 ND 8700 139 
Chronic obstructive bronchitis 
11 M 55 ++ ster RL 4700 91 2600 54 54 ND ND 
12 M 64 + ster RM 4500 92 2900 64 64 ND ND 
13 M 62 ++ - RL 4340 91 2860 66 70 7070 94 
14 M 72 ex theo LL 4040 81 1820 45 47 ND ND 
15 M 70 ++ - LU 4700 107 2500 52 ND 8000 108 
16 F 36 + sal LL 4100 111 2800 70 72 ND ND 
17 M 63 ex sal,ster RU 4060 93 2100 52 52 6950 98 
18 M 73 + theo RLIRM 3030 69 1380 46 46 5820 83 
19 M 63 ex sal LL 3500 90 2200 63 66 6700 102 
20 M 72 + - RL 3550 91 1715 48 ND 7420 110 
'Smoking: +, less than 25 cigarettes per day; ++, more than 25 cigarettes per day for one year or more prior to surgery; ex, ceased smoking 
at least 2 years previously. 
bMedication: ster, corticosteroids; theo, theophyllin; sal, salbutamol. 
'Abbreviations: RU, RM, RL: right upper, middle or lower lobe; LU, LL: left upper, left lower lobe. 
dAbbreviations: IVC, inspiratory vital capacity; FEV1, forced expiratory volume in 1 sec.; TLC, total lung capacity. Predicted values are from 
reference ( 18). 
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Figure 1. Mean cumulative concentration-response curves to methacholine of ASM preparations 
from control subjects (47 segments from 10 subjects) and patients with chronic obstructive bronchitis 
(38 segments from 10 subjects), represented by open and filled circles, respectively. The vertical 
axis depicts isotonic shortening of ASM, expressed in /-Lm, and the horizontal axis shows the molar 
methacholine concentrations on a log scale. The difference in maximal responses is significant (Students 
t-test, 0.02<p<0.05). 
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Figure 2. Mean cumulative concentration-response curves to !-isoproterenol of ASM preparations 
from control subjects (open circles, n=25 segments from 10 subjects) and patients with chronic 
obstructive bronchitis (filled circles, n = 19 segments from 10 patients). The vertical axis depicts 
relaxation of methacholine ECso-induced baseline contraction as a percentage of full relaxation 
obtained inCa-free buffer containing EDTA (4x10-3M). No difference was found between the curves. 
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Figure 3. Mean cumulative concentration-response curves to forskolin of ASM preparations from 
control subjects (open circles, n=22 segments from 10 subjects) and patients with chronic bronchitis 
(filled circles, n= 19 segments from 10 patients). The vertical axis depicts relaxation of methacholine 
ECso-induced baseline contraction as a percentage of full relaxation obtained in Ca-free buffer 
containing EDTA (4xl0-3M). No difference was found between the curves. 
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Figure 4. Mean frequency-response curves to graded electric field stimulation of bronchial strips 
from 9 control subjects (15 strips, open circles) and 10 patients with chronic obstructive bronchitis 
(20 strips, filled circles). Relaxation responses were obtained in the presence of atropine, indomethacin, 
FPL-55712 and histamine (see: methods) and are the consequence of stimulation of non-adrenergic 
inhibitory nerves in the bronchial wall. Broken lines indicate relaxation responses obtained in the 
presence of the nervous conductance blocker TTX (n = 11 strips from 9 controls and n = 8 strips 
from 8 bronchitics). The vertical axis depicts relaxation of histamine (5xl0-6M)-induced precon-
traction, as a percentage of full relaxation obtained inCa-free buffer containing EDTA (4xl0-3M). 
The horizontal axis shows the frequency of EFS in Hz on a log scale. No significant differences 
were found between relaxation responses of bronchial strips from controls and from patients with 
chronic obstructive bronchitis. 
Table 2. Results of in vitro studies 
Case 
no 
Methacholine L-isoproterenol 
-log ECso Smax -log ECso Rmax 
(/-Lm) 
Normals 
I 5.47 962 7.89 
2 6.49 546 7.46 
3 6.33 1061 6.80 
4 6.10 1099 6.80 
5 5.95 605 7.86 
6 5.97 1290 7.77 
7 5.85 2198 7.91 
8 6.36 1205 7.33 
9 6.40 901 7.56 
10 6.65 1344 7.68 
Mean 6.16 1121* 7.51 
SEM 0.11 146 0.13 
Chronic obstructive bronchitis 
II 6.25 924 7.07 
7.52 
7.56 
8.05 
7.14 
12 6.04 358 
13 6.06 690 
14 
15 
16 
17 
18 
19 
20 
mean 
SEM 
5.91 
5.91 
6.74 
6.07 
6.20 
5.96 
5.96 
6.11 
0.08 
316 
564 
216 7.31 
736 7.51 
1182 7.00 
1154 7.09 
1038 7.18 
718* 7.34 
112 0.10 
(%) 
96 
82 
91 
91 
84 
82 
92 
87 
93 
94 
89 
2 
100 
96 
90 
96 
75 
68 
87 
88 
92 
64 
86 
4 
Forskolin 
-log ECso Rmax 
7.45 
7.12 
6.71 
6.75 
7.03 
6.66 
6.80 
6.75 
7.18 
6.92 
6.94 
0.08 
7.05 
6.89 
6.73 
6.87 
6.75 
6.59 
6.98 
6.78 
6.57 
6.91 
6.81 
0.05 
(%) 
98 
97 
97 
98 
99 
97 
96 
94 
99 
94 
97 
I 
100 
98 
95 
94 
95 
96 
92 
99 
95 
96 
96 
Field stimulation 
EFso Rmax 
(Hz) (%) 
3.2 
1.6 
10.0 
6.8 
3.4 
2.9 
1.0 
2.2 
1.5 
ND 
3.6 
1.0 
3.5 
1.9 
5.0 
5.4 
1.7 
2.6 
2.0 
4.1 
2.4 
3.1 
3.2 
0.4 
39 
62 
67 
61 
55 
47 
74 
83 
83 
ND 
63 
5 
39 
49 
36 
38 
91 
61 
78 
79 
78 
50 
60 
6 
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Individual values are the means of 2-6 measurements for pharmalogical experiments, and of 1-3 
measurements for EFS experiments. 
*indicates a significant difference between the 2 groups (p < 0.05). 
contraction that was stable in time. There was no difference in the spontaneous 
contraction of ASM from bronchitics and controls (688.8±93.9 /-LID and 
709.6 ± 71.4 /-LID respectively). In addition, no relation was found between Smax 
to methacholine and intrinsic baseline contraction of the ASM. 
Discussion 
The present results indicate that ASM from subjects with chronic obstructive 
bronchitis relaxes normally in response to !-isoproterenol, forskolin and to EFS 
of NAI nerves. Contractions to methacholine were significantly higher in the 
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control group. Previous functional experiments on human airways have de~ 
monstrated no significant differences in the relaxation responses of human ASM 
from subjects with and without chronic bronchitis arid/or bronchial hyperres-
ponsiveness, which is in agreement with the present results5' 6' 13 • Furthermore 
we confirmed the observation by Taylor et al5 that ASM in chronic obstructive 
bronchitis can generate sufficient cAMP in response to forskolin to produce 
maximal relaxation. Receptor binding studies on human lung homogenates have 
shown no differences in the numbers of ,8-adrenoceptors in normal lungs and 
lungs from patients with chronic obstructive bronchitis9 • In the lung, ,8-
adrenoceptors are, however, not exclusively present on ASM cells, but also on 
many other cell types such as epithelial cells, mast cells and mucus secreting 
cells9 • Therefore the studies in tissue homogenates did not allow conclusions 
on ,8-adrenoceptor density on ASM cells. 
Airway inflammation is a uniform histopathologic feature of chronic bronchitis 
that is associated with in vivo bronchial hyperresponsiveness22• In the guinea 
pig, activated macrophages induce ,8-adrenoceptor desensitisation23 , probably 
via the production of hydroxyl radicals24 • It is likely that oxygen radicals also 
play a role in the chronic airway inflammation in chronic bronchitis25 • A decreased 
,8-adrenoceptor function might therefore occur in airways from subjects with 
chronic bronchitis. Although, in the present functional studies, no differences 
have been found in the mean responses to ,8-receptor stimulation of airways 
from patients with and without chronic obstructive bronchitis, three bronchitics 
had a low Rmax to 1-isoproterenol of 75, 68 and 64%, with a normal ECso (cases 
15, 16 and 20 respectively). These Rmax values fell outside the narrow 95% 
confidence limits of the control group. One of these 3 patients (no.16) used 
salbutamol, the other 2 had not received bronchodilators; none received cor-
ticosteroids. These 3 subjects had no common clinical features to which their 
abnormally low relaxation response to ,8-adrenoceptor stimulation could be 
attributed. Their ASM Rmax to forskolin was 95, 96 and 96% respectively, so 
the impaired relaxability was probably due to ,8-receptor dysfunction, and not 
to deficient cAMP production. It seems therefore, that impaired ,8-receptor 
function may occur in a subgroup of patients with chronic obstructive bronchitis. 
It has been speculated by Barnes9 that airway inflammation may produce 
NAI hyporesponsiveness, because proteolytic enzymes that are released by 
inflammatory cells could inactivate the NAI neurotransmitter, which is probably 
a peptide. Such an inactivation might favour bronchoconstriction. We found 
normal relaxation responses to EFS in central airways from patients with chronic 
bronchitis, which argues against this hypothesis. The present results are, however, 
not conclusive because it is not known if inflammatory cells in isolated bronchus 
behave as they do in vivo. 
There are few data in the literature on the function of the NAI system in 
human obstructive airway diseases. In one report on a relatively small number 
of non-asthmatic subjects, NAI responses were not related to bronchial hyper-
responsiveness in vivo5• We have previously found that NAI responses in human 
asthmatic airways were in the low-normal range13 • Thus, at present, there are 
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no convincing data to support a defect ofthe NAI system in subjects with chronic 
obstructive bronchitis and airway hyperresponsiveness. Since airflow limitation 
and hyperresponsiveness in asthma and chronic bronchitis have different cha-
racteristics1'26, the present results do not exclude a defect of the NAI system 
in asthma. Clearly, more work needs to be done on this subject. 
Surprisingly, ASM in the control group had a higher mean maximal contractile 
response to methacholine than ASM from bronchitics. In a previous study, we 
also found a trendwise, but not significant, difference in maximal methacholine 
responses (measured as isometric force) of ASM from similar populations of 
normals and bronchitics 7. The significance of the difference (0.02 < p < 0.05) 
found in the present study may be related to the fourfold larger number of 
observations in the present study, and possibly to methodological factors such 
as the use of bronchiolar segments in stead of spiral strips. It is not likely that 
isometric and isotonic methods produce different results, because force devel-
opment and ASM shortening are linearly related in experiments like the present27 . 
In vivo, subjects with and without chronic obstructive bronchitis are often 
hyperresponsive to inhaled methacholine 1'26 . The apparent discrepancy between 
the in vitro and in vivo responses to methacholine may be related to the fact 
that we have studied methacholine responses only in small airways. Cholinergic 
receptor density decreases from central to peripheral airways28 . In previous in 
vitro studies on central human airways, no differences in ASM responses to 
cholinergic stimulation were found between subjects with and without chronic 
bronchitis, airflow limitation or hyperresponsiveness4' 5• In peripheral lung tissue 
homogenates, receptor binding studies have suggested a decreased number of 
muscarinic receptors in chronic bronchitis29. Decreased cholinergic responses 
in chronic bronchitis may therefore be limited to small airways. 
We have considered the alternative possibility that a higher intrinsic muscle 
contraction limited the maximal response to methacholine in bronchitics. This 
appeared not to be the case, however, because a similar baseline contractile 
state was found in airways from normals and bronchitics. Furthermore there 
was no relation between Smax and baseline ASM contractile state within the 
two groups. Finally it could be that the 0.5 g isotonic load that was imposed 
on all ASM segments was not optimal for ASM from bronchitics. In preliminary 
studies, maximal contractions were invariably obtained with a 0.5 g preload, 
irrespective of the clinical diagnosis. However we did not perform length-tension 
experiments routinely before and after each CCRC, so this possibility cannot 
be excluded. 
In summary, we found normal relaxation responses to !-isoproterenol and 
forskolin, and normal responses after stimulation of NAI nerves in ASM from 
patients with chronic obstructive bronchitis. There are indications, however, that 
,8-receptor function may be defective in a subgroup of patients with chronic 
obstructive bronchitis, independent of the use of ,8-adrenergic drugs. In addition 
we found a reduced ASM contractility to methacholine in bronchitics. These 
results suggest that airflow limitation and bronchial hyperresponsiveness in 
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chronic obstructive bronchitis are neither due to an increased cholinergic 
responsiveness of small airway ASM, nor to a general impairment of ASM 
relaxability, or to a defective NAI system. Other possible mechanisms, including 
differences in baseline airway caliber, mucosal inflammation, abnormal auto-
nomic control or changes in airway mechanics, may therefore be more important. 
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Chapter 12 
Comparison of human bronchiolar smooth muscle responsive-
ness in vitro with histological signs of inflammation 
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Departments of Paediatric Respiratory Diseases, Pharmacology (LL.B.) and Bio-
statistics (R.S.), Erasmus University Rotterdam/Sophia Children's Hospital, 
Rotterdam, The Netherlands. 
Summary 
A study was carried out to test the hypothesis that chronic inflammation is 
associated with an increased sensitivity or contractility of human airway smooth 
muscle. Bronchiolar strips from 30 patients, 12 of whom had chronic bronchitis, 
were examined in the organ bath for their responses to histamine, methacholine 
and leukotriene (LT) C4. The same airways were also studied histologically and 
small airway disease (S.A.D.) was quantified by subjective grading of the degree 
of inflammatory cell infiltration, smooth muscle hypertrophy, fibrosis and goblet 
cell hyperplasia. We found a wide variation of S.A.D. in patients with and 
without chronic bronchitis. Multiple regression analysis failed to demonstrate 
increased sensitivity (-logECso) to histamine, methacholine or LTC4 in relation 
to S.A.D .. In contrast the only significant correlations found were between a 
decreased -logECso to histamine and methacholine and an increased S.A.D. score. 
Contractile responses (Tmax) to histamine and methacholine in peripheral airways 
from patients with chronic bronchitis tended to be higher than in airways from 
patients without chronic bronchitis. This increased T max was not related to the 
degree of S.A.D. These results suggest that chronic airway inflammation does 
not cause in vitro hyperresponsiveness of human small airway smooth muscle. 
Key words: airway inflammation, chronic bronchitis, small airway disease, 
bronchial smooth muscle, airway responsiveness, methacholine, histamine, leu-
kotriene c4 
De Jongste JC, Mons H, Van Strik R, Bonta IL, Kerrebijn KF. Comparison of human bronchiolar 
smooth muscle responsiveness in vitro with histological signs of inflammation. Thorax 1987, in 
press. Reprinted with permission of the British Medical Association. 
134 
Introduction 
Clinical observations have led to the view that airway inflammation may be 
an important modulator of nonspecific bronchial responsiveness in patients with 
asthma or chronic bronchitis and even in normal individualsl-5. Moreover, we 
recently found an increased histamine responsiveness in isolated peripheral 
airways from patients with chronic bronchitis and airflow limitation6• The 
mechanisms by which inflammation could enhance bronchial responsiveness are 
not clear. Few studies have examined the responsiveness of isolated human airways 
in relation to the histological appearance of the bronchial tissue, and these studies 
have shown no relation between the degree of airway disease and function7' 8 • 
In the present study, we measured the functional responses to pharmacological 
stimulation of isolated peripheral airways from patients with and without chronic 
bronchitis and/or airflow limitation and quantified various histological aspects 
of small airway disease (S.A.D.) in the same preparations by means of a subjective 
grading method. Functional data were related to histological findings to determine 
whether inflamed peripheral airways are more responsive in vitro than non-
inflamed airways. 
Methods 
Patients 
Thirty patients who underwent lobectomy or pneumonectomy, 29 for bronchial 
carcinoma and one for carcinoid, were included in the study. All patients had 
lung function tests before surgery, including inspiratory vital capacity (VC) and 
forced expiratory volume in 1 sec (FEV t) before and after 10 mg of nebulised 
isoproterenol. Chronic bronchitis was diagnosed according to the Medical 
Research Council criteria of cough and phlegm production for more than two 
years and more than three months in a year9 • Subjects were classified as normal 
when they reported no respiratory symptoms, apart from recent symptoms caused 
by their tumor, and had a normal lung function with an FEVt/VC of at least 
70%. In 11 patients bronchial responsiveness was measured in vivo before surgery. 
Nebulised histamine was administered via a Wiesbadener Doppel Inhalator in 
doubling concentrations, and the provocative concentration that caused a 20% 
fall in FEVt from baseline (PC2oFEV1) was calculated10• The study protocol 
was approved by the ethical committee of the University Hospital. 
In vitro studies 
Immediately after surgical resection a macroscopically normal piece of lung tissue 
was collected in ice-cold Krebs-Henseleit buffer (composition, in mM: NaCl 
118, KCl 4,7, CaCh 2,5, MgS04 1,2, KH2P04 1,2, NaHC03 25, glucose 5,55) 
aerated with 5% C02 and 95% 02, and rapidly transported to the laboratory. 
Bronchiolar strips (lOth to 13th generation) were dissected, stored overnight 
and studied isometrically with Grass FT03D transducers, in 10 ml organ baths 
containing aerated Krebs-Henseleit buffer at 37°C as described previously11 • A 
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baseline tension of 500 mg was applied. Histamine hydrochloride, methacholine 
bromide (Janssen pharmaceuticals, Belgium) and leukotriene (LT) C4 (a gift 
from Dr. J. Rokach, Merck Frosst, Canada) were used as contracting agents, 
and three cumulative concentration-response curves (CCRC's) were made in 
succession on a single bronchiolar strip from each patient. The sequence of 
the agonists was determined by a random digits table. From each CCRC, the 
ECso value (the molar agonist concentration that produced 50% of the maximal 
effect on a given strip) was derived as a measure of smooth muscle sensitivity. 
We have previously shown that for ECso measurements this procedure does 
not lead to interactions between these three agonists 12• The maximal force (Tmax, 
contractility) developed by a strip was calculated only for the first CCRC on 
each strip because interactions occur regarding T max when agonists are applied 
successively12• 
Histology 
After dissection of the bronchiolar strips, a proximal segment was removed, 
fixated in formalin and processed for histological examination. We used a 
simplified version of Cosio's subjective grading method 13, adapted for bronchiolar 
strips, to assess the severity of S.A.D .. The items scored were inflammatory 
cell infiltration, smooth muscle hypertrophy, goblet cell hyperplasia and fibrosis. 
Each item was assigned a score (0-3) by comparison with pictorial reference 
standards, 0 representing the normal picture and 1-3 reflecting increasing degrees 
of abnormality (Figure 1). The total S.A.D. score was the sum of scores for 
the four items, so 12 was the maximally attainable score. The validity of the 
scoring system was confirmed in a preliminary study (Kappa-coefficients for 
within and between observer agreement were 0.77±0.07 and 0.66±0.12 respec-
tively (mean± S.E.M)). 
Statistical analysis 
Data for patients with and without chronic bronchitis were compared by using 
Student's t-tests (two tailed). For each agonist, the ECso and Tmax values of 
30 strips from 30 patients were related to the total S.A.D. score by linear regression 
analysis. The relation between ECso and Tmax values and the four separate S.A.D. 
items was examined by multiple regression analysis. The significance of the 
regression was determined by analysis of variance and the F-test (a= 0.05). 
Results 
Of the 30 patients, 12 had chronic bronchitis as defined, and 18 reported no 
cough or phlegm. None of the patients had a history of asthma. The clinical 
findings are summarised in Table 1. Eight of the 18 subjects without symptoms 
of chronic bronchitis had airflow limitation (FEVJ/VC<70%). Although this 
subgroup had a higher mean age and may have had airway obstruction or 
compression by tumor, we analysed the results for this subgroup separately. 
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Figure 1. Photomicrographs showing various degrees of inflammatory cell infiltration in bronchiolar 
strips. A, Band Care increasingly abnormal pictures of inflammatory cell accumulation corresponding 
to cellular infiltration scores 1, 2 and 3 respectively. Magnification: 160x. Stain: May-Griinwald-
Giemsa. 
Table 1. Patient characteristics (mean values± S.E.M.) 
no chronic bronchitis no chronic bronchitis chronic bronchitis 
no airflow limitation airflow limitation airflow limitation 
(n = 10) (n=8) (n= 12) 
Age (years) 49±5 65±3 55±5 
Inspiratory 
vital capacity (VC) 105±4 108 ±7 97±5 
(% predicted) 
Forced expiratory 77±2 59±3 55±4 
volume in 1 sec (FEVt) 
as a% ofVC 
% increase in baseline 1 ± 1 4±1 10±3 
FEVt after isoproterenol 
Smoking habits (n) 
current 4 4 8 
ex(> 2 years) 5 4 4 
never 0 0 
Response to inhaled 
histamine >64 (n=6) >64 (n=2) >64(n=2) 
(PC2oFEVt, mg/ml) 32(n=1) 
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Table 2. Histological findings 
Small Airways Disease (S.A.D.) scores 
no chronic bronchitis no chronic bronchitis chronic bronchitis 
no airflow limitation airflow limitation airflow limitation 
(n= 10) (n=8) (n = 12) 
S.A.D. item 
Cellular infiltration 0.9±0.4 0.5±0.3 0.7±0.2 
Muscle hypertrophy 0.9±0.3 0.4±0.2 0.7±0.2 
Fibrosis 1.2±0.2 1.9±0.2 1.8±0.3 
Goblet cell hyperplasia 0.7±0.3 1.0±0.3 1.3±0.3 
Total S.A.D. score 3.7±0.9 3.8±0.5 4.5±0.7 
Values are expressed as means± S.E.M.; no significant differences existed between the groups. 
Current cigarette smoking was reported by 8 of the 12 patients with, and by 
5 of those without symptoms of chronic bronchitis. Three subjects without chronic 
bronchitis smoked pipe or cigars. Only one subject had never smoked, all others 
had ceased smoking at least 2 years previously (Table 1). 
The response to histamine in vivo was measured in 8 patients without and 
3 with chronic bronchitis. The PCzoFEV1 was greater than 64 mg/ml in all 
patients except one of the 3 with chronic bronchitis (32 mg/ml) (Table 1). 
A wide range of S.A.D. was found in patients both with and without chronic 
bronchitis. Severe S.A.D. was slightly more common in chronic bronchitis, but 
group mean S.A.D. scores did not differ significantly (Table 2). Current cigarette 
smoking was not associated with the S.A.D. score within the groups. The scoring 
system did not take account of the composition of the inflammatory cells in 
the airway wall, but most were neutrophilic granulocytes and mononuclear cells 
(Figure 1 ); eosinophils were rare. 
The results of the in vitro experiments are summarised in Table 3. The -logECso 
values of methacholine, histamine and L TC4 were similar in patients with and 
without chronic bronchitis or airflow limitation. As a consequence of the 
randomisation procedure, histamine was applied as the first drug to 15 of the 
30 airway preparations, and methacholine and L TC4 to 9 and 6 strips respectively. 
Because of the relatively large variation of Tmax within-subjects12, no conclusions 
about possible differences in Tmax between groups of patients can be drawn from 
the small numbers of observations. There was, however, a tendency for histamine 
and methacholine T max to be higher in airways from patients with chronic 
bronchitis and airflow limitation (Table 3). Because no differences were found 
in S.A.D. scores or ECso values between groups of patients, the relation between 
S.A.D. and ECso was analysed on the total population. The methacholine -logECso 
showed a weak but significant negative correlation with the total S.A.D. scores 
(P < 0.05), that is severely diseased airways tended to be less sensitive to 
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Figure 2. Relation between -log EC50 values for histamine, methacholine and LTC. and total S.A.D. 
scores for 30 bronchiolar strips from 30 patients with and without chronic bronchitis. 
Table 3. Results of in vitro studies 
no chronic bronchitis no ~hronic bronchitis chronic bronchitis 
no airflow limitation airflow limitation airflow limitation 
(n= 10) (n=8) (n = 12) 
Histamine -log ECso 5.77±0.09 5.96±0.07 5.79±0.11 
Tmax 51 ±8 (4) 73 ±21 (5) 113 ± 21 (6) 
Methacholine -log ECso 6.22±0.13 6.22±0.13 6.04±0.10 
Tmax 89 ± 13 (4) 78, 91 (2) 176 ± 68 (3) 
LTC4 -log ECso 8.24±0.08 8.00±0.06 7.89±0.08 
Tmax 53, 79 (2) 18 (1) 40 ± 12 (3) 
aT max values are expressed as mg isometric force per mg dry tissue weight. The number of observations 
is indicated between brackets; only the first CCRC in each strip was included (see methods). 
Mean± S.E.M. or, in case of less than 3 observations, individual values are given. 
ECso values are the mean± S.E.M. from 30 measurements. 
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Figure 3. Relation between -log ECso values for histamine, methacholine and LTC. and inflammatory 
cell infiltration scores of 30 bronchiolar strips from 30 patients with and without chronic bronchitis. 
methacholine. No relation between histamine or LTC4 ECso and total S.A.D. 
scores was found (Figure 2). Multiple regression analysis showed that inflam-
matory cell infiltration was the only single variable that correlated negatively 
with both methacholine -logECso (P < 0.05) and histamine -logECso 
(P<0.05)(Figure 3). Tmax values for histamine, methacholine and LTC4 were 
not related to the severity of S.A.D. 
Discussion 
Our results indicate that S.A.D. and, in particular, inflammatory cell infiltration 
of the airway wall in patients with and without chronic bronchitis is not associated 
with increased sensitivity or contractility of small airway smooth muscle to 
histamine, methacholine and LTC4 in vitro. Infiltration of inflammatory cells 
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was negatively correlated with histamine and methacholine sens1t1V1ty, which 
was the opposite of what we expected. In accordance with our earlier findings6, 
histamine T max tended to be higher in airways from patients with chronic bronchitis 
and airflow limitation than in airways from normals. In this study mean Tmax 
for methacholine was also higher in the patients with chronic bronchitis. Statistical 
analysis was not carried out because of the small numbers of observations and 
the large intrinsic variation in T max II 0 There was no correlation between T max 
and S.A.D. scores. 
Airway inflammation scores were determined before tissues were stored and 
possibly the storage procedure and further processing of the bronchiolar strips 
altered smooth muscle function, conceivably by removing humoral factors or 
inflammatory cells. We did not repeat the histological examination after the 
experiments, but preliminary investigations did not show any deleterious effects 
of storage or organ bath studies on the histological appearance of the airways. 
Moreover, we and others have shown that prolonged storage in cold buffer 
does not affect in vitro human airway smooth muscle responsiveness to histamine 
or methacholine11' 14• It therefore seems unlikely, though the possibility cannot 
be excluded, that we have missed an effect of inflammation on smooth muscle 
function as a result of factors relating to tissue processing. 
In the dog, ozone-induced acute airway inflammation is associated with airway 
hyperresponsiveness4' 15 and this has been linked to granulocyte infiltration in 
the airway wall. In the guinea pig, ozone and cigarette smoke also produce 
acute airway inflammation and hyperresponsiveness16' 17, though in this model 
hyperresponsiveness preceded cellular infiltration and the granulocytes persisted 
longer than the increased responsiveness. Possibly in chronic inflammation airway 
hyperresponsiveness does not persist if inflammatory cells continue to be present 
after the acute phase, and this would explain the contradictory results in human 
and animal airways regarding inflammation and responsiveness. Our findings 
are in agreement with the clinical observation that patients with severe chronic 
non-asthmatic airway inflammation, such as occurs in cystic fibrosis or bron-
chiectasis, usually have only mild bronchial hyperresponsiveness or none at all, 
despite large numbers of leukocytes in their airways. 
Our results confirm and extend findings by Armour et al, who did not find 
an association between inflammation and in vitro responsiveness of human airways 
to histamine and carbachol in a smaller group of patients7' 8• In the present 
study and in other reports on in vivo and in vitro responsiveness of human 
airways, there has been only a weak correlation or none between the amount 
of airway smooth muscle and airway responsiveness3' 7' 18' 19 • This suggests that 
not only the amount, but also the intrinsic properties of airway smooth muscle 
may determine airway responsiveness. In addition, the arrangement of smooth 
muscle, rather than its amount, is likely to be responsible for a large part of 
the high intrinsic variability ofT max in spirally cut strips. 
Mullen et al found that in non-asthmatic smokers inflammation of membranous 
bronchioles correlated with in vivo airway responsiveness3• These authors also 
found a relation between bronchiolar inflammation and in vivo airway caliber, 
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but the effects of these factors on airway responsiveness seemed to be inde-
pendene. Our present findings do not support a direct effect of inflammation 
on bronchiolar smooth muscle function. It remains possible, however, that 
peripheral airway inflammation modulates airway responsiveness in vivo by other 
mechanisms, for example, by altering autonomic regulation processes. Further-
more, our results do not exclude an effect o( inflammation on smooth muscle 
function in central airways. Such an effect seems unlikely, however, as in the 
study by Mullen et al no relationship was found between inflammatory changes 
in central airways and in vivo bronchial responsiveness3• In the tissues we studied, 
we found no S.A.D. scores above 8. Although our results do not point in this 
direction, we can not exclude the possibility that smooth muscle sensitivity or 
contractility would have been abnormal in bronchioles with a higher score. This 
seems very unlikely, however, because severe S.A.D. is not a characteristic of 
subjects with a greatly increased in vivo airway responsiveness3• 
We, like others20 , found S.A.D. to a variable degree in lungs from both patients 
with and patients without chronic bronchitis and airflow limitation, with a large 
overlap. This indicates that histological signs of small airways disease are not 
specific for chronic bronchitis, and may occur in otherwise healthy, non-smoking 
symptomless subjects with normal lung function. This, together with the finding 
that small airway inflammation had no relation to in vitro small airway smooth 
muscle function, suggests that airway hyperresponsiveness in chronic bronchitis 
is not due to a direct effect of chronic inflammation on airway smooth muscle 
function. Our present findings do not exclude the possibility that inflammation 
may potentiate the mechanisms that underly airway hyperresponsiveness in 
asthma. We have recently reported an increased contractility of isolated airways 
from an asthmatic patient showing eosinophilic infiltration of the bronchial 
mucosa and smooth muscle hypertrophl1• Airway hyperresponsiveness in asthma 
and chronic bronchitis has different characteristics, however, and may have a 
different pathogenesil2• 
More studies are needed to establish to what extent airway inflammation or 
alternative mechanisms, such as mucosal edema, changes in central airways, 
potentiation of local or central nervous reflexes or other abnormalities in neural 
control contribute to the pathogenesis of airway hyperresponsiveness in chronic 
bronchitis and asthma. 
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Chapter 13 
Comparison of maximal bronchoconstriction in vivo and 
airway smooth muscle responses in vitro in 
non-asthmatic humans 
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Summary 
We tested the hypothesis that maximal bronchoconstriction in humans in vivo 
is limited by the maximal contractility of airway smooth muscle by comparison 
of complete in vivo and in vitro dose-response curves to methacholine in 10 
non-asthmatic subjects who were scheduled for thoracotomy because of ma-
lignancies. The provocative dose of methacholine that produced a 10 and 20% 
decrease of baseline FEV1 (PD10,2o FEV1) and the maximal fall in FEV1 (MFEvi) 
at the response plateau to inhaled methacholine were determined prior to surgery. 
Small airway smooth muscle preparations, obtained from the 10 resected lung 
tissue specimens, were examined in vitro to determine the sensivity (-log ECso) 
and maximal isotonic shortening (Smax) to methacholine. In addition the relaxation 
responses to the /3-agonist !-isoproterenol were measured. The degree of small 
airways disease (S.A.D.) was examined histologically. 
Nine subjects showed a maximal response plateau to inhaled methacholine 
in vivo. The maximal fall in FEV1 at the plateau was 26 ± 3%. All airway smooth 
muscle preparations (n = 30) contracted to methacholine (-log ECso 5.94 ± 0.09; 
Smax 1320 ± 219 ,urn) and relaxed to !-isoproterenol (-log ECso 7.60 ± 0,11; maximal 
relaxation (Rmax) 87 ± 3% ). No significant correlations were found between Smax 
or Rmax of the airway smooth muscle in vitro and the MFEVI in vivo, and between 
-log ECso for methacholine or !-isoproterenol in vitro and PD10 or PD20 FEV1 
for methacholine in vivo. The severity of S.A.D. was significantly correlated 
with the degree of baseline airflow limitation (p < 0.05), but not with in vivo 
or in vitro responses to methacholine. These results suggest that, in non-asthmatic 
subjects, the maximal bronchoconstriction and sensitivity to inhaled methacholine 
in vivo are not determined by the maximal contractility and sensitivity, respec-
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tively, of airway smooth muscle to methacholine, are not due to an impaired 
relaxation response to ,8-receptor stimulation and are not related to the severity 
ofS.A.D. 
Key words: human airway smooth muscle, bronchial responsiveness, methacho-
line, isoproterenol, small airways disease, bronchoconstriction, chronic airflow 
limitation. 
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Introduction 
Patients with asthma or chronic airflow limitation often have an increased 
sensitivity of airway narrowing to inhaled methacholine or histamine1• The 
aetiology of this non-specific bronchial hyperresponsiveness is not clear. To 
determine whether abnormalities of airway smooth muscle (ASM) play a role 
in bronchial hyperresponsiveness, a number of studies has been done in which 
contractile responses of isolated airways from subjects with bronchial hyper-
responsiveness were measured2- 8• These studies have shown that ASM from 
subjects with varying degrees of bronchial hyperresponsiveness, as defined by 
the position of the dose-response curve in vivo, responded in vitro within a 
remarkably narrow sensitivity range, which could not explain the wide variation 
of in vivo responsiveness. 
ASM could contribute to bronchial hyperresponsiveness not only by a higher 
sensitivity, which means that a given contractile state of the muscle is reached 
at a lower stimulus intensity, but also by a higher contractility to a given stimulus 
(i.e. a higher maximal response), or by a combination of these two mechanisms9- 10• 
Furthermore, a decreased response of ASM to relaxing agents may underly an 
increased bronchial responsiveness in vivo 11' 12 • Studies of human ASM function 
in vitro have mainly focussed on sensitivity, usually measured as the effective 
concentration of an agonist that produces 50% of the maximal ASM response 
(EC5o). The maximal responses in vitro were considered less valuable because 
of a high intrinsic variabilitl. Theoretical considerations and a number of recent 
papers, however, have led to the view that ASM may contribute to bronchial 
hyperresponsiveness, both in asthma and chronic airflow limitation, by an 
increased maximal contractilitl' 13- 16. 
Bronchial responsiveness in vivo is commonly measured by determining the 
provocative dose (PD) or concentration (PC) of an inhaled bronchoconstrictor 
that produces a given worsening of a lung function parameter, e.g. a 10% fall 
in FEV1 (PD10 FEV1). 
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It has recently been shown that a reproducible maximal bronchoconstrictor 
response can be measured in vivo after administration of a relatively high dose 
of inhaled histamine 17 or methacholine18 in non-asthmatic subjects and in patients 
with mild asthma or chronic airflow limitation. In these patients, the in vivo 
dose-response curves reach a plateau at relatively mild degrees of airway 
narrowing, the cause of which is still not clear9. We have shown that, by using 
a carefully standardised method and a well-defined ASM preparation, it is also 
possible to measure maximal contractile responses of ASM in vitro with sufficient 
accuracy to detect differences between subjects 19'20. 
In the present study, we have tested the hypothesis that the maximal response 
to methacholine in humans in vivo is limited by the maximal isotonic contractility 
of ASM to methacholine, or is related to differences in ASM relaxability. This 
was done by comparison of complete in vivo dose-response curves to methacholine 
with in vitro dose-response curves to methacholine and !-isoproterenol in patients 
who underwent thoracotomy and lung resection. Because airway inflammation, 
muscle hypertrophy or epithelial changes may modulate airway responsiveness\ 
we have also examined the airways by light microscopy and compared these 
morphological findings with the various functional data. 
Methods 
Subjects and design 
Ten adults who were scheduled for thoracotomy because of bronchial malig-
nancies underwent lung function measurements and a methacholine inhalation 
test within a 2 weeks period prior to surgery, and specimens of bronchial tissue 
were studied in vitro within 24 h following surgical resection. Anthropometric 
and pre-operative lung function data are given in Table 1. None of the subjects 
had a history of asthma and none had used bronchodilators or corticosteroids. 
In vivo studies 
Methacholine inhalation tests were performed as described previously18'21 . Metha-
choline chloride, dissolved in normal saline, was administered via a DeVilbiss 
646 nebuliser (output 0.13 mlxmin -1) in doubling doses up to a mouth dose 
of 3.4x10-4M. The aerosol was inhaled by tidal breathing during 2 min at 5 
min intervals. The forced expiratory volume in 1 sec (FEV1) was measured with 
a dry rolling-seal spirometer (Mijnhardt Volugraph), and the mean of 3 repro-
ducible values was taken to calculate the baseline values. The response to inhaled 
methacholine was expressed as a percentage fall in FEV1 from baseline value. 
The provocative doses that caused a 10 or 20% fall in FEV1 (PD10 and PD2o 
FEV1 respectively) were obtained by linear interpolation and expressed in t.tM 
of nebulised methacholine. A response plateau was considered if the FEV 1 values 
after 2 or more highest methacholine doses decreased less than 5%. The maximal 
response to methacholine (MFEV1) was calculated by averaging all data points 
on the plateau, and was expressed as a% fall from baseline18. 
-.!'> 
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Table 1. Patient characteristics 
Case Sex Age Height Atopy' Current Lung functionb 
(yr) (m) smoking I.V.C. T.L.C. F.E.Vo~ F.E.Vo~/V.C. 
L % pred. L % pred. L %pred. % 
M 23 1.63 0 never 3.47 92 4.94 99 2.86 86 82 
2 M 68 1.75 0 + 4.05 98 6.57 95 2.68 87 66 
3 M 62 1.54 0 + 3.44 114 5.23 100 2.44 102 71 
4 M 63 1.60 0 + 3.40 102 5.54 97 2.70 104 79 
5 M 52 1.76 5 + 4.90 106 7.57 108 3.39 94 69 
6 F 54 1.76 1 + 4.32 119 6.92 119 3.40 112 79 
7 M 72 1.73 0 + 3.56 91 7.42 110 1.72 59 48* 
8 F 39 1.67 1 ex 3.00 84 5.07 97 1.85 61 62* 
9 M 71 1.79 0 cigars 3.77 88 6.43 89 2.68 85 71 
10 M 65 1.67 0 + 2.92 79 5.95 95 1.90 68 65* 
'Atopy: number of positive skin prick tests to common allergens (A.L.K., Copenhagen) 
b Abbreviations: I.V.C., inspiratory vital capacity; T.L.C. total lung capacity; F.E.Vo~, forced expiratory volume in 1 sec. 
Predicted values are from reference 25. 
* > 1.64 SD below pred,icted mean values (25). 
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In vitro studies. 
From all subjects a macroscopically normal piece of the middle lobe of the 
right lung was obtained within 30 min after surgery, and was quickly transported 
to the laboratory in ice-cold Krebs-Henseleit buffer (composition in mM: NaCl 
118, KCl 4.7, CaCh 2.5, MgS04 1.2, KHzP04 1.2, NaHC03 25, glucose 5.55) 
that was previously gassed with 95% Oz and 5% COz. From each tissue specimen, 
2-4 bronchiolar strips (approx. lOth to 13th generation) were dissected and stored 
overnight as described previously19. This procedure has been shown not to affect 
the response of ASM to cholinergic stimulation19. After mounting in the muscle 
bath, strips were allowed to equilibrate for 2 hat 37°C in Krebs-Henseleit buffer 
that was continuously gassed with 95% Oz and 5% COz. Throughout the 
experiments, an isotonic load of 500 mg was applied, because in preliminary 
experiments we found that this load stretched bronchiolar strips from non-
asthmatic subjects to their optimal lengths. Contractile responses were measured 
isotonically with high precision angular position transducers (Penny & Giles)22 . 
Cumulative concentration-response curves (CCRC) to methacholine were made 
by adding the drug to the organ bath in volumes smaller than 50 ,ul, to obtain 
final bath concentrations of 10-8 to 10-4 M. On each strip, 2 successive 
methacholine CCRC were made, separated by an interval of 2 h to restore a 
stable baseline. Only the second curve was used for calculations, because we 
have previously found that the first curve on a strip always had a considerably 
lower maximal response than all subsequent CCRC, which were then repro-
ducible19. After the second CCRC, methacholine was applied at its EC5o, and, 
when the resulting contraction had reached a plateau, a CCRC to !-isoproterenol 
(10-10 to 10-5 M) was made. After maximal relaxation by !-isoproterenol (10-5 
M), a high concentration of EDTA (3.10-4 M) was used to obtain full relaxation. 
From the measured values, CCRC were constructed by means of a computerised 
iterative fitting method. The following parameters were derived from each CCRC: 
-log EC5o, as a measure of sensitivity, and maximal shortening (Smax, in ,urn) 
or maximal relaxation (Rmax) as a percentage of maximal relaxation in the presence 
of EDTA as measures of contractility and relaxability, respectively. 
Pieces oflung tissue were processed for histological examination and the severity 
of small airways disease (S.A.D.) was assessed in membranous bronchioles using 
a modification of the subjective grading method described by Wright et al23·24. 
Scores (0 =normal, 1-3 =increasingly abnormal) were determined for each of 
the following items: inflammatory cell infiltration, fibrosis, smooth muscle 
hypertrophy and goblet cell hyperplasia, by comparing with pictorial reference 
standards. The sum of these four scores was taken as the total S.A.D. score. 
Drugs 
Methacholine and !-isoproterenol were purchased from Janssen Pharmaceuticals, 
Belgium; EDT A from Sigma, USA; buffer chemicals were analytical grade from 
E. Merck, FRG. Drugs were dissolved in 0,9% NaCl, prepared fresh daily and 
kept on ice for the duration of the experiments. 
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Data analysis 
The results of 2 to 4 in vitro experiments were averaged within subjects before 
being used in statistical calculations. The significance of the between-subjects 
variation of Smax in vitro was estimated by means of analysis of variance and 
the F-test in the 8 subjects from whom 3 or more strips were examined (a= 0.05). 
The relation between in vivo and in vitro experimental data was analysed by 
calculation of Spearman's rank correlation coefficient (two tailed, a= 0.05). All 
values are presented as means± S.E.M. 
Results 
In vivo studies 
Baseline lung function measurements showed mild to moderate airflow limitation 
in 3 of the 10 subjects and normal values (within± 1.64 SD from predicted25) 
in the remaining 7 (Table 1). Eight subjects currently smoked cigarettes. All 
subjects reached a PD10 and 7 a PDzo FEV1 (Table 2, Figure 1). A plateau 
in the dose-response curve was reached in 9 subjects. In one patient, no plateau 
could be measured because of severe degree of airway obstruction during the 
test. This subject (no.7) had the worst baseline FEV1/VC (48%). Case no 3 
showed a response plateau between 21.3 and 170 ,uM of nebulised methacholine, 
but showed a 5.9% further decline after 340 ,uM. We considered this nevertheless 
as a plateau, because the response at 340 ,uM was only 3.6% lower than the 
response after 85.1 ,uM (Figure 1). Patients 2, 7 and 10 had a PDzo FEV1 in 
the asthmatic range (i.e.< 10.6 ,uM), although there was no clinical history of 
wheezing attacks. Two of these 3 patients had significant baseline airflow 
limitation (Table 1). The mean fall from baseline FEV1 after the highest 
methacholine doses was 26 ± 3%. Individual results of the methacholine inhalation 
tests are given in Table 2. 
In vitro studies 
A total of 30 bronchiolar strips was examined. All preparations responded 
concentration-dependently to methacholine and !-isoproterenol. The -log ECso 
to methacholine showed a range within llog unit (5.47 to 6.40; mean: 5.95 ± 0.09). 
The Smax to methacholine varied much more from 105 to 2198 ,urn (mean: 
1320 ± 219 ,urn). Analysis of variance was performed on the results of experiments 
in which 3 or more strips within-subjects were studied and the outcomes indicated 
a significant between-subjects variation (p < 0.05, F-test). For relaxation responses 
to !-isoproterenol, the -log ECso ranged between 6.80 and 7.91 (mean: 7.60 ± 0.11) 
and Rmax varied between 64% and 96% (mean: 87 ± 3% ). Individual values are 
given in Table 2. The relation between the maximal plateau bronchoconstriction 
in vivo (MFEvJ) and maximal contraction in vitro (Smax) to methacholine is depicted 
in Figure 2. No correlation was found (Spearman p -0.06, p > 0.10). Also, the 
Rmax to !-isoproterenol was not correlated with MFEVI in vivo (Spearman p 
-0.33, p > 0.10). Measures of sensitivity in vivo (PD10 FEV1, PD20 FEV1) were 
Table 2. Bronchial responses in vivo and in vitro 
Responses to methacholine in vivo Responses to methacholine and isoproterenol in vitro 
Case PD10 FEVr PD2o FEVr DrL Dmax MFEV! Methacholine L-isoproterenol 
(/iM) (!lM) (!lM) (!lM) (%) -log ECso Sm.x(llm) -log ECso Rm, (%) 
85.1 - 85.1 340.0 11.9 5.47 962 7.89 96 
2 3.9 8.2 42.6 85.1 36.7 5.59 105 7.49 93 
3 8.8 19.2 85.1 340.0 24.1 6.10 1099 6.80 91 
4 3.1 13.8 85.1 340.0 33.7 5.95 605 7.86 84 
5 15.6 67.2 42.6 340.0 19.9 6.40 1821 7.62 93 
6 16.0 - 21.3 340.0 14.0 5.97 1290 7.77 82 
7 0.5 2.9 - 10.6 38.3 5.96 1038 7.18 64 
8 6.2 - 10.1 21.3 16.5 6.16 1925 7.71 89 
9 9.1 49.2 42.6 340.0 21.5 5.85 2198 7.91 92 
10 1.1 4.9 85.1 340.0 39.3 6.00 2152 7.72 90 
Mean± S.E.M. 25.6±3.3 5.94±0.09 1320±219 7.60±0.11 87±3 
Abbreviations: PD10,2o FEVr, provocative methacholine doses that caused a 10 or 20% decline of FEVr from baseline values; DrL, dose of methacholine 
at which the response plateau is reached; Dm.x, maximal dose of methacholine that was given; MFEvr, maximal in vivo response to methacholine, 
expressed as the mean of FEVr values on the plateau (% fall from baseline); EC5o, effective concentration that produces 50% of the maximal 
effect; Smox, maximal isotonic shortening; Rm,, maximal relaxation, expressed as a % of relaxation in Ca-free buffer. 
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Figure 1. In vivo dose-response curves to methacholine. The vertical axis depicts the decline in 
FEV1 expressed as a% fall from baseline, andlhe horizontal axis the dose of nebulised methacholine. 
Case numbers are indicated in the circles. All subjects except no. 7 exhibited a plateau in their 
response to methacholine. 
not correlated with measures of sensitivity in vitro (-log ECso to methacholine 
or isoproterenol) (Figure 2). 
Histological examination of membranous bronchioles showed mild to moderate 
S.A.D. The most consistent findings were smooth muscle hypertrophy, inflam-
matory cell infiltration of the bronchiolar wall, predominantly with mononuclear 
cells, and thickening of the basal membrane. The bronchiolar epithelium was 
intact and relatively normal in all tissues studied, with only minimal degrees 
of goblet cell hyperplasia. Especially no obvious differences in mucosal thickness 
were found between subjects. The S.A.D. score was determined in 8 of the 10 
patients, because histological sections contained insufficient numbers of suitable 
bronchioles in subjects 9 and 10. The mean scores for the separate items and 
the total S.A.D. scores for patients 1-8 are shown in Table 3. The total S.A.D. 
score showed a weak but significant (0.02 < p < 0.05) negative correlation with 
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Figure 2. Comparison of in vivo and in vitro bronchial responses to methacholine Left panel: 
relationship between the maximal response to methacholine in vivo (mean % decline in FEVt at 
the response plateau, MFEVt, vertical axis) and the maximal airway smooth muscle contraction in 
vitro (Smax, expressed as Jl-m isotonic shortening, horizontal axis) in the 9 subjects that reached 
a response plateau. No correlation was found (Spearman p -0.06, p>O.lO). Right panel: relationship 
between the position of the dose-response curve to methacholine in vivo, as indicated by the PD10 
FEVt (vertical axis) and the sensitivity to methacholine of airway smooth muscle in vitro (-log 
EC5o, horizontal axis). No significant correlation was found (Spearman p -0.02, p> 0.10; n= 10). 
Table 3. Histological examination of small airways 
Case Inflammatory Fibrosis Smooth Goblet Total 
no. cell infiltration muscle cell S.A.D. 
hypertrophy hyperplasia score 
1.0 0.0 0.3 1.0 2.3 
2 1.3 0.3 0.7 1.2 3.5 
3 1.0 0.0 1.3 0.7 3.0 
4 1.2 0.1 0.4 0.5 2.2 
5 1.3 0.8 1.4 1.3 4.8 
6 0.7 0.3 1.3 0.3 2.6 
7 1.5 0.5 1.5 1.5 5.0 
8 1.5 0.5 1.5 1.0 4.5 
Mean 1.2±0.1 0.3 ± 0.1 1.1 ±0.2 0.9±0.2 3.5 ±0.4 
±S.E.M. 
Abbreviation: S.A.D., small airways disease. 
All figures are mean scores for 2-24 bronchioles within a subject. 
baseline FEV1/VC (Figure 3). No other significant correlations were found 
between S.A.D. variables and in vivo or in vitro measures of bronchial respon-
siveness. 
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Figure 3. Relation between mean total S.A.D. scores and baseline airway caliber, expressed as FEV1/ 
VC%. 
Discussion 
The present results show that, in non-asthmatic subjects, the response of the 
airways to inhaled methacholine in vivo is not related to the responses of isolated 
ASM to either methacholine or isoproterenol in vitro. This was not only shown 
for the position ofthe dose-response curves, which confirms previous reports4' 5' 7, 
but also for the maximal responses, which has not been reported before. 
Several reports in the literature have indicated that ASM is not more sensitive 
to e.g. histamine .or methacholine in subjects with nonspecific airway hyper-
responsiveness than in normals2- 8• In addition, no relationship between PD in 
vivo and maximal isometric responses in vitro has been found2- 8• However, the 
in vivo dose-response curves that were obtained in these previous studies made 
it impossible to determine 'sensitivity' in the pharmacological sense because a 
maximal effect was not measured. Moreover, human ASM has a relatively high 
intrinsic within-subject variability of maximal responses in vitro, which made 
it often impossible to draw valid conclusions on this aspect of ASM function2- 8. 
Recent insight in airway mechanics has led to the view that an increased 
maximal contractility might be an important aspect of airway hyperresponsi-
veness9. Therefore it is relevant to compare maximal responses of the airways 
in vivo and in vitro. Maximal bronchoconstriction can be measured in vivo in 
normals, in patients with mild asthma and in subjects with chronic airflow 
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limitation by administering relatively high doses of methacholine or histamine 
by inhalation17' 18' 21 ' 26 • The maximal response (e.g. decline in FEV,) thus obtained 
is, however, not merely a reflection of ASM contractility, but also depends on 
many other variables, such as aerosol deposition, penetration of the agonist 
through the mucosa, clearance of the agonist, baseline airway caliber, elastic 
load of the airway wall and lung parenchyma, inflammatory changes (e.g. mucosal 
swelling) in the airways or on humoral or neural regulation processes9' 12 • In 
contrast, contractile responses of isolated airways reflect mainly ASM function 19 • 
We can elucidate the role of ASM contractility on the maximal degree of airway 
narrowing in vivo by comparison of in vivo and in vitro responses in the present 
study. 
The sensitivity (-log ECso) of ASM can be measured accurately and reproducibly 
in vitro 19' 20 • The relatively high intrinsic variation within-subjects of maximal 
responses, however, has been a problem. In the present study we have tried 
to limit the variability of absolute ASM responses in vitro by a careful dissection 
technique and by using only bronchioles obtained from the same site in the 
lung (the right middle lobe). We have previously shown that it is possible to 
detect differences between-subjects regarding maximal responses by using a similar 
method13' 14' 19' 20 • Because of the many confounding variables that influence the 
airway responses in vivo, the lack of correlation between in vivo and in vitro 
data is not surprising. From the factors that co-determine FEV,, several may 
in particular be relevant to the comparison of in vivo and in vitro maximal 
responses to methacholine in this study. Baseline airway caliber is an important 
determinant of bronchial hyperresponsiveness in non-asthmatic subjects in vivo27• 
This seems also true for some subjects in the present study (Table 1). The 
contraction of a spiral strip in vitro will certainly not reflect this factor. 
Furthermore, part of the in vivo response may result from central airway 
constriction, whereas the in vitro experiments were only done using peripheral 
airways. It is not likely, however, that airway hyperresponsiveness in vivo is 
mainly a central airway phenomenon28 • In addition, lung elastic recoil is likely 
to be a major determinant of the maximal degree of airway narrowing in vivo29 , 
but not in vitro. Finally, airways smooth muscle function is dependent on the 
initial length of the muscle. It is not known whether in humans ASM functions 
near its optimal length in vivo9• We did not perform length-tension experiments 
before each CCRC in vitro. Therefore, differences in length-tension relationships 
of airways from subjects with varying degrees of in vivo bronchial responsiveness 
may have biased our results and those of others. Further studies are needed 
to clarify this point. Airway smooth muscle, especially of non-cartilaginous 
airways, probably functions semi-isotonically in vivo9• Unlike most previous 
studies, the present results were obtained by measuring the isotonic shortening 
of the ASM preparations, which seemed more relevant than isometric tension 
recording. It is not likely, however, that in this type of study both methods 
will produce important differences30• 
156 
We found no correlation between the -log ECso and Rmax to !-isoproterenol of 
isolated ASM and airway responsiveness in vitro. Such a relation was suggested 
by studies of Paterson et ae 1 and Goldie et ae2, who used autopsy tissue from 
asthmatics, most of whom died during an asthma attack, and by a recent report 
by Cerrina et al8 who examined airways from elderly asthmatics who also had 
considerable baseline airflow limitation. We have recently reported normal 
relaxation responses of asthmatic human airways to isoproterenol in vitro 14 and 
found a normal .B-adrenergic relaxability in airways from patients with chronic 
obstructive pulmonary disease (unpublished observation). The present results 
are also in agreement with those of Taylor et ae who, in 10 subjects, found 
no relationship between non-asthmatic airway hyperresponsiveness in vivo and 
relaxation responses of isolated bronchi to the .Bz-agonist salbutamol. Therefore, 
differences in responsiveness to .Bz-adrenergic stimulation may not explain the 
degree of maximal airway narrowing that is possible in vivo. 
We found a negative correlation between the degree of baseline airflow. 
limitation and the severity of S.A.D., which confirms earlier reports33' 34• Both 
the airflow limitation and the S.A.D. score were, however, not significantly 
correlated with the in vivo and in vitro responsiveness to methacholine. Similarly, 
we previously found no relation between the sensitivity or contractility of human 
bronchiolar smooth muscle to methacholine in vitro and the degree of bronchiolar 
inflammation24• Mullen and coworkers have found a weak significant correlation 
between both baseline airflow limitation and S.A.D. scores, and in vivo airway 
responsiveness to histamine or methacholine34• It seems that such relationships 
are more likely to reach significance if more patients are studied than we have 
done in the present report. 
There is a recent interest in the role of mucosal thickening or edema in the 
pathogenesis of airway hyperresponsiveness9• However, no apparent differences 
in the structure of the epithelium or the submucosal connective tissue were found 
in bronchioles from the subjects in this study, who had widely varying degrees 
of airway hyperresponsiveness. This suggests that other mechanisms may be 
more important. 
In conclusion, we found that, in non-asthmatic subjects, the maximal metha-
choline-induced bronchoconstriction in vivo is not related to the maximal isotonic 
contractility of ASM to methacholine in vitro. We also confirmed earlier reports 
that the position of the in vivo response curve to methacholine is not related 
to the sensitivity of the ASM to methacholine, and is not determined by the 
relaxation response of ASM to .Bz-receptor stimulation. The lack of correlation 
may however also be due to the many variables that can influence the outcomes 
of in vivo measurements. Although the severity of histologically determined S.A.D. 
correlated significantly with baseline airflow limitation, no relation was found 
between S.A.D. variables and measures of bronchial responsiveness to metha-
choline in vivo and in vitro. The present results do not exclude a possible role 
of ASM abnormalities in asthma, because bronchial hyperresponsiveness in 
asthma and in chronic airflow limitation has different characteristics27' 35, and 
157 
may therefore have a different etiology. Moreover several reports have suggested 
increased ASM contractility in asthma 14- 16• Further studies are needed to 
investigate whether alternative mechanisms, such as decreased lung elasticity, 
increased airway compressibilitl or abnormal autonomic control mechanisms 
are responsible for the variation in bronchial sensitivity and maximal response 
in humans. 
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Chapter 14 
Leukotriene generation and small airway smooth muscle 
responsiveness in human lung 
J.C. de Jongste, H. Mons, F.J. Zijlstra and K.F. Kerrebijn. 
Departments of Paediatric Respiratory Diseases and Pharmacology (F.J.Z.), 
Erasmus University Rotterdam/ Sophia Children's Hospital, Rotterdam, 
The Netherlands. 
Summary 
The hypothesis was tested that a high endogenous leukotriene (LT) production 
in the lung causes desensitisation of airway smooth muscle to LT. The synthesis 
of L TB4, C4, D4 and E4 by human lung tissue, obtained at thoracotomies, after 
stimulation with Ca-ionophore was assessed by HPLC. Functional studies of 
small airway smooth muscle from the same tissue specimens were carried out 
using L TC4 and methacholine as the contracting agents. Generation of L TB4, 
C4, D4 and E4 was 453±82, 84±15, 71±27 and 40±16 pmollg fresh tissue 
respectively (mean± S.E.M., n = 10). All airway smooth muscle preparations 
responded to LTC4 in a concentration dependent way with a -log ECzo of 
8.56± 0.13, a -log ECso of 7.95 ± 0.08 and a Tmax of 82± 11 mg force/mg tissue 
weight, corresponding to 79 ± 4% of the maximal response to methacholine 
(mean± S.E.M.; 27 preparations from 10 patients). No correlations were found 
between any of the functional parameters (-logECzo, -logECso, Tmax to LTC4 
and methacholine) and the amounts of LT's generated by the lung tissue. 
Furthermore airway smooth muscle contractility was not significantly reduced 
after repeated exposure of bronchiolar strips to LTC4 in vitro. These findings 
suggest that the contractility of human peripheral airway smooth muscle is not 
decreased in lungs that can produce relatively large amounts of sulfidopeptide 
LT's. 
Key words: human airway smooth muscle, bronchial responsiveness, le~kotrienes, 
methacholine. 
De Jongste JC, Mons H, Zijlstra FJ, Kerrebijn KF. Leukotriene generation and small airway smooth 
muscle responsiveness in human lung. Submitted to Prostaglandins, Leukotrienes and Medicine. 
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Introduction 
An increased bronchoconstriction in response to non-allergic stimuli is a 
characteristic of asthma and occurs frequently in chronic obstructive pulmonary 
disease (COPD( The mechanism of this bronchial hyperresponsiveness is not 
clear, although airway inflammation or increased bronchial smooth muscle 
contractility may play a role2' 3. It is likely that leukotrienes (LT's) are involved 
in the pathogenesis of asthma and COPD4'5• Human lung parenchyma, bronchial 
epithelium, mast cells, alveolar macrophages and leukocytes can produce the 
L T's B4, C4, D4 and E4, which induce bronchial smooth muscle contraction, 
mucus secretion, capillary leakiness and recruitment of inflammatory cells. LT's 
may therefore contribute to airways obstruction and bronchial hyperrespon-
siveness both directly, by an effect on airway smooth muscle, and indirectly, 
by enhancement of airway inflammation5' 6• It has recently been shown that the 
relative potencies of the sulfidopeptide L T's C4, D4 and E4 as compared with 
methacholine or histamine are markedly lower in asthmatics than in normals7•8, 
i.e. asthmatics are less hyperresponsive to L T's than to methacholine or histamine. 
This discrepancy could result from smooth muscle desensitisation to L T's, but 
not to methacholine or histamine. This could possibly be due to chronic exposure 
of smooth muscle to L T's in inflamed airways. The present study was done 
to test the hypothesis that a high endogenous LT synthesis by the lung causes 
specific desensitisation of airway smooth muscle to LT's. For this purpose, we 
measured the L T generation by human lung tissue in vitro and related these 
data to the maximal contractile responses and the sensitivity of isolated airway 
smooth muscle preparations to L TC4 and methacholine. Furthermore, we 
examined whether repeated exposure to LTC4 produced tachyphylaxis in isolated 
human airways. 
Methods 
Human lung tissue was obtained from 10 patients at thoracotomies. Preope-
ratively, the medical history was taken and patients underwent lung function 
studies, including the determination of the inspiratory vital capacity (VC) and 
the forced expiratory volume in 1 sec (FEV 1). Immediately after surgical resection, 
a piece of macroscopically normal lung tissue was collected in Krebs-Henseleit 
buffer (composition in mM: NaCl 118, KC14.7, CaC12.5, MgS04 1.2, KHzP04 
1.2, NaHC03 25, glucose 5.55) gassed with 5% COz and 95% 02. For the 
measurements of LTB4, C4, D4 and E4 synthesis, lung parenchyma was kept 
at 4°C, prepared free of macroscopically visible blood vessels, airways and pleura 
and chopped in pieces of approx. 0.5 mm3 using a mechanical tissue chopper. 
At least 10 g of chopped parenchyma was washed in 25 ml of fresh aerated 
buffer, followed by 2 min centrifugation at 400 g, three times. Finally, the pellet 
was resuspended in 25 ml of aerated cold buffer to which the Ca-ionophore 
A 23187 (4xl0-6 M), glutathion (2xl0-6 M) and arachidonic acid (13xl0-6 M), 
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as a substrate, were added. The tissue fragments were incubated at 37°C for 
10 min while the buffer was stirred (900 rpm) and gassed. At the end of the 
10 min incubation, known amounts of 3H-LTC4 and 3H-LTD4 were added and 
the suspension was centrifuged at 1400 g for 10 min, at 4°C. The clear supernatants 
were now processed for High Performance Liquid Chromatography (HPLC) 
as described previousll. Shortly, the supernatant was passed through SEP-PAK 
C1s and silica cartridges (Waters). In the redissolved extract, LT's were detected 
by reversed-phase HPLC on a Nucleosil 5 C1s column (Chrompack, The 
Netherlands) using a Hewlett-Packard 1082 HPL chromatograph. The absorption 
at 280 nm (LTC4, D4 and E4) and 270 nm (LTB4) was recorded and compared 
to a standard. Samples were collected and radioactivity measured in order to 
calculate the recovery of LT's. The amount of LT recovered was expressed in 
pmol L T per g fresh tissue. The reproducibility of L T measurements with this 
method has been determined in a previous studl. Small airway smooth muscle 
preparations were dissected and stored overnight as described previously10. Two 
or 3 airway smooth muscle strips from each patient were mounted in 10 ml 
organ baths and allowed to equilibrate for 2 hours under an isometric tension 
of 0.5 g, at 37°C in aerated buffer. Isometric responses to LTC4 (10-10 to 10-7 
M) were measured with Grass FT03D force transducers. Cumulative concen-
tration response curves (CCRC's) were made as described previously11 • When 
the response to the highest concentration of LTC4 (10-7 M) had reached its 
plateau, methacholine (10-4 M) was added to obtain a maximal contraction. 
From each CCRC the following parameters were derived: -logEC2o and -logECso 
(the negative logarithm of the concentrations of LTC4 that produced 20% and 
50% of the maximal response) as a measure of sensitivity and T max (the maximal 
tension in the presence of 10-7M LTC4 or 10-4M methacholine, expressed in 
mg isometric force per mg dry tissue weight) as a measure of contractility. In 
separate experiments we examined whether repeated exposure of isolated human 
airways to exogenous LTC4 would cause tachyphylaxis. Under conditions 
described above, strips were stimulated 6 times with 10-s M LTC4 during 15 
min, followed by washing and restoration of baseline tone. Exposures were 
separated by 30 min intervals. The responses were expressed as a percentage 
of the initial response of that strip. 
Drug sources 
Synthetic LT's B4, C4, D4 and E4 were a gift of Dr. J. Rokach (Merck Frosst, 
Canada). Methacholine hydrobromide was purchased from Janssen, Belgium; 
Ca-ionophore A 23187 from Hoechst, Calbiochem-Behring, USA; reduced 
glutathion from ICN, Cleveland, USA; arachidonic acid from Bio Data Cor-
poration, Hatboro, USA and 3H-LTC4 and 3H-LTD4 from the Radiochemical 
Centre, Amersham, UK. HPLC liquids and buffer chemicals were analytical 
grade from E. Merck, Darmstadt, FRG. 
Data analysis 
From each of the 10 tissue specimens, the mean values of -logEC2o, -logECso 
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and Tmax from 2 or 3 LTC4 CCRC's were used for calculations.The relation 
between these functional data and the produced quantities of LTB4, C4, D4, 
E4 and total sulfidopeptide L T's (C4 + D4 + E4) was examined by calculating 
Spearman's rank correlation coefficient (p )(two tailed a= 0.05). 
Results 
Patients 
Lung tissue was obtained from 10 male patients. Their mean age was 63 ± 
2.1 years (mean±S.E.M., range: 54 to 72 years). The mean VC was 89±6% 
of predicted values, FEV 1/VC was 59± 5%. All subjects had bronchial carcinoma. 
Seven had chronic bronchitis, and 7 reported current cigarette smoking. None 
of the patients had a history suggestive of asthma. Three used bronchodilators 
({3-agonists, theophylline, ipratropiumbromide) and 1 of these received a short 
course of dexamethasone prior to surgery. 
LT generation by lung tissue fragments 
All specimens produced LTB4, C4 and D4. LTE4 was recovered from 8 out of 
the 10 supernatants. The individual and mean data are provided in Table 1. 
Although the quantities of the various LT's varied markedly between individuals, 
LTB4 was always the major metabolite recovered. The mean total sulfidopeptide 
(C4 + D4 + E4) LT synthesis was less than 50% of that of LTB4 (204± 16 and 
453 ± 82 pmol/ g fresh tissue respectively). Of the sulfidopeptide L T's, LTC4 
was produced in the largest amounts, followed by LTD4 and LTE4 (84± 15; 
71 ±27; 40± 16 pmollg respectively). 
Table 1. In vitro synthesis of L T's by lung fragments and functional responses of airway smooth 
muscle to LTC. and methacholine 
LT production" Functional responses' 
Case LTB4 LTC. LTD. LTE. LTC. -log EC2o -log ECso Tmax Tmax 
+D4+E. LTC. LTC. LTC. Methacholine 
363 69 8 4 81 8.52 7.90 51 75 
2 210 105 18 0 123 8.00 7.53 45 67 
3 282 60 9 11 80 8.86 8.15 44 51 
4 147 44 64 0 108 8.57 8.17 101 116 
5 893 181 291 63 535 8.97 8.01 82 97 
6 608 57 44 74 175 8.79 8.16 71 86 
7 399 53 34 38 125 9.28 8.24 134 160 
8 216 66 48 39 153 7.97 7.69 100 105 
9 696 153 137 162 452 8.32 7.93 131 149 
10 720 51 60 13 124 8.29 7.72 60 123 
Mean 453 84 71 40 196 8.56 7.95 82 103 
S.E.M. 82 15 27 16 51 0.13 0.08 11 11 
a L T production is expressed as pmo1 L T per gram of fresh tissue. 
b T mox is expressed as mg isometric force per mg dry tissue weight. 
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Responses of airway smooth muscle 
Concentration-dependent contractions to L TC4 were seen in all bronchiolar strips: 
Values of -logECzo, -logECso and Tmax are given in Table 1. The -logECso of 
LTC4 varied within llog concentration unit (range: 7.53 to 8.24) and was similar 
to our earlier findings 11 • Methacholine 10-4M always produced an additional 
increase in tone when L TC4 responses were at their plateau. The mean increase 
was 21 ± 4% (range 5 to 51%) of the maximal response after methacholine (10-4M). 
The maximal responses to L TC4 and methacholine were significantly linearly 
related (R= 0.89, p<O.OOl)(Figure 1). The production of LTC4 in relation to 
TMAX LTC 4 (mg/mg dry weight) 
150 
R 0,89 •• 
p ,;; 0.001 
100 •• 
• 50 
• • 
0 
0 50 100 150 200 
T MAX METHACHOLINE (mg/mg dry weight) 
Figure 1. Relation between the Tmax to LTC4 (vertical axis) and to methacholine (horizontal axis) 
in human bronchiolar strips. Each dot represents the mean of 2-3 measurements. Tmax is expressed 
in mg force per mg dry tissue weight. The linear correlation coefficient R=0.89 (p<O.OOl). 
LTC 4 PRODUCTION (pmol/g) 
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100 • 
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• 
• 
• 
• 
• 
• •• 
• 
8.00 
LTC 4-Iog EC 50 
8.50 
Figure 2. Relation between L TC4 production, expressed in pmol L T per g of fresh tissue, by human 
lung fragments (vertical axis) and -logECso of LTC4 in bronchiolar strips (horizontal axis). -logECso 
values are the mean of 2-3 measurements in each subject. 
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Figure 3. Effect of repeated LTC4 administration 10-8M to isolated human peripheral airway smooth 
muscle strips on isometric force development. Incubations lasted for 15 min until the contractile 
response had reached a plateau, and were separated by 30 min intervals. Responses to each of 
6 stimulations are expressed as a percentage of the first response of a given strip. The mean values 
of 4 separate experiments are shown, S.E.M. values were smaller than 5%. 
EC50 of LTC4 is shown in Figure 2. No significant correlation was found 
(Spearman p = 0.16, p > 0.10). Also no significant correlations were found 
between the amounts of LTB4, C4, D4 or E4 or of the total sulfidopeptide L T's 
(C4 + D4 + E4) synthetised and any of the other functional parameters (-logECzo, 
-logEC5o and T max)- Contractile responses after repeated exposure to LTC4 are 
shown in Figure 3. No tachyphylaxis was found. 
Discussion 
The present results show that the sensitivity and contractility of airway smooth 
muscle to LTC4 are not decreased in lungs that have a high capacity to produce 
LT. Because some conversion of LTC4 in LTD4 and E4 might have occurred 
during the processing of the chopped tissue, we also examined the relation between 
the total amounts of sulfidopeptide L T synthetised and ECso and T max to L TC4, 
but no significant correlations were found. Repeated LTC4 exposure in vitro 
caused no tachyphylaxis. These findings do not support our initial hypothesis 
that a high endogenous LT synthesis leads to desensitisation of airway smooth 
muscle. 
The results of the experiments with chopped lung tissue are in agreement 
with previous studies12'13 • The predominant synthesis of LTB4 suggests that 
alveolar macro phages and/ or neutrophilic granulocytes were activated, because 
these cell types have been shown to produce mainly LTB414. This LT has 
chemotactic activity, and produces bronchial hyperresponsiveness in dogs 15. 
Furthermore, L TB4 has been demonstrated in bronchial secretions from patients 
with chronic bronchitis, that did not contain LTC4 or D416. LTB4 is, however, 
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only a weak and indirectly acting bronchoconstrictor17• The sulfidopeptide LTC4 
and D4 are highly potent bronchoconstrictors both in vivo and in vitro7' 11' 12• 
Therefore we chose LTC4, which probably acts via the same receptor as LTD418, 
for the in vitro functional experiments. We found a close correlation of Tmax 
to methacholine and L TC4 (Figure 1 ), which is unlike the discrepancy between 
methacholine and LTC4-induced airway obstruction in asthmatics in vivo found 
by Adelroth7 • Furthermore, it was previously found in non-asthmatic subjects 
that, in vivo, LTC4 is roughly 500-1000 times more potent than methacholine 
in causing airway narrowing7, whereas the potencies in vitro differ only by a 
factor 10011 • These differences in relative and absolute potencies of LTC4 and 
methacholine in vivo and in vitro suggest that in vivo LTC4 acts not only directly 
on airway smooth muscle, but has also indirect effects that cause an additional 
airway narrowing. Such effects may include the release of bronchoconstricting 
substances in the lungs, or induction of vagal reflex bronchoconstriction. 
In the present study, we did not measure bronchial responsiveness in vivo, 
which could be relevant to airway smooth muscle function. It is possible that 
airway smooth muscle of asthmatics differs from that of normals or patients 
with chronic bronchitis. In a previous study, we have found that the response 
to LTC4 of airway smooth muscle from subjects with and without chronic 
bronchitis and airflow limitation was not different19 • We have also documented, 
however, that airway smooth muscle from an asthmatic patient had a highly 
increased maximal response to LTC4 and methacholine, with normal EC50 
values20• Fresh asthmatic lung tissue is rarely available for pharmacological 
studies. In the present study, we have therefore examined lung tissue from non-
asthmatic subjects with and without chronic bronchitis and airflow limitation; 
it cannot be excluded that different results would have been obtained had 
asthmatic airways been studied. 
A bias may have resulted from the various medications used by some of the 
patients prior to surgery. Several drugs may have suppressed LT generation 
(dexamethasone) or L T effects ({3-agonists, theophylline). This seems unlikely, 
however, because our thorough washing procedure should have removed any 
residual drug activity before the start of the experiments10, and airways from 
patients using bronchodilators were not obviously less responsive to LTC4 and 
methacholine than those of patients who used no bronchoactive drugs. 
In conclusion, we found· that airway smooth muscle from human lung tissue 
that produced relatively large amounts of LT was not less sensitive to LT, and 
furthermore that no tachyphylaxis to exogenously added L TC4 occurred. This 
suggests that the relatively low potency of LTC4 in asthmatics with a highly 
increased bronchial responsiveness to methacholine may not be due to tachy-
phylaxis of airway smooth muscle to endogenous LTC4. 
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Chapter 15 
Human asthmatic airway responses in vitro 
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The Netherlands. 
Summary 
Responses of human isolated airways, obtained from an asthmatic patient at 
thoracotomy, were compared to responses of airways from 10 non-asthmatic 
subjects in vitro. Asthmatic bronchiolar strips exhibited increased contractile 
responses to histamine, methacholine and leukotriene (LT) C4, and relaxed 
normally in response to !-isoproterenol and forskolin. The non-adrenergic 
inhibitory response to electric field stimulation was low, but was not significantly 
different from control values. These results suggest that increased airway smooth 
muscle contractility may contribute to the asthmatic airways hyperresponsiveness 
in this patient. 
Key words: airway smooth muscle, asthma, bronchial hyperresponsiveness, non-
adrenergic inhibitory system, methacholine, histamine, leukotriene c4, isopro-
terenol, forskolin. 
De Jongste JC, Mons H, Bonta IL, Kerrebijn KF. In vitro responses of airways from an asthmatic 
patient. Eur J Respir Dis 1987;71:23-29. Reprinted with permission of Munksgaard International 
Publishers. 
Introduction 
The mechanisms which underlie the nonspecific bronchial hyperresponsiveness 
in asthmatics are poorly understood. A number of studies have compared in 
vitro responses of isolated human airways to in vivo responsiveness. A narrow 
in vitro response range was found in airways from patients who exhibited a 
wide variation of in vivo responses to inhaled methacholine or histaminel-7. The 
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subjects included in these studies were, however, not asthmatic but had various 
degrees of COPD, and usually smoked. Bronchial hyperresponsiveness may have 
a different pathogenesis in asthma and COPD. In COPD, bronchial hyperres-
ponsiveness is well correlated with baseline airway caliber, whereas in most 
asthmatics this relation is poor or absent8- 9 . Furthermore, bronchial respon-
siveness in COPD is usually moderate, whereas in asthma the response can 
progress to severe bronchoconstriction. There have been few reports on functional 
in vitro studies of human asthmatic airways5'6'10-14. We now report here our 
measurements of in vitro responses of isolated airways from an asthmatic patient. 
In addition to pharmacological experiments, we performed electrical field 
stimulation (EFS) in order to assess the function of the non-adrenergic inhibitory 
(NAI) system, which probably represents the only inhibitory innervation of human 
airways15. We have compared our findings to our own measurements of in vitro 
responses of airways from subjects without asthma or COPD. 
Patients and methods 
The patient was a male aged 41 years, who had had asthma since early childhood. 
House mite atopy was confirmed by skin tests and IgE-RAST. He had never 
smoked. Lung function was normal except for a largely reversible broncho-
constriction (inspiratory vital capacity (VC) 5810 ml (112% of predicted value); 
forced expiratory volume in 1 s (FEV1) 3530 ml (61% of VC) before, and 70% 
of VC after inhalation of 0,4 mg salbutamol). The histamine responsiveness, 
determined by inhalation of doubling concentrations of histamine by tidal 
breathing for 30 s, was highly increased (provocative concentration that produced 
a 20% fall in FEV1 1 mg/ml; normal value> 16 mg/ml). Maintenance treatment 
consisted of inhaled beclomethasone. No bronchodilators had been used prior 
to surgery. A resection of the apical segment of the right upper lobe was performed 
for a solitary coin lesion, which turned out to be a tuberculoma. 
In vitro studies 
Lung tissue was collected immediately after surgical resection in ice-cold Krebs-
Henseleit buffer (composition in mM : NaCl 118, KCl 4.7, CaCh 2.3, MgS04 
1.2, KHzP04 1.2, NaHC03 25, glucose 5.55), aerated with 95% Oz and 5% C02. 
Strips of segmental bronchus (internal diameter 3-4 mm) and of bronchioles 
(internal diameter 1 mm) were dissected carefully, as described previously16. 
Bronchiolar strips were stored overnight and studied the next day for their 
response to pharmacological stimulation. Bronchial strips were examined on 
the day of surgery for their response to EFS. 
Pharmacological stimulations were carried out as described previously17 • 
Cumulative concentration-response curves (CCRC) were made using histamine, 
methacholine and leukotriene (LT)C4 as contracting agents. Tension changes 
were measured with Grass FT03D isometric force transducers, employing a 
baseline tension of 500 mg. Maximal responses (T max) were expressed as mg 
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isometric force per mg dry weight of the bronchiole. The ECso (the molar 
concentration of an agonist that produces 50% of the maximal effect) was derived 
from each CCRC by means of a computerized iterative curve fitting method. 
Relaxation of methacholine ECso-induced contraction by !-isoproterenol and 
forskolin was measured isotonically using Penny & Giles transducers, because 
reference values had been obtained previously with the respective techniques's. 
Relaxation responses to !-isoproterenol and forskolin were expressed as a 
percentage of the difference between methacholine ECso induced contraction 
and maximal relaxation, determined after each experiment by adding EDT A 
( 4x10-3 M) and, after forskolin CCRC, also isoproterenol lO-s M. EFS of bronchial 
strips was carried out via platinum plate electrodes. Rectangular 0,3 ms pulses 
of alternating polarity and supramaximal voltage (50 V) were delivered by a 
custom made tissue stimulator. An isotonic load of 1 g was applied to bronchial 
strips. In all field stimulation experiments, atropine (1.2x10-6M), indomethacin 
(6x10-6M) and the leukotriene (LT) receptor antagonist FPL 55712 (11.5xl0-6M), 
were added to the organ bath in order to block the effects of cholinergic nerve 
stimulation, the production of prostaglandins and the effects of L T formation. 
This was done because we had previously found that EFS, apart from stimulating 
cholinergic and NAI nerves, induces production of contracting prostaglandins 
and leukotrienes by fresh bronchial tissues, which may obscure NAI responses 19• 
EFS frequency-response curves were preceded by a histamine CCRC followed 
by washing; histamine was then applied at its ECso to precontract the airway 
before EFS. Frequency-response curves were made by applying continuous EFS 
with stepwise increasing frequency (1 to 50 Hz), and relaxation responses were 
expressed as described for pharmacological relaxation curves. 
A paired experiment was performed simultaneously on a second bronchial 
strip from the same patient which was pretreated with the nervous conductance 
blocker tetrodotoxin (TTX, 3x10-6 g/ml) in order to estimate the role of nerve 
conduction. Proximal segments were removed from the bronchiolar strips before 
the in vitro experiments and were processed for histological examination. The 
amount of airway smooth muscle was assessed semi-quantitatively by subjective 
grading, using a modification of the method described by Wright et ae0• A 
score 0-3 was determined for normal (score 0) or increasingly abnormal (score 
1-3) airways, using pictorial reference standards. 
Data analysis 
Responses of asthmatic tissue were compared to reference values, obtained in 
previous experiments with airways from 10 non-asthmatic subjects (mean age: 
59±3 years; VC 104±4%; FEV,/VC 75±2%, mean± S.E.M.), who had no 
respiratory symptoms prior to surgery's. Geometric mean values (for contractile 
responses) or individual values (for relaxation responses) of asthmatic tissues 
were compared to the mean values and 95% confidence limits of non-asthmatic 
mrways. 
Table 1. Responses of human asthmatic and non-asthmatic airways in vitro 
-log ECso 
histamine 
asthmatic' 5.93±0.28 
normalsb 5.85 (5.34-6.36) 
(n= 10) 
-log ECso 
!-isoproterenol 
asthmatic 7.44 
normalsb 7.25 (5.48-9.02) 
(n=10) 
methacholine 
6.29±0.26 
6.24 (5.35-7.13) 
forskolin 
6.77 
6.80 (6.29-7.31) 
LTC4 
8.06±0.13 
8.09 (7.65-8.53) 
EFS 
(EF50)' 
2.4 
2.1 (0.4-3.8) 
'Geometric mean values± S.E.M. of triplicate measurements for each agonist. 
b Geometric mean values and 95% confidence limits. 
Tmox (mg force/mg dry weight) 
histamine 
321 ± 99 
52 (26-76) 
Rmaxd 
isoproterenol 
92 
92 (67-100) 
methacholine 
301 ± 109 
100 (0-231) 
forskoline 
84 
95 (82=100) 
' EF5o =the frequency (Hz) that produces 50% of maximal relaxation in a given strip. 
LTC4 
222±83 
74 (0-163) 
EFS 
46 
71 (33-100) 
d Rm., =maximal relaxation, expressed as a percentage of the difference between histamine or methacholine-induced contraction and maximal 
relaxation in the presence of isoproterenol 10-5M and EDTA 4x!0-3M. 
...... 
......:) 
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Results 
The results of the pharmacological experiments are shown in Figures 1 and 
2. Contractile responses to histamine, methacholine and L TC4 were significantly 
higher in asthmatic (n = 3 for each agonist) compared to non-asthmatic airways 
(n = 10). The absolute contractile responses of asthmatic airways showed a large 
scatter, which was not unexpected, because of the relatively high intrinsic 
variability of Tmax in human bronchiolar strips17 • The ECso values of asthmatic 
and non-asthmatic airways were similar (Table 1). No differences were found 
in the relaxation responses to both isoproterenol and forskolin between one 
ISOMETRIC FORCE (MG/MG DRY WEIGHT) 
350 
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HISTAMINE 
LTC 4 
(MEAN ± S.E.M.) 
10-9 10-B 10- 7 10-G 10-s 
MOLAR AGONIST CONCENTRATION 
Figure 1. Cumulative concentration-response curves of human asthmatic (closed symbols) and non-
asthmatic (open symbols) bronchiolar strips to histamine, methacholine and leukotriene C4. Asthmatic 
and non-asthmatic curves are from 1 and 10 subjects respectively; asthmatic curves are the mean 
of triplicate measurements for each agonist. 
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Figure 2. Cumulative concentration-response curves of human asthmatic (closed symbols) and non-
asthmatic (open symbols) bronchiolar strips to !-isoproterenol and forskolin as relaxing agents. 
Asthmatic curves are from 1 bronchiolar strip each, nonasthmatic curves are the mean of 10 separate 
experiments. Relaxations are expressed as a percentage of the difference between initial methacholine 
ECso-induced tone and maximal relaxation in calcium-free buffer containing EDTA (4x10 _, M) 
and isoproterenol 10-5M. 
asthmatic and 10 non-asthmatic tissues (Table 1, Figure 2). EFS produced 
frequency-dependent relaxations in the two asthmatic and 10 non-asthmatic 
bronchi. Individual responses of the asthmatic and mean frequency- response 
curves of 10 non-asthmatic airways with and without TTX are shown in Figure 
3 and in Table L The maximal NAI-response of one asthmatic bronchus (46% 
of histamine EC5o-induced contraction) was considerably less then the mean 
maximal response of 10 non-asthmatic tissues (71 ± 6%) but fell within the 95% 
confidence limits of the normal values. In the presence of TTX, only a minor 
relaxation (14%) remained in the other asthmatic bronchus, whereas in 10 non-
asthmatic airways the mean relaxation was reduced to 55± 8% (NS). 
Histological examination of three asthmatic airways showed characteristic 
abnormalities such as derangement of the epithelium, thickening of the basal 
membrane, goblet cell hyperplasia and eosinophil infiltration in the submucosal 
layer; smooth muscle hypertrophy (score 3) was always a prominent feature 
(Figure 4). The mean muscle hypertrophy score of 10 non-asthmatic airways 
was 0.6 ± 0.3 (mean± S.E.M., range 0-2). 
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173 
Figure 3. Non-adrenergic inhibitory responses of human asthmatic (closed symbols) and non-asthmatic 
(open symbols) segmental bronchus to electric field stimulation in the absence (continuous lines) 
and presence (broken lines) of the nervous conductance blocker tetrodotoxin (3xl0-6 g/ml). Asthmatic 
curves are from one bronchial strip each, non-asthmatic curves are the mean of 10 separate experiments. 
The vertical axis depicts relaxation responses as a percentage of the difference between initial histamine 
ECso-induced contraction and maximal relaxation in calcium-free buffer containing EDTA (4xl0-3M) 
and isoproterenol 10-5M. All experiments were performed in the presence of atropine (L2x10-6M), 
indomethacin (6x10-6M) and FPL 55712 (1 1.5x10-6M). 
Discussion 
In bronchial tissues from an asthmatic patient we found significantly increased 
contractile responses to histamine, methacholine and L TC4, and normal relax-
ations to isoproterenol and forskolin. NAI relaxations to EFS were low but 
not significantly different from control values. The patient was well characterized 
by clinical history, the demonstration of atopy, a reversible bronchoconstriction 
and a highly increased bronchial responsiveness to histamine. This asthmatic 
represents a rare case because he had no features of chronic bronchitis, never 
smoked and underwent lung tissue resection without having bronchial malig-
nancy. 
There are only few reports in the literature on in vitro functional responses 
of isolated asthmatic human airways5' 6' 10-14. Increased contractile responses to 
histamine, carbachol and LTC4 have been observed by Schellenberg et al13 and 
selective hyperresponsiveness to histamine was found in a single asthmatic 
bronchus by Schellenberg and Foster12• Histamine and carbachol or methacholine 
responses of asthmatic cases reported by Paterson et al 10, Roberts et al5' 6 , and 
Cerrina et al14, however, were similar to those of non-asthmatic airways. There 
are important differences in patient characteristics and in vitro methodology 
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Figure 4. Photomicrograph of a section through an asthmatic bronchus, showing epithelium 
derangement, thickening of the basal membrane, infiltration of the submucosa with inflammatory 
cells, including many eosinophils, and severe hypertrophy of airway smooth muscle (ASM). Stain: 
May-Griinwald-Giemsa; magnification: 200x. 
between these studies that make it difficult to compare the results. In contrast 
to the present case, most asthmatics in two of the previous studies were elderly 
subjects with chronic bronchitis and more or less severe airflow obstruction, 
who smoked cigarettes and used bronchodilators5' 14• These factors may influence 
in vivo and, perhaps, in vitro airway responsiveness8' 9' 18• The asthmatic lung tissue 
studied by Paterson et al10 was obtained 4-16 h post mortem. Prolonged hypoxia 
and acidosis may have attenuated the absolute responses to contractile agonists, 
in spite of unchanged ECso values. 
In the present case, a remarkable degree of smooth muscle hypertrophy 
suggested that the exaggerated isometric force development may have resulted 
from an increased amount of muscle, although muscle volume and isometric 
force do not seem to be closely correlated in non-asthmatic human airways2'3• 
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In animal experiments, hyperresponsiveness may result from atopic sensiti-
zation21-23. However, human airways from non-asthmatic individuals with positive 
skin prick tests and elevated serum IgE levels have not beet} found to be 
hyperresponsive in vitro1' 2' 5' 6• Since atopy often occurs without asthma, the 
relevance of the animal experiments seems questionable. 
Finally, asthmatic airways may be more responsive because they a:re more 
inflamed. Animal studies have shown that granulocyte infiltration of airways 
produces hyperresponsiveness24 and we found histamine hyperresponsiveness in 
small airways from patients with chronic bronchitis18. However, small airway 
inflammation is not specific for chronic bronchitis, and is not related to in vitro 
responsiveness3'4' 2~. It cannot be excluded, however, that asthmatic airway 
inflammation, which may be different from airway inflammation in chronic 
bronchitis, has an effect on human airway smooth muscle function. 
In two previous reports, a defective isometric response of human asthmatic 
airways to ,8-adrenergic stimulation has been described 10'14. Experiments on 
sensitized 'asthmatic' airways from experimental animals have produced con-
flicting results in this respect23'26. We observed normal isotonic relaxations to 
isoproterenol and forskolin in two asthmatic bronchiolar strips, indicating normal 
,8-receptor function and sufficient cAMP generation to produce near-maximal 
relaxations in these asthmatic airways. Again, methodological factors may be 
responsible for the discrepancy of our results and those of others; it is unlikely, 
however, that isotonic and isometric measurements produce different results27 • 
N AI relaxations of asthmatic bronchus were unusually low, but not significantly 
different from control values. NAI responses of human asthmatic airways have 
not been reported before; Taylor et al. found normal NAI responses of non-
asthmatic airways from hyperresponsive COPD patients7• Clearly, these limited 
data allow no conclusions on possible NAI dysfunction in asthmatic airways15. 
In conclusion, we found significantly increased absolute force development 
and normal sensitivities as measured by ECso, to histamine, methacholine and 
LTC4, normal relaxation responses to isoproterenol arid forskolin, and low NAI 
relaxations in isolated airways from an asthmatic patient. It is suggested that 
the increased contractile responses may be the result of smooth muscle hyper-
trophy, although alternative mechanisms have not been excluded. The charac-
teristic in vivo airway hyperresponsiveness in this case seems at least partly due 
to exaggerated responses of the airway smooth muscle. 
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Chapter 16 
Cholinergic and non-adrenergic inhibitory nerve-mediated 
responses of isolated human airways from patients with and 
without COPD or asthma 
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Summary 
Abnormalities in the balance between the excitatory and inhibitory components 
of the autonomic innervation of the airways may contribute to the airways 
obstruction and hyperresponsiveness in chronic obstructive pulmonary diseases 
(COPD) and asthma. This balance is reflected by the nerve-mediated biphasic 
contraction-relaxation response of isolated human airways to electric field 
stimulation (EFS). We measured the responses to EFS of human airway smooth 
muscle preparations from 10 normal subjects, 5 patients with COPD and 2 
asthmatics. All airways from normals and COPD patients showed biphasic 
responses to EFS consisting of a rapid cholinergic contraction followed by a 
slower non-adrenergic relaxation. Precontraction of airway smooth muscle with 
methacholine led to a decrease of the cholinergic component; the non-adrenergic 
inhibitory (NAI) component increased when the airway was precontracted from 
0 to 60% of the maximal response to methacholine, and decreased when the 
strip was further contracted to 100%. For a given contractile state of the muscle, 
the response to EFS was relatively constant. No differences in nerve-mediated 
cholinergic and NAI responses were found in airways from normals and COPD 
patients. The 2 asthmatic airways, however, showed exaggerated contractions 
to methacholine and EFS. The relaxation response of asthmatic bronchi was 
reduced. In airways from normal subjects the inflammatory mediators histamine 
and PGF2a had no effect on the response to EFS but LTC4 reduced the NAI 
relaxation response significantly (P < 0.05). 
These results suggest that the cholinergic/NAT balance in human airways is 
normal in COPD, but may be abnormal in asthma due to an increased cholinergic 
response and a reduced activity of the NAI system. Reduced NAI responses 
might result from exposure to L TC4. 
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Introduction 
In humans, the autonomic nervous system directly controls airway caliber by 
both a cholinergic excitatory and a peptidergic nerve supply to airway smooth 
muscle1• The peptidergic system in the airways probably contains both excitatory 
and inhibitory components 1. Functional studies on human airways, however, 
have only provided evidence for a non-adrenergic inhibitory (NAI) innervation I-s. 
Obstructive disorders of the gastrointestinal tract have been demonstrated to 
be associated with a defect of the NAI system. Since the gastrointestinal tract 
and the bronchi have a similar ontogenesis, it seems likely that NAI defects 
may also occur in the airways, and give rise to airways obstruction1' 2' 6' 7 • The 
role of the NAI system in obstructive airway diseases, however, is difficult to 
assess because the neurotransmitter is not known, and specific blockers are not 
available. At present, most evidence suggests that the NAI transmitter might 
be vasoactive intestinal polypeptide (VIP) or a related peptide1' 5• However, in 
guinea pig trachea electric field stimulation (EFS) still produces NAI relaxations 
in the presence of maximally effective concentrations of VIP9• Because the 
neurotransmitter is not known, the only valid way· to study the NAI response 
of human airways is to measure the response of airway smooth muscle to selective 
stimulation of NAI nerves. Electric field stimulation (EFS) of human airways 
in vitro produces a biphasic contraction-relaxation (C-R) response, which is due 
to stimulation of cholinergic and NAI nerves in the bronchial wall3'4'7' 8• The 
configuration of the C-R response to EFS is, however, not only determined 
by the relative contribution of the cholinergic and NAI innervation, but also 
by the baseline contractile state of the muscle, as has been shown for guinea 
pig central airways10, where precontracted airways exhibit small C and large 
R responses, whereas relaxed airways have large C and absent R responses. 
The present study was undertaken to determine the effects of airway smooth 
muscle contraction on the C-R response to EFS in human airways from patients 
with and without chronic obstructive pulmonary disease (COPD) or asthma, 
in order to document a possible cholinergic/NAI dysbalance in obstructive airway 
disease. In addition, we examined whether the presence of inflammatory mediators 
changed the C-R response of normal human airways, because inflammation is 
considered to be a determinant of airways obstruction and hyperresponsiveness 11 • 
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Methods 
Patients 
Patients, scheduled for pneumonectomy or lobectomy, preoperatively underwent 
lung function measurements (inspiratory vital capacity, VC, and forced expiratory 
volume in 1 sec, FEV1) using a water-locked spirometer. The reversibility of 
airways obstruction was determined by repeated spirometry after inhalation of 
10 mg nebulised isoproterenol. The medical history was taken and a physical 
examination was done. Subjects were classified as normal when they had no 
respiratory symptoms and a normal lung function. COPD was diagnosed 
according to the criteria of the American Thoracic Society, i.e. when patients 
reported cough and sputum production for two or more years during at least 
three months each_ year, and when they had airways obstruction (FEV1/VC 
% < 70) that did not normalise after inhalation of 10 mg nebulised isoproterenol. 
Asthma was diagnosed when patients reported episodes of wheezing with acute 
onset that responded to bronchodilator treatment, had a highly increased 
responsiveness to inhaled histamine as measured by the fall in FEV 1 after 
inhalation of doubling concentrations of nebulised histamine, and showed a 
10% or more improvement of baseline FEV1 after 10 mg of nebulised iso-
proterenoL 
In vitro studies 
Human lung tissue was obtained at thoracotomies for bronchial malignancy. 
Immediately after resection, a macroscopically normal piece oflung was collected 
in Krebs Henseleit buffer (composition in mM: NaCl 118, KCl 4.7, CaClz, 2.5, 
MgS04 1.2, KHzP04 1.2, NaHC03 25, glucose 5.55) aerated with 95% Oz and 
5% C02. Bronchial strips (fourth to seventh generation) were carefully dissected 
free from parenchyma and blood vessels as we have described previously12, and 
were mounted in 10 ml double jacketed organ baths at 37°C. 
We previously demonstrated that, after this procedure, the function of smooth 
muscle preparations was stable for many hours after surgery, which allowed 
reproducible measurements of sensitivity to pharmacological agonists with a 
small within-subject variability12'13 • Contractile responses were measured iso-
tonically using high precision angular displacement transducers14 and employing 
an isotonic load of 1 gram which stretched the preparations to their optimal 
length, as found in preliminary experiments. The airway preparations were 
allowed to equilibrate for 2 h and were washed extensively to remove drugs 
used during anaesthesia (halothane, Oz/N20, fentanyl, pentothal, atropine, 
pancuronium) and substances possibly liberated during the dissection. After 
stabilisation of the baseline, all preparations were contracted with methacholine 
(10-8 to 10-4 M in 10 fold concentration steps) followed by washing and return 
to baseline. 
Electric field stimulation 
Rectangular pulses of alternating polarity were delivered by a custom-made tissue 
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stimulator via platinum plate electrodes (40x5 mm) glued to both sides of the 
organ bath parallel to the bronchial strip (electrode distance: 15 mm). 
A series of experiments was carried out to determine optimal EFS stimulus 
characteristics. Voltage-response curves were made employing a constant fre-
quency (30 Hz) and pulse width (0.3 msec) and an increasing voltage (5 to 
50 V). Similarly, frequency-response curves (5 to 50 Hz, 30 V, 0.3 msec) and 
pulsewidth-response curves (0.2 to 0.75 msec, 30 V, 30Hz) were made employing 
30 sec pulse trains. All experiments were done on 5 bronchial strips from 5 
different subjects without COPD. Before EFS, a moderate contraction was 
induced with histamine (10-6 M) to allow measurement of the NAI relaxation 
responses. Both C and R responses were expressed as a percentage of the maximum 
response in a given strip, and means± SEM for a given stimulus were calculated. 
To confirm the nerve-mediated cholinergic and NAI nature of the biphasic 
response to EFS, the effects of atropine (10-6 M), the nervous conductance blocker 
tetrodotoxin (TTX, 3xl0-6 g/ml) and the /3-receptor blocker timolol (10-6 M) 
were examined in separate experiments. 
EFS responses in COPD, asthmatic and normal airways 
EFS was applied to airways from patients with and without COPD and asthma 
in the absence and presence of increasing concentrations of methacholine (10-8 
to 10-4 M) to precontract the airway smooth muscle, as examplified in Figure 
1. The inherent high variability of the absolute responses of isolated human 
airways 12 made normalisation of responses necessary. We therefore followed 
the procedure proposed by Mansour and Daniel15 and calculated all responses 
to pharmacological and field stimulation as a percentage of the difference between 
'zero contraction', determined at the end of each experiment by adding L-
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Figure 1. Representative example of a field stimulation experiment in the presence of increasing 
concentrations of methacholine. Arrows indicate onset of a 30 sec. train of 30 V, 30 Hz, 0.3 msec 
pulses. Dots indicate when methacholine was added in order to produce baseline elevation (final 
bath concentrations: 0, 10-8, 10-7, 3x107, 10-6, 3xl0-6, 10-5 and 104 M). At the end of the experiment, 
the strip was exposed to Ca-free euffer containing EDTA (4xl0-3 M) and isoproterenol (10-4 M) 
in order to produce maximal relaxation. The difference between maximal methacholine-induced 
contraction and maximal relaxation is indicated (100% MC). 
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isoproterenol (10-4 M) and EDTA (4xl0-3 M), which relaxed the strips completely, 
and 'maximal contraction' in the presence of 10-4 M methacholine. Responses 
were expressed as a percentage of maximal contraction(% MC)(Figure 1). 
Effects of inflammatory mediators on responses to EFS 
Bronchial strips from normal subjects were precontracted by increasing con-
centrations of either histamine (10-8 to 10-4 M), prostaglandin (PG) F2a (10-7 
M to 10-5 M), or leukotriene (LT) C4 (10-10 to 10-7M), and EFS was applied 
when a contraction plateau was reached after a given mediator concentration. 
Both the responses to the mediators and to EFS were expressed as a %MC. 
The maximal contraction (100 % MC) was determined by adding 10-4 M 
methacholine when the response to the highest concentration of a mediator had 
reached its plateau. From each pharmacological cumulative concentration-
response curve (CCRC), the negative logarithm of the effective concentration 
of an agonist that produced 50% of its maximal effect (-logECso) was derived 
by linear interpolation. 
Drug sources 
Methacholine hydrobromide, histamine dihydrochloride and L-isoproterenol 
were obtained from Janssen, Belgium; EDTA, TTX and PGF2a from Sigma, 
USA; Atropine sulphate from Brocacef; Timolol maleate from Merck, Sharp 
& Dhome; synthetic LTC4 was a gift from Merck Frosst, Canada. 
Statistical analysis 
The measured values of C and R responses to EFS at increasing levels of muscle 
contraction, induced by methacholine, were plotted against baseline contractile 
state. From these curves, C and R response amplitudes at 0,10,20 etc. up to 
100% MC were obtained by linear interpolation. Mean± SEM for C and R 
responses were calculated in different airway preparations at corresponding 
contraction levels. Mean C and R values at corresponding baseline contraction 
levels were compared in strips from normals and COPD patients. The amplitudes 
of C and R responses of normal airways in the presence of inflammatory mediators 
were compared to C and R responses at corresponding baseline contraction 
levels induced by methacholine. The statistical significance of differences in means 
was determined by Student's t-test for unpaired samples (two tailed, a= 0.05). 
Whenever more strips from a patient were studied, the results of that patient 
were averaged before being used in statistical calculations. 
Results 
Patients 
Lung tissue was obtained from 10 normals, 5 patients with COPD and 2 
asthmatics. The clinical data of these patients are summarized in Table 1. Both 
asthmatics had a highly increased bronchial responsiveness to histamine (pro-
vocative concentration of inhaled histamine that produced a 20% fall in FEV,: 
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Table 1. Patient characteristics 
Normals 
COPD 
Asthma 
N 
10 
5 
2 
Age 
(yr) 
57±3 
62±3 
40,41 
VC FEV1/VC 
(%predicted) (%) 
108±6 
89±5 
107,112 
71±5 
53±4 
62, 61 
Values reported as mean±SEM 
Regularly 
used 
medication 
Ipratropium (1) 
Salbutamol (1) 
Theophylline (2) 
Salbutamol (2) 
Theophylline (1) 
Beclomethasone (1) 
Current 
smoking (n)' 
4 
2 
' Non-smokers were all ex-smokers who ceased smoking at least 3 years prior to surgery. One 
asthmatic had never smoked. 
1 mg/ml in both subjects). Skin tests and lgE-RAST were positive for house 
dust mite in one asthmatic and negative in the other. All subjects were operated 
because of bronchial carcinoma except for one of the asthmatics, who had a 
coin lesion which turned out to be a tuberculoma. 
Determination of optimal EFS stimulus characteristics 
All bronchial strips from normals and COPD patients responded to EFS with 
biphasic responses. Voltage-response curves showed that the C-phase was 
maximal at 40 V and the R-phase at 30 V (Figure 2A). Frequency-response 
curves produced maximal C and R responses at 30 and 40 Hz respectively (Figure 
2B), and pulsewidth appeared to have a relatively minor effect on both C and 
R responses, with a maximal C and R response at 0.4 msec (Figure 2C). In 
all further experiments, 30 sec trains of 30 V, 30 Hz and 0.3 msec pulses were 
used in order to obtain near-maximal responses. Atropine blocked the C-response 
completely; TTX, the nervous conductance blocker, blocked the C-phase com-
pletely and reduced the R-phase, and timolol, a f3 receptor-blocker, had no 
effect on both C and R phases (data not shown). 
EFS responses in normal, COPD and asthmatic patients' 'airways 
We examined 10 airway preparations from 10 normals, 10 preparations from 
5 patients with COPD, and 2 strips from 2 asthmatics. All strips had some 
stable intrinsic contractile activity (spontaneous baseline contraction: 11 ± 3 %MC 
and 18 ± 3 %MC in normal and COPD tissues respectively, NS). EFS produced 
a C phase of 36 ± 5 %MC in normals and 42 ± 7 %MC in COPD (NS) and 
an R phase of2 ± 1% MC in both groups. Inducing contraction with methacholine 
was followed by a gradual decrease of the C phase, which always disappeared 
at 100 %MC. The R response increased between 0-60 %MC. The maximum 
relaxation was 16 ± 3 %MC in normal airways and 17 ± 3 %MC in COPD airways, 
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Figure 2. Effect of changes in pulse voltage, -frequency and -width on the contraction and relaxation 
responses of human bronchial strips. A: effect of voltage (0 to 50 V) with constant frequency (30 
Hz) and pulse width (0.3 msec). B: effect of frequency (0 to 50 Hz) with constant voltage (30 
V) and pulse width (0.3 msec). C: effect of pulse width (0.2 to 0.75 msec) with constant voltage 
(30 V) and frequency (30 Hz). Pulse trains of 30 sec. Contractions and relaxations are expressed 
as a percentage of the maximal response in a given strip. Mean values± SEM of 4-5 experiments 
are shown. 
at 60 %MC baseline. When the baseline was raised further up to 100% MC, 
R responses decreased and usually disappeared at 100 %MC (Figure 3). At 
corre~ponding levels of induced contraction, C and R responses showed relatively 
little variation and were not different in normal and COPD airways. The 
methacholine CCRC was also similar in normal and COPD airways (Figure 
4), with a -logECso of 6.04 ± 0.13 and 6.13 ± 0.14 respectively (NS). 
The 2 airways from asthmatic subjects had a spontaneous baseline contraction 
of 11 and 32 %MC, which was within the 95% confidence limits of the non-
asthmatic tissues. EFS produced C phases of 22 and 33 %MC and R phases 
of 0 %MC. After precontraction with increasing methacholine concentrations, 
asthmatic airways also showed a decrease of the C response, but the R phase 
was grossly deficient, only being detectable as a 1 %MC relaxation to EFS 
at 40 %MC baseline in one of the two subjects' airways (Figure 5). 
Methacholine CCRC's in asthmatic airways had a -logECso of 6.26 and 6.05. 
The maximal contraction to methacholine of asthmatic airways was, however, 
roughly 3-4 times higher than that of the most responsive non-asthmatic airways. 
Effect of inflammatory mediators 
The effect of histamine, PGF2" and LTC4 on the C-R response to EFS was 
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Figure 3. Response to EFS of 10 airway smooth muscle preparations from 10 normals (open circles) 
and 10 preparations from 5 patients with COPD (closed circles). Contraction and relaxation responses 
are expressed as % MC, baseline elevation was produced by·adding increasing concentrations of 
methacholine (10-8 to 10-4 M) as shown in figure 1. At all levels of induced contraction, the contraction 
and relaxation responses in normals and COPD patients were not different (P>0.05). 
measured in 20 bronchial strips from normal subjects. Baseline conditions were 
not different regarding the patients ages, lung function and smoking habits; 
the spontaneous baseline contractile state of the bronchial strips was also not 
different in experiments with the various mediators and methacholine. Histamine, 
PGF2" and LTC4 produced CCRC's with a mean -logECso of 5.92 ± 0.14 (n = 7), 
6.25 ± 0.31 (n = 7) and 7.87 ± 0.13 (n = 6) respectively. Maximal responses 
to histamine (10-4M), PGF2" (10-5M) and LTC4 (10-7M) were 89 ± 4, 64 ± 7 
and 61 ± 7 % MC respectively (Figure 4). The results of the induction of 
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Figure 4. Cumulative concentration-response curves (CCRC) of human bronchi. Methacholine CCRC 
were made on 10 bronchial strips from 10 subjects without COPD and on 10 strips from 5 patients 
with COPD; CCRC to histamine, PGF2a and LTC4 were made on 6-7 strips from subjects without 
COPD. The vertical axis depicts contractions, expressed as a percentage of the difference between 
maximal contraction, induced by methacholine, and maximal relaxation by Ca-free buffer containing 
isoproterenol (see: methods). Spontaneous baseline contractile state of the preparations before each 
CCRC was similar, as shown left from the curves ('before'). 
contraction by these mediators on the C-R responses to EFS is shown in Figure 6. 
Although C responses in the presence of the inflammatory mediators (Figure 6) 
tended to be lower than C responses in the presence of methacholine (Figure 3), 
the mean values at corresponding baseline levels were not significantly different. 
R responses in the presence of LTC4 were reduced compared to R responses 
in the presence of methacholine (shown in Figures 6 and 3 respectively). This 
reduction was present onwards from 30 %MC baseline, and reached significance 
at 60 %MC (the mean R phase was 16 ± 3 %MC in the presence of methacholine 
and 7±2 %MC in the presence of LTC4 at 60 %MC, p<0.05). The mean 
concentration of LTC4 necessary to produce 60 %MC was 3.47xl0-8M. Histamine 
and PGF2a had no effect on the R phase. 
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Figure 5. Responses to EFS of 2 bronchi from 2 asthmatic patients (individual values are shown). 
Baseline elevation was produced by methacholine (10-8 to 10-4 M) as shown in Figure I. Note 
the absence of a relaxation response at all levels of induced contraction. 
Discussion 
In the present study, we used the contraction-relaxation response of human 
airways to EFS as a measure of the balance between the contractile and inhibitory 
components of the autonomic innervation of the airway smooth muscle. Our 
results suggest that this balance is similar in airways from patients with and 
without COPD. Airways from two asthmatics, however, showed increased 
contractile and reduced inhibitory responses. Furthermore, the inflammatory 
mediator L TC4 appeared to reduce the relaxation phase in non-asthmatic airways. 
Our field stimulation characteristics chosen to produce near-maximal responses 
were similar to those reported by others3' 8• The contractile phase was completely 
blocked by atropine and, thus, was due to muscarinic receptor stimulation. This 
cholinergic phase was neurally mediated because it could also be blocked by 
TTX. The relaxation phase was not affected by timolol, and was partially reduced 
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Figure 6. Responses to EFS of normal human bronchus in the presence of increasing concentrations 
of histamine (n=7, squares), PGF2"' (n=7, open triangles) or LTC4 (n=6, closed triangles). 
Mean± SEM of 3-7 separate experiments are shown; due to the submaximal contraction produced 
by these mediators and differences in spontaneous baseline contractile state of the preparations, 
no complete curves were obtained. Only when a given baseline level was reached in at least 3 
experiments, the data were included in the figure. Relaxation responses at 60% MC were significantly 
reduced by LTC4 (P<0.05), as compared to relaxations at the corresponding baseline level in the 
presence of methacholine (shown in figure 3). 
by TTX. This phase was therefore non-adrenergic and partly nerve-mediated. 
Incomplete blockade of NAI relaxation responses to EFS by TTX has been 
documented previously and suggests a non-neural component in the NAI 
relaxation response5' 8' 16' 17 . The origin of this TTX-insensitive component is 
unclear, but may represent release of a mediator or transmitter from a non-
neural site. 
EFS-induced C-responses under basal conditions were roughly 20 to 40% of 
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maximal methacholine-induced contraction, which is in the same order as reported 
previously17 • Figure 3 shows that only about one third of methacholine-induced 
contraction could be antagonised by stimulation of the NAI system. This is 
less than the 50 to 70% reported by others8' 17 • This difference may be explained 
by the fact that we did not block the cholinergic response, which may have 
reduced the NAI phase due to superposition of residual cholinergic contraction. 
In previous experiments, we have also found more effective NAI relaxations 
in the presence of atropine and histamine, which supports this explanation 16 • 
Our findings in normal and COPD airways confirm earlier reports by Roberts 
et al18 and Taylor et al17 and our own previous work19 in that COPD airways 
responded normally to exogenous cholinergic stimulation by methacholine, and 
to intrinsic cholinergic nerve stimulation by EFS. At all levels of induced 
contraction, the C-responses of normal and COPD airways were similar, and 
decreased linearly when contraction was induced from 0 to 100 %MC. This 
was to be expected because both methacholine and EFS had their effect through 
stimulation of muscarinic receptors. Futhermore, NAI-responses of normal and 
COPD airways were similar, which confirms previous observations by others17• 
We have demonstrated that NAI responses of human airways are optimal between 
40 and 70 %MC precontraction and decline when the baseline is elevated further. 
The degree of airway smooth muscle shortening that is possible in vivo is probably 
much less than the maximal contraction in vitro due to increasing loads that 
impede muscle shortening in vivo. Calculations have suggested that at most 30-
45% of maximal smooth muscle shortening is possible in vivo20 • Our findings 
suggest that in this contraction range, NAI relaxations are near-optimal and 
could therefore be important in counteracting bronchoconstriction. 
It is difficult to obtain asthmatic lung tissue for pharmacological experiments. 
In the present study, we had the rare opportunity to examine airways from 
2 patients with pertinent asthma. Our observations are highly suggestive of both 
an increased contractility to cholinergic stimulation and a decreased relaxation 
after stimulation of NAI nerves at all levels of induced contraction, although 
the number of observations is insufficient to draw firm conclusions. 
We have reported the responses of one of the asthmatic patients' airways 
to pharmacological stimulation with a number of contractile and relaxant agonists 
and to graded EFS in more detail previously16• These experiments also indicated 
an extremely high contractility of asthmatic bronchi to cholinergic stimulation. 
NAI responses in the presence of atropine and after precontraction with histamine 
were, however, only slightly reduced in comparison with normal control tissues. 
It seems likely, therefore, that the virtual absence of NAI responses in asthmatic 
airways in the present study is not only due to a reduced activity of the NAI 
system, but is also the consequence of partial superposition of the pronounced 
cholinergic contractions. Exaggerated contractile responses of isolated human 
asthmatic airways to various agonists have also been reported by others21' 22 • 
No satisfactory explanation for this increased contractility has been found. Its 
non-specific nature suggests a postreceptor mechanism, such as an increased 
effectiveness of receptor activation-contraction coupling or an increased capacity 
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of the contractile elements to shorten. Also, smooth muscle hypertrophy might 
produce increased contractility16' 20. We have not performed passive and active 
length-tension studies on asthmatic airways; the isotonic load of 1 g that we 
have used in all experiments was determined to be optimal for non-asthmatic 
airways in preliminary experiments. By definition however, sub-optimal loads 
could not result in a higher contractility of the asthmatic airways. 
Reduced NAI responses of human asthmatic airways could also contribute 
to airways obstruction, as suggested in the introduction. Several mechanisms 
might be responsible for a NAI dysfunction. Acquired defects of the NAI system 
could result from chronic airway inflammation in case of inactivation of the 
peptide transmitter by proteolytic enzymes1• If this were true, a NAI defect 
would be expected in chronically inflamed COPD' airways. We showed normal 
NAI responses in COPD airways, however. These airways were not examined 
histologically, but it has been shown that cartilaginous bronchi in COPD exhibit 
the various features of chronic inflammation23 . Therefore, it seems unlikely that 
chronic inflammation such as occurs in COPD will cause NAI hyporespon-
siveness. 
Airway inflammation has also been reported in asthma. Inflammation in asthma 
is different from that in COPD in that eosinophils constitute an important part 
of the inflammatory cell population24. 
On histological examination, both asthmatic bronchi used in this study showed 
marked infiltration of the submucosa with inflammatory cells, including numerous 
eosinophils. Eosinophils seem to play an important role in the pathogenesis 
of asthma24'25 • They have been shown to generate preferentially LTC/6, and 
LTC4 is probably one of the main mediators of human asthmatic allergic 
bronchoconstriction27 • We found reduced NAI relaxations after pretreatment 
of human non-asthmatic airways with LTC4. Likewise, in a study by Taylor 
and coworkers8, frequency- response curves to EFS on 6 human bronchi, that 
were precontracted with either histamine or LTC4, showed a 10% lower mean 
maximal NAI response in the presence of a similar concentration of LTC4 that 
inhibited NAI relaxations in the present study. This leads to the speculation 
that, in asthma, exposure to LTC4 may induce or enhance NAI hyporespon-
siveness. This may be of clinical relevance in the abovementioned airway smooth 
muscle contraction range that occurs during asthmatic attacks. 
There is no good explanation for this putative action of LTC4. Indirect evidence 
suggests that L T's may decrease the number of gap junctions, which are probably 
responsible for the electrical coupling of smooth muscle cells28• Reducing the 
number of gap junctions, therefore, would result in slower propagation of 
contractile or relaxation responses from cell to cell. It has been shown that 
cholinergic nerves are abundant in the airway generations we studied29. The 
NAI innervation may be less dense30, especially in peripheral airways5, although 
comparative quantitative data are not available. If NAI nerves are sparser than 
cholinergic nerves, NAI responses may be more dependent on smooth muscle 
cell-to-cell coupling than cholinergic responses, and may be reduced selectively 
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when the number of gap junctions is decreased, which would explain a possible 
effect of LTC4 pretreatment on NAI responses to EFS. Further studies are needed 
to examine the effect of L T on EFS-induced responses in more detail. 
A reduced NAI response in asthma may also result from an impaired relaxability 
that is not confined to the NAI system. Decreased relaxations to f3-receptor 
stimulation have been found in human asthmatic airways31' 32 , and both decreased 
/3-adrenergic and NAI responses were found in an animal model of asthma 
by Souhrada et al 10• However, we have recently reported normal relaxation 
responses to isoproterenol and forskolin of airways from one of the two asthmatic 
subjects, so impaired relaxability is not a general feature of asthmatic airways16 . 
In conclusion, we found that near-maximal responses of human airways from 
normals and patients with COPD to EFS in vitro were similar both with respect 
to cholinergic contractions and NAI relaxations. Methacholine-induced contrac-
tions were also similar. Airways from 2 subjects with asthma who had a highly 
increased bronchial responsiveness in vivo showed exaggerated cholinergic con-
tractions and reduced NAI relaxations. In normal airways, histamine and PGF2a 
had no effect on the response to EFS, but LTC4 reduced the NAI relaxation 
responses. 
These results suggest an imbalance between the contractile and relaxant 
components of the autonomic regulation of airway caliber in asthma, but not 
in COPD, that may be related to exposure of the airways to LTC4. 
References 
1. Barnes PJ. Neural control of human airways in health and disease, state of the art. Am Rev 
Respir Dis 1986;134:1289-1314. 
2. Barnes PJ. The third nervous system in the lung: physiology and clinical perspectives. Thorax 
1984;39:561-567. 
3. Davis C, Kannan S, Jones TR, Daniel EE. Control of human airway smooth muscle: in vitro 
studies. J Appl Physioll982;53:1080-1087. 
4. Doidge JM, Satchell DG. Adrenergic and non-adrenergic inhibitory nerves in mammalian 
airways. J Auton Nerv Syst 1982;5:83-99. 
5. Palmer JBD, Cuss FMC, Barnes PJ. VIP and PHM and their role in non-adrenergic inhibitory 
responses in isolated human airways. J Appl Physioll986;61:1322-1328. 
6. Richardson JB. Non-adrenergic inhibitory innervation of the lung. Lung 1981;159:315-322. 
7. Richardson J, Beland J. Non-adrenergic inhibitory nervous system in human airways. J Appl 
Physiol1976;41:764-771. 
8. Taylor SM, Pare PD, Schellenberg RR. Cholinergic and non-adrenergic mechanisms in human 
and guinea pig airways. J Appl Physiol 1984;56:958-965. 
9. Karlsson JA, Persson CGA. Neither vasoactive intestinal peptide (VIP) nor purine derivates 
may mediate non-adrenergic tracheal inhibition. Acta Physiol Scand 1984;122:589-598. 
10. Souhrada JF, Melzer E, Grantham P. Some characteristics of the purinergic nervous system 
in normal and sensitized airway smooth muscle. Respir Physiol 1980;40:199-209. 
11. Chung KF. Role of inflammation in the hyperreactivity of the airways in asthma. Thorax 
1986;41 :657-662. 
12. De Jongste JC, Van Strik R, Bonta IL, Kerrebijn KF. Measurement of human small airway 
193 
smooth muscle function in vitro with the bronchiolar strip preparation. J Pharmacol Methods 
1985;14: 111-118. 
13. De Jongste JC, Mons H, Van Strik R, Bonta IL, Kerrebijn KF. Human small airway smooth· 
muscle responses in vitro: actions and interactions of methacholine, histamine and leukotriene 
c •. Eur J Pharmacoll986;1'25:29-35. 
14. Mellor PM. A precision isotonic measuring system for isolated tissues. J Pharmacol Methods 
1984; 12:259-264. 
15. Mansour S, Daniel EE. Maintenance of tone, role of arachidonate metabolites, and effects 
of sensitization in guinea pig trachea. Can J Physiol Pharmacol 1985;64: 1096-1103. 
16. De Jongste JC, Mons H, Bonta IL, Kerrebijn KF. In vitro responses of airways from an 
asthmatic patient. Eur J Respir Dis 1987;71: 23-29. 
17. Taylor SM, Pare PD, Armour CL, Hogg JC, Schellenberg RR. Airway reactivity in chronic 
obstructive pulmonary disease. Failure of in vivo methacholine responsiveness to correlate 
with cholinergic, adrenergic or non-adrenergic responses in vitro. Am Rev Respir Dis 1985;132:30-
35. 
18. Roberts JA, Raeburn D, Rodger IW, Thomson NC. Comparison of in vivo airway responsiveness 
and in vitro smooth muscle sensitivity to methacholine in man. Thorax 1984;39:837-843. 
19. De Jongste JC, Mons H, Block R, Bonta IL, Fredriksz AP, Kerrebijn KF. Increased in vitro 
histamine responses in human small airway smooth muscle from patients with chronic obstructive 
pulmonary disease. Am Rev Respir Dis 1987;135:549-553. 
20. Moreno RJ, Hogg JC, Pare PD. Mechanisms of airway narrowing. Am Rev Respir Dis 
1986;133:1171-1180. 
21. Schellenberg RR, Foster A. In vitro responses of human asthmatic airway and pulmonary 
vascular smooth muscle. Int Arch Allergy Appl Immunoll984;75:237-241. 
22. Schellenberg RR, Duff MJ, Foster A, Pare PD. Asthmatic bronchial reactivity in vitro. Proc 
Can Soc Clin Invest 1985;A 202. 
23. Mullen JBM, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of 
airways in chronic bronchitis. Br Med J 1985;291:1235-1239. 
24. De Monchy JGR, Kauffmann HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, De Vries 
K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev 
Respir Dis 1985;131:373-376. 
25. Frigas E, Gleich GJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 
1986;77:527-537. 
26. Taniguchi N, Mita H, Saito H, Yui Y, Kajita T, Shida T. Increased generation of leukotriene 
c. from eosinophils in asthmatic patients. Allergy 1985;42:571-573. 
27. Dahlen SE, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B. Allergen challenge 
of lung tissue from asthmatics elicits bronchial contraction that correlates with the release 
of leukotrienes c., D. and E •. Proc Nat! Acad Sci USA 1983;80: 1712-1716. 
28. Agrawal R, Daniel EE. Control of gap junction formation in canine trachea by arachidonic 
acid metabolites. Am J Physiol 1986;250: 495-505. 
29. Daniel EE, Kannan M, Davis C, Posey-Daniel V. Ultrastructural studies on the neuromuscular 
control of human tracheal and bronchial muscle. Respir Physioll986;63:109-128. 
30. Dey RD, Shannon WA, Said SI. Localisation of YIP-immunoreactive nerves in airways and 
pulmonary vessels of dogs, cats and human subjects. Cell Tissue Res 1981;220:231-238. 
31. Cerrina J, Le Roy Ladurie M, Labat C, Raffestin B, Bayol A, Brink C. Comparison of human 
bronchial muscle responses to histamine in vivo with histamine and isoproterenol agonists 
in vitro. Am Rev Respir Dis 1986;134:57-61. 
32. Paterson JW, Lulich KM, Goldie RG. The role of ,8-adrenoceptors in bronchial hyperreactivity. 
In: Morley J, ed. Bronchial hyperreactivity. London: Academic Press, 1982:19-32. 

Chapter 17 
Summary and general discussion 
Most patients with asthma and many patients with chronic bronchitis have an 
increased bronchial responsiveness, which means that their airways constrict 
after pharmacological, physical, chemical or allergenic stimuli that do not have 
such an effect in normals. In asthma, the degree of bronchial hyperresponsiveness 
correlates with the severity of respiratory symptoms, and hyperresponsive subjects 
probably have an increased risk of developing chronic airflow limitation. It seems 
important, therefore, to elucidate the mechanisms that underly bronchial hy-
perresponsiveness. That in hyperresponsive subjects so many unrelated stimuli 
can provoke bronchoconstriction suggests a dysfunction of the end organ. Airways 
contain bundles of smooth muscle in their walls, that run spirally around the 
bronchial circumference. Their contraction causes airway narrowing. The physical 
characteristics of airway smooth muscle suggest that it may well be involved 
in the pathogenesis of bronchial hyperresponsiveness. This thesis contains 
investigations on human airway smooth muscle function in patients with and 
without chronic bronchitis and asthma. Human lung tissue was obtained during 
surgery for bronchial malignancies, and methods were developed to measure 
the functional responses of isolated central and peripheral airways to pharma-
cological agents and to electric field stimulation. All patients preoperatively 
underwent lung function measurements and, when possible, a bronchial challenge 
with histamine or methacholine. We have compared airway smooth muscle 
function in patients with and without chronic bronchitis or asthma. 
As an introduction to the studies, Part I contains a literature review on airway 
smooth muscle physiology and pathophysiology. 
In Chapter I, the structure of airway smooth muscle and the biochemistry, 
electrophysiology and mechanics of airway smooth muscle contraction and 
relaxation are reviewed. 
Chapter 2 describes the organisation of the autonomic control of human airway 
smooth muscle, which consists of a direct cholinergic and non-adrenergic 
inhibitory innervation and, perhaps, the circulating adrenalin from the adrenal 
medulla. 
The effects of inflammatory mediators on airway smooth muscle are sum-
marized in Chapter 3. 
Chapter 4 is a review of the present insights in the pathogenesis of nonspe'cific 
bronchial hyperresponsiveness. Although the many theories on this subject 
indicate the poor understanding of its etiology, it seems likely that indeed many 
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intrinsic and exogenous factors interact to produce bronchial hyperresponsi-
veness. Important factors seem to be acute airway inflammation and mucosal 
thickening. 
The role of airway smooth muscle abnormalities in bronchial hyperrespon-
siveness is discussed in Chapter 5. From the literature data, the aims of this 
thesis are derived. 
Part II contains four studies on the methodological aspects of the measurement 
of human airway smooth muscle function in vitro. 
Chapter 6 gives a detailed description of the method to prepare human 
bronchiolar strips. With this preparation, it is possible to perform accurate and 
reproducible measurements of airway smooth muscle sensitivity (ECso). Maximal 
effects could also be measured reproducibly, and with sufficient accuracy to 
detect differences between subjects. These responses were stable in time for a 
period of 55 h including 2 storage episodes in cold buffer. 
In Chapter 7, we describe the effects of methacholine, histamine and LTC4 
on human bronchiolar strips. Methacholine and histamine were equipotent; L TC4 
was a factor 100 more potent than the latter 2 agonists. The mean maximal 
effects of these three agents were similar. We demonstrated that ECso measu-
rements for all three agonists could be performed successively on a single 
preparation without interactions. The maximal responses, however, were influ-
enced: It was shown that histamine pretreatment induced an increase in smooth 
muscle maximal responsiveness to L TC4. 
Isometric and isotonic measurements of human airway smooth muscle function 
have been compared in Chapter 8. It was found that, with the isotonic method, 
the sensitivities to methacholine, histamine, L TC4, PG F 2a, isoproterenol and 
theophylline were slightly lower than with the isometric method. The maximal 
isotonic and isometric responses to methacholine were linearly related. We 
concluded that these differences were of little practical importance for conven-
tional pharmacological studies. 
Chapter 9 describes the response of fresh human isolated central airways to 
electric field stimulation. Maximal stimulation produced complex responses 
consisting of a rapid cholinergic nerve-mediated contraction, that, in 20% of 
all preparations, was followed by a non-neural smaller contractile peak that 
was due to synthesis of a PG-like substance. The next phase was a non-adrenergic 
nerve-mediated relaxation, followed by a fourth, sustained, non-neural contractile 
phase, caused by the synthesis of a L T -like substance. It was demonstrated that 
the sustained non-neural contractions were abolished by transient cooling to 
4°C for 30 min, but returned in the course of several hours. The recognition 
of these non-neural components is important where the neural response patterns 
of human airways are studied. 
Part III contains chapters on airway smooth muscle function in patients with 
chronic bronchitis or asthma. 
Chapter 10 describes airway smooth muscle responsiveness in patients with 
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and without COPD. This study showed that the EC5o of human airway smooth 
muscle to contracting agonists showed no important between-patients variation, 
and was similar In patients with and without COPD. Bronchiolar strips from 
patients with COPD had a significantly higher maximal response to histamine, 
responded normally to L TC4, and tended to contract less to methacholine than 
strips from control subjects. The difference in histamine contractility of airways 
from patients with and without COPD was probably not due to histamine 
tachyphylaxis or the production of relaxing prostaglandins in airways without 
COPD. 
In Chapter 11, relaxation responses to isoproterenol, forskolin and electric 
field stimulation and responses to methacholine of bronchiolar smooth muscle 
from patients with and without chronic obstructive bronchitis have been 
compared. Nonspecific hyperresponsiveness and airflow limitation could result 
from an impaired relaxability of airway smooth muscle. The response of bronchitic 
airways to isoproterenol in vitro was normal, however, and complete relaxation 
occured in response to activation of adenylate cyclase by forskolin. This indicates 
that an impaired relaxability of airway smooth muscle is probably not involved 
in bronchial obstruction and hyperresponsiveness in chronic bronchitis. Although 
no significant differences were found between the group mean relaxations to 
L-isoproterenol, forskolin and electric field stimulation of NAI nerves, three 
patients with chronic obstructive bronchitis had a significantly decreased re-
laxability of their airways to L-isoproterenol but not to forskolin. In this chapter, 
the methacholine response of airways from patients with chronic bronchitis was 
significantly lower than of control airways. That this was not found in Chapter 
10 may be due to the fourfold lower number of observations in that study. 
The reduced effect of methacholine in peripheral but not in central airways 
from patients with chronic bronchitis is unexpected, and could not be explained 
easily. 
In Chapter 12, histological signs of small airway inflammation were quantified 
and compared to airway smooth muscle contractions in vitro. It was found that 
inflamed airways were not hyperresponsive, but, in contrast, tended to be less 
responsive to histamine, methacholine and LTC4 than non-inflamed airways from 
subjects with varying degrees of chronic bronchitis. Acute airway inflammation 
is regarded as an important determinant of bronchial hyperresponsiveness in 
vivo. Our findings suggest that chronic inflammation does not enhance airway 
smooth muscle contractile function. We have not excluded, however, that the 
many substances that are released by inflammatory cells may have transient 
effects on muscle cells that facilitate bronchoconstriction during an acute 
inflammation. 
Chapter 13 is a study on the relationship between the degree of bronchial 
hyperresponsiveness to methacholine in non-asthmatic subjects in vivo and the 
structure and function of bronchiolar strips in vitro. No correlations were found 
between the sensitivity and maximal response to methacholine in vivo and' the 
responsiveness of bronchiolar smooth muscle to methacholine and L-isopro-
terenol in vitro. The severity of membranous bronchiole inflammation was 
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significantly correlated with the degree of baseline airflow limitation, but not 
with airway responsiveness in vivo or in vitro. These findings suggest that, in 
chronic bronchitis, the in vivo hyperresponsiveness to methacholine is not due 
to intrinsic abnormalities of the airway smooth muscle. 
Chapter 14 compares the capacity of human lung parenchyma to synthetize 
leukotrienes to the in vitro responsiveness of bronchiolar smooth muscle to L TC4 
and methacholine. This was done to examine the possibility of endogenous 
desensitization of the muscle in response to high levels of L T's. The parenchyma 
produced LTB4, C4, D4 and E4 in decreasing amounts. Airway smooth muscle 
responses to L TC4 were not decreased in tissue that had the highest capacity 
to generate L T's, and maximal responses after LTC4 were linearly related to 
those after methacholine. 
Chapter 15 is a case report of human asthmatic airway responses in vitro. 
Bronchiolar smooth muscle from an atopic asthmatic patient developed a four-
to five-fold higher isometric tension in response to histamine, methacholine and 
LTC4 than normal control tissues. The relaxation responses to L-isoproterenol 
and forskolin were normaL The NAI relaxation after field stimulation was low 
compared to the response of non-asthmatic tissues. 
In Chapter 16, the balance between the cholinergic and the NAI components 
of the autonomic nervous system in human central airways has been studied 
in relation to baseline smooth muscle contractile state in patients with and without 
chronic obstructive bronchitis and asthma. The results suggested that the 
cholinergic/NAI balance in chronic bronchitis was normaL In 2 asthmatic 
airways, a reduction of NAI responses together with cholinergic hyperrespon-
siveness were found. Incubation of bronchiolar strips with the inflammatory 
mediators histamine, PGF2a or LTC4 indicated that LTC4 reduced the effect 
of NAI stimulation. 
Airway smooth muscle function in asthma 
Since 1982, a few reports on asthmatic human airway smooth muscle function 
in vitro have been published. In some of these studies, an increased maximal 
tension development after histamine, cholinergic agonists and L TC4 has been 
observed. Others found normal or low contractions, sometimes with a variably 
reduced sensitivity and maximal response to f3 agonists. We have reported a 
pronounced non-specific increase in maximal isometric tension of asthmatic 
human airway smooth muscle. We also found normal relaxation responses to 
forskolin, which stimulates cAMP production receptor-independently, and to 
L-isoproterenoL Non-adrenergic inhibitory responses to electric field stimulation 
were low in bronchi from two asthmatics who were highly hyperresponsive in 
vivo, and had a normal baseline lung function. Histologic examination showed 
marked airway smooth muscle hypertrophy. Discrepancies in the results of the 
various published in vitro studies on human asthmatic airways may be due to 
differences in methodology and patient selection. It is remarkable, for instance, 
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that increases in contractile force have been found in fresh tissue, whereas impaired 
relaxation responses were present in autopsy tissues from patients who died 
of asthma. This suggests that an impaired function of /3-receptors is not an 
'intrinsic' abnormality of airway smooth muscle in asthma, but may occur 
transiently during severe asthma attacks. 
Airway smooth muscle function in chronic bronchitis 
Several studies have been published on the function of airway smooth muscle 
in well-defined populations of patients with and without chronic bronchitis, 
airflow limitation and bronchial hyperresponsiveness. Previous studies have 
mainly concentrated on the sensitivity of human airway smooth muscle to 
constricting agonists, expressed as the EC5o. There is now general agreement 
that, in chronic bronchitis, the degree of non-specific bronchial hyperrespon-
siveness is not related to the sensitivity of airway smooth muscle to contracting 
agonists. 
Absolute responses and maximal effects previously showed a troublesome 
within-subject variability. By using a carefully standardised method and a well-
defined airway preparation, the bronchiolar strip, we accomplished a reduction 
of this variability so that we could detect differences in maximal responses 
between-subjects. We found no relation between the maximal response plateau 
after inhalation of methacholine in vivo and the maximal isotonic contraction 
of airway smooth muscle in vitro. This suggested that, in bronchial hyperres-
ponsiveness without asthma, both the position and the maximal response plateau 
of the dose-response curve to inhaled methacholine are not determined by airway 
smooth muscle function. Bronchial hyperresponsiveness to methacholine in 
chronic bronchitis can therefore not be explained by an abnormal smooth muscle 
responsiveness to methacholine. However, things may be different with respect 
to histamine. Histamine is more active in peripheral airways, and produces more 
airway narrowing than methacholine in patients with chronic bronchitis and 
airflow limitation. Our finding that the maximal response of bronchiolar smooth 
muscle to histamine, but not to methacholine and LTC4, is significantly higher 
in patients with chronic bronchitis than in controls, suggests that a histamine-
specific hyperresponsiveness of airway smooth mu·scle in small airways may be 
partly responsible for the exaggerated bronchoconstriction after inhaled histamine 
in chronic bronchitis. 
Not only an increased contractility, but also a decreased relaxability of airway 
smooth muscle could be important in causing bronchial hyperresponsiveness. 
We have found similar mean relaxation responses to L-isoproterenol and forskolin 
of bronchiolar segments from patients with chronic bronchitis and from control 
subjects without chronic bronchitis. Our findings suggest however that /3-receptor 
dysfunction may occur in a subgroup of patients with chronic bronchitis. 
Acute airway inflammation is probably a major factor in the pathogenesis 
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Figure 1: Mechanisms of hyPerresponsiveness in chronic bronchitis. 
of bronchial hyperresponsiveness. We have examined human airway smooth 
muscle function in relation to the degree of airway wall inflammation, and found 
a negative correlation between the severity of airway wall inflammation and 
the sensitivity of bronchiolar smooth muscle to histamine and methacholine, 
i.e. inflamed airways were less sensitive than non-inflamed airways. This suggests 
that, in non-asthmatic subjects, chronic airway inflammation does not cause 
bronchial hyperresponsiveness via a direct effect on airway smooth muscle. It 
is highly probable, however, that other effects of chronic inflammation, such 
as mucosal swelling, mucus hypersecretion, and, perhaps, a decreased elastic 
lung recoil, are important factors in the pathogenesis of hyperresponsiveness 
in chronic bronchitis. The good correlation between baseline airway caliber and 
the degree of bronchial hyperresponsiveness in chronic bronchitis strongly 
suggests that, in vivo, geometric factors are of major importance. These will 
not influence the function of the isolated bronchi in the organ bath. 
It has also been speculated that inflammation might produce hyperrespon-
siveness by impairing the action of relaxing peptidergic neurotransmitters. We 
examined the function of the cholinergic and the non-adrenergic inhibitory 
components of the autonomic iimervation of airway smooth muscle, and showed 
that both were normally functioning in airways from patients with chronic 
bronchitis. It seems unlikely, therefore, that chronic inflammation causes hy-
poresponsiveness of the non-adrenergic inhibitory system. 
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Figure 2: Mechanisms of hyperresponsiveness in asthma. 
Conclusions 
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Comparative in vivo-in vitro studies have shown that in non-asthmatic humans 
with bronchial hyperresponsiveness, increased responsiveness of the airways in 
vivo is not caused by an abnormal sensitivity (ECso) of airway smooth muscle 
to contracting stimuli, and is not due to an impaired relaxability to e.g. /3-
receptor stimulation. The strong correlation between baseline airway caliber and 
the degree of hyperresponsiveness indicates that mechanical factors such as 
mucosal thickening are of major importance as a mechanism underlying non-
specific hyperresponsiveness in chronic bronchitis. An increased histamine 
efficacy in small airways may, however, contribute to the in vivo bronchocon-
striction after histamine inhalation. The concept of the mechanisms that lead 
to bronchial hyperresponsiveness in chronic bronchitis is illustrated in Figure 1. 
Because of the different nature of bronchial hyperresponsiveness in asthma and 
chronic bronchitis, the results obtained with airway smooth muscle from patients 
with chronic bronchitis are probably not relevant ~o hyperresponsiveness in 
asthma. In asthma, an intrinsic nonspecific increase of airway smooth muscle 
strength may exist which is dependent on the degree of smooth muscle hyper-
trophy. This is suggested by in vitro studies on fresh airways from stable 
asthmatics. An increased strength may lead to bronchial hyperresponsiveness 
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because when the stronger muscle contracts, it will more easily overcome the 
elastic recoil forces that may normally prevent excessive airway narrowing. During 
acute phases, inflammatory mediators may further enhance smooth muscle 
responsiveness via various putative mechanisms, such as presynaptic facilitation 
of cholinergic nervous transmission, modulation of the number of gap junctions, 
or stimulation of axon reflexes and local release of tachykinins. Furthermore, 
mucosal swelling and mucus plugging may occur that worsen airway obstruction 
and responsiveness. 
The relaxability of airway smooth muscle in asthma is essentially normal. 
However, studies on autopsy tissue from asthmatics who died during attacks 
have suggested, that an impaired ,8-receptor function may occur during severe 
asthma attacks. This corresponds with the clinical observation that ,8 agonists 
are excellent bronchodilators in asthmatic patients, but are usually only partly 
effective during severe attacks. Finally, the non-adrenergic inhibitory system 
may be impaired in asthma, secondary to asthmatic airway inflammation. Figure 2 
depicts the mechanisms that may be relevant for the pathogenesis of bronchial 
hyperresponsiveness in asthma. 
In summary, it seems that not only in vivo, but also in vitro there are fundamental 
differences in the nature of bronchial hyperresponsiveness in patients with asthma 
or chronic bronchitis (Table 1). Several important questions remain, however, 
that need to be answered. It is not known, for instance, whether these differences 
Table 1. Putative abnormalities of airway smooth muscle in asthma and chronic bronchitis 
Contractility 
-histamine 
- methacholine 
-LTC. 
Relaxability 
- f3 receptor 
-cAMP 
Autonomic control 
- cholinergic 
- non-cholinergic excitatory 
- non-adrenergic inhibitory 
Inflammation 
-acute 
-chronic 
Abbreviation: n =normal 
Airway smooth muscle responsiveness 
Asthma 
tt 
tt 
tt 
n, ( ~ ~ during attacks) 
n 
tt 
t (?) 
~ 
tt 
(decreases airway caliber) 
Chronic bronchitis 
t 
~ 
n 
n, ( ~ in subgroup) 
n 
n 
? 
n 
? 
(decreases airway caliber) 
~ (decreases sensitivity to 
contracting agonists) 
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are genetically determined or acquired. It seems also important to know whether 
the asthmatic type of hyperresponsiveness can lead to chronic airflow limitation 
and a 'bronchitic-type' of hyperresponsiveness in later life. It is clear that much 
more work needs to be done both in vivo and in vitro to substantiate the concepts 
presented, and to further elucidate the mechanisms that underly bronchial 
hyperresponsiveness in chronic bronchitis and asthma. 
Directions for future research 
Thusfar, the study of human asthmatic airway smooth muscle has progressed 
slowly, due to a limited supply. The study of lung tissue from experimental 
animals or from patients with non-asthmatic hyperresponsiveness may not give 
relevant results. 
It is further clear that the preparations used for in vitro studies by most 
investigators have serious disadvantages. Bronchial strips contain various com-
ponents such as epithelium, connective tissue and inflammatory cells, that may 
influence muscle function, and can only be obtained at thoracotomies or after 
death. It is important, therefore, to develop techniques that will make it possible 
to study pure human airway muscle, either in small cell bundles or as single 
cells. It seems now technically feasible to do mechanical, pharmacological, 
biochemical and electrophysiological studies on small amounts of muscle or 
even on single cells. This makes it possible to examine airway tissue from 
endobronchial biopsies obtained via bronchoscopy. Bronchoscopy and biopsies 
can be safely performed in mild asthmatics and normal subjects, and smooth 
muscle cells thus obtained may be used directly or can be cultured with 
preservation of contractile function. It seems possible, that studies of this kind 
may eventually answer the question whether human· airway smooth muscle is 
intrinsically abnormal in asthma. 
It seems also important to study the interactions between muscle tissue and 
inflammatory cells. This requires a more or less pure muscle preparation, which 
makes it possible to examine the effect of activation of various types of 
inflammatory cells or epithelial cells on muscle tone, muscle responsiveness or 
its control by the autonomic nervous system. Studies of this kind will provide 
insight in the many possible ways in which the various cell types in the airways 
may interact to produce hyperresponsiveness, and allow the study of mechanisms 
of action of putative anti-asthmatic drugs. 
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Samenvatting 
Bronchiale hyperreactiviteit is een basiskenmerk van astma en komt vaak voor 
bij patienten met chronische bronchitis. Bij deze patienten ontstaat broncho-
constrictie na farmacologische, fysische, chemische of allergene stimuli die dit 
effect niet hebben bij normale personen. De mate van bronchiale prikkelbaarheid 
correleert met de ernst van de symptomen bij astma, en patienten met bronchiale 
hyperreactiviteit lopen waarschijnlijk een verhoogd risico op chronische obstruc-
tieve longziekten. Het lijkt daarom belangrijk het mechanisme van bronchiale 
hyperreactiviteit te onderzoeken. 
Dat zoveel verschillende soorten stimuli bronchoconstrictie kunnen veroor-
zaken bij patienten met bronchiale hyperreactiviteit duidt erop dat er een 
functiestoornis zou kunnen bestaan van het eindorgaan. In de wand van de 
.).luchtwegen bevinden zich bundels glad spierweefsel, die spiraalsgewijs verlopen 
zodat zij de luchtwegdiameter verkleinen wanneer zij samentrekken. De fysische 
eigenschappen van het bronchiaal glad spierweefsel wijzen erop dat het een rol 
zou kunnen spelen bij bronchiale hyperreactiviteit. 
Dit proefschrift bevat de resultaten van een aantal studies naar de rol van 
het bronchiale spierweefsel bij bronchiale hyperreactiviteit en luchtwegvernau-
wing, zoals die voorkomen bij patienten met chronische bronchitis en astma. 
Hiertoe werden methoden ontwikkeld om de functionele responsen van ge!so-
leerde perifere en centrale menselijke luchtwegen te meten na stimulatie met 
farmacologische stoffen en electrische veldstimulatie. 
Longweefsel werd verkregen van patienten die een thoracotomie ondergingen 
wegens maligniteit. Bij deze patienten werd preoperatief longfunctieonderzoek 
en zo mogelijk een inhalatie-provocatietest met histamine of methacholine 
verricht. 
Nadat de nauwkeurigheid en de reproduceerbaarheid van de in vitro metho-
dieken was nagegaan, werd vergelijkend onderzoek verricht met luchtwegpre-
paraten van patienten met en zonder chronische bronchitis of astma. 
In Dee! I wordt de fysiologie en pathofysiologie van bronchiaal glad spierweefsel 
beschreven aan de hand van literatuurgegevens. 
Hoofdstuk I bevat een beschrijving van de structuur van bronchiaal glad 
spierweefsel en van de biochemische, electrofysiologische en mechanische as pecten 
van contractie en relaxatie. 
Hoofdstuk 2 beschrijft de autonome regulatie van menselijk bronchiaal spier-
weefsel. Het autonome zenuwstelsel innerveert het bronchiale spierweefsel met 
cholinerge en met niet-adrenerge inhiberende vezels. Een niet-adrenerg exciterend 
systeem is mogelijk van belang bij locale axonreflexen. Circulerende catecho-
lamines zijn waarschijnlijk vooral belangrijk tijdens stress. 
De effecten van een aantal mediatoren van ontsteking op bronchiaal glad 
spierweefsel worden samengevat in Hoofdstuk 3. 
Hoofdstuk 4 bevat een overzicht van de theorieen over de pathogenese van 
aspecifieke bronchiale hyperreaktiviteit bij patienten met astma of chronische 
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bronchitis. Ret grote aantal theorieen duidt erop, dat de mechanismen van 
bronchiale hyperreactiviteit nog onvoldoende worden begrepen. Ret is echter 
waarschijnlijk, dat ontsteking en zwelling van het bronchiale slijmvlies een 
belangrijke rol spelen. 
De mogelijke rol van bronchiaal glad spierweefsel bij bronchiale hyperreac-
tiviteit wordt besproken in Hoofdstuk 5. Uit de literatuurgegevens worden 
conclusies getrokken die hebben geleid tot de vraagstellingen van het onderzoek, 
beschreven in dit proefschrift. 
Dee! II bestaat uit vier hoofdstukken, waarin de methodologische as13ecten zijn 
beschreven van de meting van de functie van menselijk bronchiaal spierweefsel 
in vitro. 
Hoofdstuk 6 bevat een gedetailleerde beschrijving van de techniek waarmee 
menselijke bronchiolus-strips "worden geprepareerd. Met de b~onchiolus-strip is 
het mogelijk om nauwkeurige en reproduceerbare metingen te verrichten van 
de gevoeligheid van bronchiaal glad spierweefsel. Maximale effecten konden ook 
reproduceerbaar worden bepaald, met voldoende nauwkeurigheid om verschillen 
tussen personen te kunnen aantonen. De responsen waren stabiel gedurende 
55 uur na chirurgische resectie van het longweefsel, en werden niet be1nvloed 
door bewaren van de preparaten in koude buffer. 
In Hoofdstuk 7 beschrijven wij de effecten van methacholine, histamine en 
LTC4 op menselijke bronchiolus-strips. Methacholine en histamine waren equi-
potent, L TC4 was 100 maal potenter dan deze twee stoffen. De maximale effecten 
van de drie agonisten waren vergelijkbaar. Ret bleek dat methacholine, histamine 
en LTC~ geen interacties vertoonden met betrekking tot de gevoeligheid (ECso), 
maar wel wat betreft de maximale respons. Histamine voorbehandeling leidde 
tot een toegenomen maximaal effect van LTC4, hetgeen duidt op een interactie 
voorbij het niveau van receptoractivatie. 
In Hoofdstuk 8 worden isotonische en isometrische metingen met elkaar 
vergeleken. De ECso, bepaald met de isotonische methode, voor methacholine, 
histamine, LTC4, PFG2a, isoprenaline en theophylline was iets groter dan met 
de isometrische methode. De maximale isotonische en isometrische responsen 
na methacholine waren lineair gerelateerd. Wij concludeerden dat de gevonden 
verschillen tussen deze methoden van weinig belang waren voor conventionele 
farmacologische proeven. 
In Hoofdstuk 9 wordt het reactiepatroon van verse menselijke centrale lucht-
wegen na electrische veldstimulatie in vitro beschreven. Maximale veldstimulatie 
leidde tot complexe responsen die begonnen met een snelle, cholinerge contractie 
ten gevolge van stimulatie van cholinerge zenuwen in het preparaat. Bij 20% 
van alle bronchi werd vervolgens een tweede contractiepiek waargenomen, die ' 
berustte op het vrijkomen van een prostaglandine-achtige stof. De volgende 
component was een door niet-adrenerge inhiberende zenuwen veroorzaakte 
relaxatie, en deze fase werd in vrijwel alle bronchi gevolgd door een trage 
contractie, die veroorzaakt werd door de productie van een leukotriene-achtige 
stof. Deze langzame contractiefase verdween vrijwel na tijdelijke afkoeling tot 
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4°C gedurende 30 min, maar ontstond hierna geleidelijk opnieuw in de loop 
van enkele uren. Deze niet door zenuwstimulatie veroorzaakte contracties kunnen 
de cholinerge en vooral de niet-adrenerge respons sterk vervormen, hetgeen van 
belang is bij neurofysiologisch onderzoek. 
Dee! III bevat een zevental hoofdstukken waarin onderzoek wordt beschreven 
naar de functie van geisoleerd bronchiaal glad spierweefsel in vitro en kenmerken 
van patienten met chronische bronchitis of astma, zoals luchtwegobstructie, 
bronchiale hyperreactiviteit en ontsteking van de bronchi. 
Hoofdstuk I 0 beschrijft de functie van bronchiaal glad spierweefsel bij patienten 
met en zonder chronische bronchitis en luchtwegobstructie. Bronchiolus-strips 
van patienten met bronchitis vertoonden een significant grotere maximale 
isometrische respons na histamine dan strips van controlepersonen. Er was een 
normale respons na LTC4, en mogelijk een iets lagere contractiekracht ten aanzien 
van methacholine. Verschillen in ECso werden niet gevonden. 
In Hoofdstuk II zijn de relaxatieresponsen van bronchiolus strips van patienten 
met en zonder chronische bronchitis en luchtwegobstructie vergeleken, en werd 
bovendien het effect van methacholine in vitro nagegaan. Hoewel de relaxatie 
responsen na isoprenaline, forskoline en veldstimulatie van het niet-adrenerge 
inhiberende systeem niet significant van elkaar verschilden in de twee groepen, 
waren er drie patienten met bronchitis, van wie het bronchiaal spierweefsel een 
significant verlaagde respons vertoonde na isoprenaline, maar niet na forskoline. 
In deze studie was de maximale respons na methacholine in vitro bij patienten 
met chronische bronchitis significant lager dan bij controlepersonen. Dit verschil 
met de studie beschreven in het vorige hoofdstuk, wordt waarschijnlijk veroor-
zaakt doordat in hoofdstuk 11 een viermaal groter aantal preparaten in vitro 
werd onderzocht dan in hoofdstuk 10. 
In Hoofdstuk 12 zijn histologische kenmerken van ontsteking in kleine 
luchtwegen van patienten met en zonder chronische bronchitis gekwantificeerd 
en gerelateerd aan de functie van het bronchiale spierweefsel in vitro. Het bleek 
dat ernstig ontstoken luchtwegen niet hyperreactief, maar daarentegen minder 
gevoelig zijn voor histamine, methacholine en leukotriene C4 dan minder 
ontstoken bronchioli. 
Hoofdstuk 13 bevat de resultaten van een onderzoek naar de mate van bronchiale 
hyperreactiviteit bij patienten zonder astma in vivo en de structuur en functie 
van bronchiolusstrips in vitro. Er werden geen correlaties gevonden tussen de 
gevoeligheid en maximale respons ten aanzien van methacholine in vivo enerzijds, 
en de gevoeligheid en maximale isotonische contracties en relaxaties van bron-
chiolus-strips na methacholine en isoprenaline in vitro, of de ernst van de 
histologische afwijkingen in membraneuze bronchioli anderzijds. Wel was de 
'basale' luchtwegobstructie significant groter naarmate ernstiger histologische 
afwijkingen in de kleine luchtwegen bestonden. 
In Hoofdstuk 14 wordt het vermogen van het longweefsel om leukotrienen 
te produceren gerelateerd aan de in vitro responsen van bronchiaal spierweefsel 
na leukotriene C4 of methacholine. Dit is gedaan om na te gaan of een hoge 
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endogene leukotrieneproduktie zou kunnen leiden tot desensitisatie van de 
spiercellen. Het bleek, dat longparenchym leukotriene B4, C4, D4 en E4 pro-
duceerde in afnemende hoeveelheden. De respons van bronchiolusstrips na 
leukotriene C4 was niet lager in weefsel dat een hoge capaciteit had om leukotriene 
te produceren. De maximale responsen na leukotriene C4 waren lineair gerelateerd 
aan de respons na methacholine. 
Hoofdstuk 15 bevat een casuistische mededeling over de functie van bronchiaal 
spierweefsel van een astmapatient. Bronchiolusstrips van deze patient ontwik-
kelden een vier tot vijf maal grotere isometrische kracht na histamine, metha-
choline, leukotriene C4 en veldstimulatie dan controlepreparaten van patienten 
zonder astma of chronische bronchitis, die een normale longfunctie hadden. 
De relaxatie na isoprenaline en forskoline was normaal. De niet-adrenerge 
inhiberende respons na veldstimulatie was lager dan controlewaarden. 
In Hoofdstuk 16 wordt een onderzoek beschreven naar het evenwicht tussen 
de cholinerge en niet-adrenerge inhiberende componenten van het autonome 
zenuwstelsel in centrale bronchi. Dit evenwicht is bestudeerd in relatie tot de 
basale contractietoestand van het bronchiale spierweefsel bij patienten met en 
zonder chronische bronchitis of astma. De resultaten lieten zien dat het evenwicht 
tussen het cholinerge en het niet-adrenerge inhiberende systeem normaal was 
bij patienten met chronische bronchitis. Twee bronchi van astmapatienten 
vertoonden echter een sterk toegenomen cholinerge respons en een zeer lage 
niet-adrenerge inhiberende respons. Incubatie van bronchuspreparaten met 
onstekingsmediatoren (histamine, PGF2"' LTC4) leidde aileen na voorbehandeling 
met LTCdot verminderde niet-adrenerge relaxatie. 
In de algemene discussie wordt gesteld dat bij patienten met chronische bronchitis 
een afwijkende functie van bronchiaal glad spierweefsel werd aangetoond die 
een rol zou kunnen spelen bij de bronchoconstrictie na inhalatie van histamine. 
De gevonden afwijking vormt echter geen verklaring voor aspecifieke bronchiale 
hyperreactiviteit. Dit suggereert dat andere factoren dan het spierweefsel bij deze 
patienten van belang zijn, zoals bijvoorbeeld zwelling van de bronchiale mucosa 
tengevolge van chronische ontsteking. Dit zou geen invloed hebben op de 
contracties van bronchuspreparaten in vitro. Een verminderde relaxatie van 
bronchiaal spierweefsel na stimulatie van fi-receptoren zou bij sommige patienten 
met chronische bronchitis een rol kunnen spelen, maar is geen typisch kenmerk. 
Ook werd een normale respons na stimulatie van het cholinerge, en van het 
niet-adrenerge inhiberende zenuwstelsel gevonden. 
De bevindingen met longweefsel van een astmapatient duidden echter wel 
op een aspecifiek toegenomen contractiliteit van het bronchiale spierweefsel. 
Histologisch onderzoek van astmatische luchtwegen toonde een sterke mate van 
hypertrofie van het bronchiale spierweefsel, die een verklaring zou kunnen vormen 
voor de toegenomen contractiliteit. Bovendien werden bij twee astmapatienten 
aanwijzingen gevonden voor een verminderde functie van het niet-adrenerge 
inhiberende systeem. Stimulatie van fi-receptoren leidde tot een normale relaxatie 
van astmatische bronchi. Literatuurgegevens suggereren echter dat een vermin-
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derde relaxatie na fi-receptor stimulatie kan optreden na ernstige astma-aanvallen. 
Tenslotte wordt uit de resultaten van eigen onderzoek en uit literatuurgegevens 
een concept afgeleid dat een verklaring poogt te geven voor bronchiale hyper-
reactiviteit. Hierbij lijkt dat, zowel in vivo als in vitro, de aard van de bronchiale 
hyperreactiviteit bij patienten met astma belangrijk verschilt van die bij patienten 
met chronische bronchitis. 
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Professor dr. K.F. Kerrebijn, leermeester en promotor, dank ik voor zijn 
stimulerende en kritische begeleiding bij alle fasen van het onderzoek. Zijn grote 
kennis en ervaring, en zijn feilloos gevoel voor wat belangrijk is en wat 'holklap', 
hebben de kwaliteit van het onderzoek en de eruit voortgekomen publicaties 
in hoge mate bepaald. Ook dank ik hem voor mijn opleiding tot kinderlongarts, 
welke ik als een voorrecht heb ervaren. 
Professor dr. I.L. Bonta, tweede promotor, dank ik voor zijn deskundig oordeel 
over- en filosofische benadering van onze resultaten. Zijn gastvrijheid, waardoor 
wij kunnen beschikken over een ruim en goed uitgerust laboratorium, waardeer 
ik zeer. 
Professor dr. C. Hilvering dank ik voor zijn kritische en nauwgezette be-
oordeling van het manuscript. Ook ben ik hem en alle collegae van de afdeling 
Longziekten van het Academisch Ziekenhuis Dijkzigt zeer erkentelijk voor de 
prettige samenwerking. 
· Professor dr. J. Zaagsma heeft mij vanaf het begin van het onderzoek laten 
profiteren van zijn grote kennis. Onze plezierige discussies tijdens mijn pelgrimages 
naar Groningen waren steeds buitengewoon waardevol en behoedden mij voor 
menige beginnersfout. Ook dank ik hem voor zijn deskundige beoordeling van 
het manuscript. 
Professor dr. R. van Strik was nauw betrokken bij de opzet van het me-
thodologisch onderzoek. Ik dank hem voor de vele uren die hij besteedde aan 
de bewerking van de resultaten, en voor het geduld waarmee hij mij de fijne 
kneepjes van de variantie-analyse heeft proberen bij te brengen. 
Harry Mons verrichtte de in vitro experimenten met grote toewijding, nauw-
keurigheid en met een onverwoestbaar goed humeur dat bestand was tegen zeer 
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onregelmatige werktijden. Ook automatiseerde hij de verwerking van de meet-
resultaten. Voor onze bijzonder prettige samenwerking ben ik hem zeer dankbaar. 
Freek Zijlstra leerde mij de beginselen van het farmacologisch in vitro onderzoek 
van luchtwegpreparaten. Ik dank hem voor zijn hulp en adviezen, en voor de 
plezierige sfeer in zijn laboratorium waar wij te gast zijn. 
Mijn collegae drs. Hein Brackel, drs. Frans de Baets, drs. Mark Raes, dra. Lies beth 
van Essen-Zandvliet en dr. Eric Duiverman hebben op talloze onvoorziene 
momenten mijn werkzaamheden in het ziekenhuis bereidwillig overgenomen, 
waarvoor ik hen veel dank verschuldigd ben. De voortreffelijke wijze waarop 
mijn poliklinische spreekuur werd waargenomen door Hein Brackel heeft m 
hoge mate bijgedragen tot het tijdig voltooien van dit proefschrift. 
Drs. Fibo ten Kate en alle andere collegae van de afdeling Pathologische Anatomie 
dank ik voor hun bereidheid om ons op meestal ongelegen momenten te helpen 
bij het uitzoeken van geschikt longweefsel. De medewerkers van het Histologisch 
Laboratorium dank ik voor het vervaardigen van de histologische coupes. 
De medische en verpleegkundige staf van de afdeling Thoraxchirurgie ben 
ik zeer erkentelijk voor hun vertrouwen en voor de prettige samenwerking bij 
het verkrijgen van gereseceerd longweefsel. Drs. A.P. Fredriksz (t, in leven 
thoraxchirurg) ben ik zeer veel dank verschuldigd voor zijn grote inzet, en voor 
het enthousiasme waarmee hij ons introduceerde in het Thoraxcentrum. 
De medische staf van de afdelingen Longziekten, Chirurgie en Pathologische 
Anatomie van het Ziekenhuis Leijenburg te 's-Gravenhage en het Ikazia Zie-
kenhuis te Rotterdam dank ik voor hun bereidwilligheid om mee te werken 
aan dit onderzoek. Ik dank alle betrokkenen, en in het bijzonder dr H.D. Meijer, 
dr A. Hoek (longartsen) en dhr J. van Bergen-Henegouw (afdeling P.A.) uit 
het Ziekenhuis Leijenburg, die ondermeer een essentiele bijdrage leverden aan 
het onderzoek beschreven in hoofdstuk 15; en dr G. Nakratzas (longarts), dr 
A.P. Brinkhorst en dr J.J. van Gogh (chirurgen) uit het Ikazia Ziekenhuis, voor 
hun grote inzet, die zeer belangrijk was voor de kwaliteit en kwantiteit van 
onze resultaten. 
De studie beschreven in hoofdstuk 13 was mogelijk dankzij de expertise en 
inspanningen van dr. Peter Sterk, drs. Luuk Willems, Hillie van der Veen en 
Mieke Timmers van de afdeling Longziekten, Academisch Ziekenhuis Leiden 
(hoofd: prof. dr. J.H. Dijkman). Ik dank hen hartelijk voor de plezierige 
samenwerking. 
De heren J.B.F. Ekas, A. Hoegee, W. Boender, H.R. Thon, F. Schuhmacher 
en hun medewerkers van de Centrale Research Werkplaatsen zorgden voor het 
vervaardigen en bedrijfsklaar houden van alle apparatuur. Naast meesterschap 
toonden zij een grote creativiteit en betrokkenheid, die het onderzoek zeer ten 
goede kwamen. 
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Dr. R. van Mastrigt dank ik voor zijn praktische adviezen en hulp bij het 
ontwikkelen van de veldstimulatietechniek. 
De meeste illustraties werden op voo:rbeeldige wijze vervaardigd door de 
medewerkers van het Audiovisueel Centrum van de Erasmus Universiteit onder 
leiding van de heer C.J. van Dijk, en door de heer J.R.M. de Kuyper van de 
Audiovisuele Dienst van het SKZ. De omslagfoto werd kunstzinnig vervaardigd 
door de heer V. Nyckl. 
Professor dr. J.H.P. Wilson dank ik voor het corrigeren van de Engelse tekst. 
Dat hij hiertoe ondanks zijn drukke werkzaamheden steeds onmiddellijk bereid 
was heb ik zeer gewaardeerd. 
Ellen Nelemans-van den Broek dank ik voor het corrigeren van de litera-
tuurlijsten. 
Alice Bakker dank ik voor de prettige en vlotte wijze waarop zij de uiteindelijke 
versie van het manuscript typte en tot 'floppies' heeft verwerkt. Marike van 
Groen en Annelies de Reus waren hierbij vaak behulpzaam en typten de originele 
versies van verscheidene hoofdstukken, waarvoor ik hen hartelijk dank. 
Dr. Judith Black, University of Sydney, kindly advised us during the early stages 
of our studies. Since then, our many pleasant and stimulating contacts have 
been of great value. 
Professor E. E. Daniel, McMaster University, Hamilton, gave us many valuable 
advices and looked over several of the manuscripts. His comments have improved 
our work very much, for which I am indebted. 
Tenslotte betuig ik gaarne mijn dank aan het Nederlands Astma Fonds, dat 
het onderzoek subsidieerde, en mijn vervolgopleiding in longziekten bij kinderen 
mogelijk maakte. 

215 
Curriculum vitae 
Johannes Cornelis de Jongste was born on April the 7th, 1955, in Rotterdam, 
The Netherlands. He passed his secondary school exam (HBS-B) in 1972 at 
the 'Groen van Prinsterer Lyceum' in Vlaardingen. He started his medical training 
in 1972 at the Medical Faculty of the Erasmus University Rotterdam. In 1978 
he obtained his medical degree. From November 1978 to March 1979 he was 
a clinical fellow in Internal and Tropical Medicine at the Harbour Hospital 
in Rotterdam (head: prof. dr. P.C. Stuiver). From March 1979 to April 1980, 
he completed a professional training at the Department of General Practise, 
Erasmus University Rotterdam (head: prof. dr. H.J. Dokter). During this year 
he worked as assistant General Practitioner in Zierikzee (practise: drs. A.W. 
van Geer) and followed clinical fellowships at the Department of Revalidation 
(head: drs. J.M. Oostlander), St. Franciscus Gasthuis, Rotterdam, and at the 
Department of Paediatrics, Sophia Children's Hospital, Rotterdam (head: prof. 
dr. H.K.A. Visser). In 1980 he was registered as General Practitioner. In this 
same year, he started his specialist training in Paediatrics in the Sophia Children's 
Hospital, which is part of the University Hospital Rotterdam. He was recorded 
as a Paediatrician in the register of the Royal Netherlands Medical Association 
in April1984. From April1984 to April1987, he followed a clinical- and research 
fellowship at the Department of Paediatric Respiratory Diseases (head: prof. 
dr. K.F. Kerrebijn) of the Sophia Children's Hospital, under auspices of The 
Netherlands Asthma Foundation. The research bundled in this thesis was 
performed during this period at the Department of Pharmacology (head: prof. 
dr. LL. Bonta) of the Erasmus University Rotterdam. Since April 1987, he is 
a staff paediatric pulmonologist at the Sophia Children's HospitaL 
He is married to Klasine Karoline Breeman, M.D., and has two children: 
Evert-Jan and Arjen. 

List of abbreviations 
AA 
ASM 
ATP 
c 
cAMP 
CCRC 
CE 
COB 
COPD 
Dmax 
Dpl 
DSCG 
DW 
ECso 
EDTA 
EFso 
EFS 
EJP 
FEV1 
HETE 
HPLC 
IVC 
Lo 
LT 
MC 
MFEVI 
NAI 
NANC 
NCCRC 
NS 
PAF 
PC 
PD 
PEC 
PG 
PHI 
PL 
R 
Rmax 
SAD 
SEC 
SEM 
sGAW 
arachidonic acid 
airway smooth muscle 
adenosine triphosphate 
contraction 
cyclic adenosine monophosphate 
cumulative concentration-response curve 
contractile element 
chronic obstructive bronchitis 
chronic obstructive pulmonary disease 
maximal dose 
dose of agonist at which a response plateau is reached 
disodium cromoglycate 
dry weight 
effective concentration that causes 50% of the maximal effect 
ethylene diamine tetra acetic acid 
effective frequency that causes 50% of the maximal effect 
electric field stimulation 
excitatory junctional potential 
forced expiratory volume in 1 sec 
hydroxyeicosatetraenoic acid 
high performance liquid chromatography 
inspiratory vital capacity 
optimal length 
leukotriene 
maximal contraction 
maximal fall in FEV 1 
non-adrenergic inhibitory 
non-adrenergic, non-cholinergic 
non-cumulative concentration-response curve 
not significant 
platelet-activating factor 
provocative concentration 
provocative dose 
parallel elastic component 
prostaglandin 
peptide histidine isoleucine 
phospholipase 
relaxation 
maximal relaxation 
small airways disease 
series elastic component 
standard error of the mean 
specific airway conductance 
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Smax maximal isotonic shortening 
TLC total lung capacity 
T max maximal isometric tension 
TTX tetrodotoxin 
Tx thromboxane 
VC vital capacity 
VIP vasoactive intestinal peptide 
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